507620584 11/29/2022

PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1 Stylesheet Version v1.2 EPAS ID: PAT7667477

SUBMISSION TYPE:	NEW ASSIGNMENT
NATURE OF CONVEYANCE:	ASSIGNMENT

CONVEYING PARTY DATA

Name	Execution Date
GE HEALTHCARE BIO-SCIENCES AB	12/30/2015

RECEIVING PARTY DATA

Name:	GE HEALTHCARE BIOPROCESS R&D AB
Street Address:	BJORKGATAN 30
City:	UPPSALA
State/Country:	SWEDEN
Postal Code:	751 84

PROPERTY NUMBERS Total: 1

Property Type	Number
Application Number:	18059929

CORRESPONDENCE DATA

Fax Number: (404)853-8806

Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent

using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.

Phone: 4048538000

Email: jolierowe@eversheds-sutherland.com,

PatentDocket@eversheds-sutherland.us

Correspondent Name: EVERSHEDS SUTHERLAND (US) LLP

Address Line 1: 999 PEACHTREE STREET, N.E.

Address Line 4: ATLANTA, GEORGIA 30309

ATTORNEY DOCKET NUMBER:	P1005-1235-US0234428-0745
NAME OF SUBMITTER:	WILLIAM L. WARREN
SIGNATURE:	/William L. Warren/
DATE SIGNED:	11/29/2022

Total Attachments: 93

source=GE Healthcare Bio-Sciences AB to GE Healthcare BioProcess R&D AB#page1.tif source=GE Healthcare Bio-Sciences AB to GE Healthcare BioProcess R&D AB#page2.tif source=GE Healthcare Bio-Sciences AB to GE Healthcare BioProcess R&D AB#page3.tif source=GE Healthcare Bio-Sciences AB to GE Healthcare BioProcess R&D AB#page4.tif source=GE Healthcare Bio-Sciences AB to GE Healthcare BioProcess R&D AB#page5.tif

507620584 PATENT REEL: 062019 FRAME: 0228

source=GE Healthcare Bio-Sciences AB to GE Healthcare BioProcess R&D AB#page6.tif source=GE Healthcare Bio-Sciences AB to GE Healthcare BioProcess R&D AB#page7.tif source=GE Healthcare Bio-Sciences AB to GE Healthcare BioProcess R&D AB#page8.tif source=GE Healthcare Bio-Sciences AB to GE Healthcare BioProcess R&D AB#page9.tif source=GE Healthcare Bio-Sciences AB to GE Healthcare BioProcess R&D AB#page10.tif source=GE Healthcare Bio-Sciences AB to GE Healthcare BioProcess R&D AB#page11.tif source=GE Healthcare Bio-Sciences AB to GE Healthcare BioProcess R&D AB#page12.tif source=GE Healthcare Bio-Sciences AB to GE Healthcare BioProcess R&D AB#page13.tif source=GE Healthcare Bio-Sciences AB to GE Healthcare BioProcess R&D AB#page14.tif source=GE Healthcare Bio-Sciences AB to GE Healthcare BioProcess R&D AB#page15.tif source=GE Healthcare Bio-Sciences AB to GE Healthcare BioProcess R&D AB#page16.tif source=GE Healthcare Bio-Sciences AB to GE Healthcare BioProcess R&D AB#page17.tif source=GE Healthcare Bio-Sciences AB to GE Healthcare BioProcess R&D AB#page18.tif source=GE Healthcare Bio-Sciences AB to GE Healthcare BioProcess R&D AB#page19.tif source=GE Healthcare Bio-Sciences AB to GE Healthcare BioProcess R&D AB#page20.tif source=GE Healthcare Bio-Sciences AB to GE Healthcare BioProcess R&D AB#page21.tif source=GE Healthcare Bio-Sciences AB to GE Healthcare BioProcess R&D AB#page22.tif source=GE Healthcare Bio-Sciences AB to GE Healthcare BioProcess R&D AB#page23.tif source=GE Healthcare Bio-Sciences AB to GE Healthcare BioProcess R&D AB#page24.tif source=GE Healthcare Bio-Sciences AB to GE Healthcare BioProcess R&D AB#page25.tif source=GE Healthcare Bio-Sciences AB to GE Healthcare BioProcess R&D AB#page26.tif source=GE Healthcare Bio-Sciences AB to GE Healthcare BioProcess R&D AB#page27.tif source=GE Healthcare Bio-Sciences AB to GE Healthcare BioProcess R&D AB#page28.tif source=GE Healthcare Bio-Sciences AB to GE Healthcare BioProcess R&D AB#page29.tif source=GE Healthcare Bio-Sciences AB to GE Healthcare BioProcess R&D AB#page30.tif source=GE Healthcare Bio-Sciences AB to GE Healthcare BioProcess R&D AB#page31.tif source=GE Healthcare Bio-Sciences AB to GE Healthcare BioProcess R&D AB#page32.tif source=GE Healthcare Bio-Sciences AB to GE Healthcare BioProcess R&D AB#page33.tif source=GE Healthcare Bio-Sciences AB to GE Healthcare BioProcess R&D AB#page34.tif source=GE Healthcare Bio-Sciences AB to GE Healthcare BioProcess R&D AB#page35.tif source=GE Healthcare Bio-Sciences AB to GE Healthcare BioProcess R&D AB#page36.tif source=GE Healthcare Bio-Sciences AB to GE Healthcare BioProcess R&D AB#page37.tif source=GE Healthcare Bio-Sciences AB to GE Healthcare BioProcess R&D AB#page38.tif source=GE Healthcare Bio-Sciences AB to GE Healthcare BioProcess R&D AB#page39.tif source=GE Healthcare Bio-Sciences AB to GE Healthcare BioProcess R&D AB#page40.tif source=GE Healthcare Bio-Sciences AB to GE Healthcare BioProcess R&D AB#page41.tif source=GE Healthcare Bio-Sciences AB to GE Healthcare BioProcess R&D AB#page42.tif source=GE Healthcare Bio-Sciences AB to GE Healthcare BioProcess R&D AB#page43.tif source=GE Healthcare Bio-Sciences AB to GE Healthcare BioProcess R&D AB#page44.tif source=GE Healthcare Bio-Sciences AB to GE Healthcare BioProcess R&D AB#page45.tif source=GE Healthcare Bio-Sciences AB to GE Healthcare BioProcess R&D AB#page46.tif source=GE Healthcare Bio-Sciences AB to GE Healthcare BioProcess R&D AB#page47.tif source=GE Healthcare Bio-Sciences AB to GE Healthcare BioProcess R&D AB#page48.tif source=GE Healthcare Bio-Sciences AB to GE Healthcare BioProcess R&D AB#page49.tif source=GE Healthcare Bio-Sciences AB to GE Healthcare BioProcess R&D AB#page50.tif source=GE Healthcare Bio-Sciences AB to GE Healthcare BioProcess R&D AB#page51.tif source=GE Healthcare Bio-Sciences AB to GE Healthcare BioProcess R&D AB#page52.tif source=GE Healthcare Bio-Sciences AB to GE Healthcare BioProcess R&D AB#page53.tif

> PATENT REEL: 062019 FRAME: 0229

source=GE Healthcare Bio-Sciences AB to GE Healthcare BioProcess R&D AB#page54.tif source=GE Healthcare Bio-Sciences AB to GE Healthcare BioProcess R&D AB#page55.tif source=GE Healthcare Bio-Sciences AB to GE Healthcare BioProcess R&D AB#page56.tif source=GE Healthcare Bio-Sciences AB to GE Healthcare BioProcess R&D AB#page57.tif source=GE Healthcare Bio-Sciences AB to GE Healthcare BioProcess R&D AB#page58.tif source=GE Healthcare Bio-Sciences AB to GE Healthcare BioProcess R&D AB#page59.tif source=GE Healthcare Bio-Sciences AB to GE Healthcare BioProcess R&D AB#page60.tif source=GE Healthcare Bio-Sciences AB to GE Healthcare BioProcess R&D AB#page61.tif source=GE Healthcare Bio-Sciences AB to GE Healthcare BioProcess R&D AB#page62.tif source=GE Healthcare Bio-Sciences AB to GE Healthcare BioProcess R&D AB#page63.tif source=GE Healthcare Bio-Sciences AB to GE Healthcare BioProcess R&D AB#page64.tif source=GE Healthcare Bio-Sciences AB to GE Healthcare BioProcess R&D AB#page65.tif source=GE Healthcare Bio-Sciences AB to GE Healthcare BioProcess R&D AB#page66.tif source=GE Healthcare Bio-Sciences AB to GE Healthcare BioProcess R&D AB#page67.tif source=GE Healthcare Bio-Sciences AB to GE Healthcare BioProcess R&D AB#page68.tif source=GE Healthcare Bio-Sciences AB to GE Healthcare BioProcess R&D AB#page69.tif source=GE Healthcare Bio-Sciences AB to GE Healthcare BioProcess R&D AB#page70.tif source=GE Healthcare Bio-Sciences AB to GE Healthcare BioProcess R&D AB#page71.tif source=GE Healthcare Bio-Sciences AB to GE Healthcare BioProcess R&D AB#page72.tif source=GE Healthcare Bio-Sciences AB to GE Healthcare BioProcess R&D AB#page73.tif source=GE Healthcare Bio-Sciences AB to GE Healthcare BioProcess R&D AB#page74.tif source=GE Healthcare Bio-Sciences AB to GE Healthcare BioProcess R&D AB#page75.tif source=GE Healthcare Bio-Sciences AB to GE Healthcare BioProcess R&D AB#page76.tif source=GE Healthcare Bio-Sciences AB to GE Healthcare BioProcess R&D AB#page77.tif source=GE Healthcare Bio-Sciences AB to GE Healthcare BioProcess R&D AB#page78.tif source=GE Healthcare Bio-Sciences AB to GE Healthcare BioProcess R&D AB#page79.tif source=GE Healthcare Bio-Sciences AB to GE Healthcare BioProcess R&D AB#page80.tif source=GE Healthcare Bio-Sciences AB to GE Healthcare BioProcess R&D AB#page81.tif source=GE Healthcare Bio-Sciences AB to GE Healthcare BioProcess R&D AB#page82.tif source=GE Healthcare Bio-Sciences AB to GE Healthcare BioProcess R&D AB#page83.tif source=GE Healthcare Bio-Sciences AB to GE Healthcare BioProcess R&D AB#page84.tif source=GE Healthcare Bio-Sciences AB to GE Healthcare BioProcess R&D AB#page85.tif source=GE Healthcare Bio-Sciences AB to GE Healthcare BioProcess R&D AB#page86.tif source=GE Healthcare Bio-Sciences AB to GE Healthcare BioProcess R&D AB#page87.tif source=GE Healthcare Bio-Sciences AB to GE Healthcare BioProcess R&D AB#page88.tif source=GE Healthcare Bio-Sciences AB to GE Healthcare BioProcess R&D AB#page89.tif source=GE Healthcare Bio-Sciences AB to GE Healthcare BioProcess R&D AB#page90.tif source=GE Healthcare Bio-Sciences AB to GE Healthcare BioProcess R&D AB#page91.tif source=GE Healthcare Bio-Sciences AB to GE Healthcare BioProcess R&D AB#page92.tif source=GE Healthcare Bio-Sciences AB to GE Healthcare BioProcess R&D AB#page93.tif

> PATENT REEL: 062019 FRAME: 0230

SCHEDULE 2.1.1(a) GE Healthcare Bio-Sciences AB and GE Healthcare BioProcess R&D AB Transferred Intellectual Property Rights



1. Transferred Intellectual Property Rights

1.1 Patents and patent applications

Patents and patent applications listed in Sub-Schedule 2.1.1(a)(i).

1.2 Trademarks and trademarks applications

Trademarks and trademarks applications listed in Sub-Schedule 2.1.1(a)(ii).

1.3 Registered designs and applications for design registrations

Registered designs and applications for design registrations listed in <u>Sub-Schedule</u> 2.1.1(a)(iii).

1.4 Copyrights and neighbouring rights

All copyrights and neighbouring rights attributable to the Chromatography Media Business, including but not limited to, the copyrights and neighbouring rights contained in the documents referred to in <u>Sub-Schedule 2.1.1(a)(iv)</u>.

1.5 Trade secrets and know-how

All trade secrets and know-how attributable to the Chromatography Media Business, including but not limited to, trade secrets and know-how contained in the documents referred to in <u>Sub-Schedule 2.1.1(a)(iy)</u>.

(A)

PATENT REEL: 062019 FRAME: 0232

SUB-SCHEDULE 2.1.1(a)(i) GE Healthcare Bio-Sciences AB and GE Healthcare BioProcess R&D AB Patents and patent applications



255,490	255490	245897	245897	227831	227831	227831	227831	227831	227831	175077	175077	175077	175077	176077	175077	175077	175077	175077	175077	175077	175077	175077	175077	175077	
4 PU1947	3 PU1247	4 PU:033	3,201033	9 PU0777	8 PU0777	7 PU0777	6 PU0777	5 PU6777	3 PU0777	18 PU0318	17 PU0318	16 PU0318	15 PU0318	14 PU0318	13 PU0516	11 PU0318	10, PU0318	8 PU0318	7 PU0318	6 PU0318	5 PU0318	4 FU9316	3 PU0318	2 PU0318	
CHROMATOGRAPHY MEDIA AND USE	CHROMATOGRAPHY MEDIA AND USE THEREOF	MOVEL CHELATOR AND USE THEREOF	NOVEL CHELATOR AND USE THEREOF	METHOD FOR PREPARATION OF A BIOMOLECULE ADSORBENT	BIOMOLECULE ADSORBENT	BIOMOLECULE ADSORBENT	METHOD FOR PREPARATION OF A	METHOD FOR PREPARATION OF A BIOMOLECULE ADSORBENT	METHOD FOR PREPARATION OF A	A METHOD OF GENERATING METAL CHELATING AFFINITY LIGANDS	A METHOD OF GENERATING METAL CHELATING AFFINITY LIGANDS	A METHOD OF GENERATING METAL CHELATING AFFINITY LIGANDS	A METHOD OF GENERATING METAL OHELATING AFFINITY LIGANDS	CHELATING AFFINITY LIGANDS	A METHOD OF GENERATING METAL CHELATING AFFINITY LIGANDS	A METHOD OF GENERATING METAL CHELATING AFFINITY LIGANDS	A METHOD OF GENERATING METAL CHELATING AFFINITY LIGANDS	METHOD OF GENERATING METAL CHELATING AFFINITY LIGANDS	A METHOD OF GENERATING METAL	CHELATING AFFINITY LIGANDS	CHELATING AFFINITY LIGANUS	A METHOD OF GENERATING METAL	OHELATING AFFINITY LIGANDS	A METHOD OF GENERATING METAL	
NON-CROSS LINKED GST	MON-CROSS LINKED GST MEDIA	DIMER PENTA DENTATE	DIMER PENTA DENTATE	PENTA DENTATE LIGAND	PENTA DENTATE LIGAND	PENTA DENTATE LIGAND	FENTA DENTATE LIGAND	PENTA DENTATE LIGAND	PENTA DENTATE LIGAND	COUPLED MAC LIGANDS	SYNTHESIS OF THIOL COUPLED MAC LIGANDS	SYNTHESIS OF THIOL COUPLED MAC LIGANDS	COUPLED MAC LIGANDS	COUPLED IMAC LIGANDS	SYNTHESIS OF THIOL COUPLED IMAC LIGANDS	COUPLED IMAC LIGANOS	SYNTHESIS OF THIOL COUPLED IMAC LIGANOS	SYNTHESIS OF THIOL COUPLED IMAC LIGANDS	SYNTHESIS OF THIOL COUPLED IMAC LIGANOS	COUPLED IMAC LIGANDS	COUPLED IMAC LIGANDS	SYNTHESIS OF THICL COUPLED IMAC LIGANDS	COUPLED IMAC LIGANDS	COUPLED IMAC LIGANDS	
<u>n</u>	Tiled.	Tiled	. E	issued	issued	issued	issued	issued	issued	issued	tssued	issued	ssued	issued	Esued	Esued	issued	issued	Filed	Issued	ssued	Issued	(ssued	Issued	
G G	æ.	US.	ļ	se C	ଞ୍ଚ	C C	F 70	EE EE	% %	F)	C 10	X)	m S	E E	2	X	Ž	2	CA S	AU 1	ъ́	S	ဓ္ဌ	m	
12/12/2014	17/12/2014	30/11/2012	20/11/2012	02/12/2009	02/12/2009	02/12/2009	02/12/2008	02/12/2009	22/12/2009	28/08/2005	28/08/2005	28/08/2005	28/08/2005	28/08/2005	28/08/2005	26/08/2005	26/06/2005	29/08/2005	25/08/2005	11/08/2005	08/12/2003	31/10/2093	30/10/2003	28/02/2003	
				2164591	2164591	602008024448.2	2164591	2164591	8999157	1597269	1597269	1597269	1597269	60331370.1	1697269	10-1060896	244848	2L209380110021 9		2003303976	5015426	7005071	2398782	526214	
14/407892	13603586.0	13/701074	11790086.0								-								2517231						
11/06/2033	11/06/2033	30/05/2031	30/05/2031	07/07/2028	07/07/2028	07/07/2028	07/07/2028	97/97/2028	29/10/2030	08/12/2023	08/12/2023	08/12/2023	08/12/2023	08/12/2020	08/12/2023	08/12/2023	08/12/2023	08/12/2023	08/12/2023	08/12/2023	08/12/2023	27/05/2024	30/10/2023	28/02/2023	
http://www.google.com/pa tents?yid=USPAT		http://www.google.com/pa tents/yid=USPAT							http://www.googla.com/pa tents/vid=USPAT699915 7													hitp://www.pcodie_com/ea tents?vid=USPAT700507 1			
GHBSAB BSAB	GHBSAB	GHBSAB	GHESAS	GHBSAB	OHBWAR	GHBSAB	GHBSAB	GHBSAB	GHESAB	GHBSAB	GHBSAB	GHBSAB	GHSSAB	GHBSAB	GHBSAB	GHBSAB	GHBSAB	SHBSAB	SHESAB	OHBSAR	GHBSAB	GHBSAB	GHBSAB	GHESAB	
													1			-	į		P	ΔTE	EN.	<u> </u> 			

Carris Carris

243604	243604	243604	243604	243604	238835	225849	225849	225849	225849	219100	219100	219099	
5:PU03114	4 PU09114	6 PU09114	3 PU09114	7 PU09114	8 PU0934	12 PU0720	11 PU0720	10 PU0720	8 PU0720	14 US CONZ	10 PU0674	9 PU0668	
METHOD FOR DRY PACKING CHROMATOGRAPHY COLUMNS	CHROMATOGRAPHY COLUMNS	CHROMATOGRAPHY COLUMNS	METHOD OF DRY PACKING OF CHROMATOGRAPHY COLUMNS	METHOD OF DRY PACKING OF CHROMATOGRAPHY COLUMNS	FILTER HOLDER IN A CHROMATOGRAPHY COLUMN	PACKING SYSTEM AND METHOD FOR CHROMATOGRAPHY COLUMNS	CHROMATOGRAPHY COLUMNS, SYSTEMS	CHROMATOGRAPHY COLUMNS, SYSTEMS AND METHODS	AXIAL CHROMATOGRAPHY COLUMNS AND METHODS				
DRY PACKING	DRY PACKING	DRY PACKING	DRY FACKING	DRY PACKING	FILTER HOLDER WITH CHANNELS	DISPOSABLE COLUMN PACKING METHOD	DISPOSABLE COLUMN PACKING METHOD	DISPOSABLE COLUMN PACKING METHOD	DISPOSABLE COLUMN PACKING METHOD	BOTTOMLESS	COLUMN	ASYMMETRIC	
T C	Filed	T C	Filed	Filed	THE Cd	T.	Filed.	Filed	Filed	Filed	Filed	Filed	
S)	CA	m	<u>.</u>	ž	Z	Ű	Ç Z	m m	Z	US.	Ē	Z	
21/06/2012	20/06/2012	19/06/2012	18/06/2012	21/05/2012	01/11/2011	10/05/2013	07/02/2013	30/10/2012	24/08/2009	15/04/2014	15/12/2008	12/12/2008	
13/518029	2785198	10839693.4	2012-545900	4408/DELNP/2012 20/12/2030	8451/DELNP/2011 10/05/2030	2013-100205	201310049327.3	12190564.0	5414/DELNP/2009 05/03/2028	14/252874	10333/DELNP/200	10314/DELNP/200	
20/12/2030	20/12/2030	20/12/2030	20/12/2030	12 20/12/2030	11 10/05/2030	05/03/2028	05/03/2028	05/03/2028	05/03/2028	16/07/2027	17/07/2027	17/07/2027	
<a href="http://www.googls.com/<br">patents?vid=USPAT>									i i i i	</a 			
GHBSAB	GHBSAB	GMBSAB	GHBSAB	GHBSAB	GHBSAB	СНВSAВ	GH8SAB	GHBSAB	GHBSAB	GHBSAB	GHBSAB	GHBSAB	
					i i i i i i				PATE	ENT		# b 5 6	

Carrie Green

244857 S.PU1020	244857 6 PU1020	244857 9 PU1020	244857 7 PU1020	244867 6 PU1020	244856 6 PU1019	244856 6 FU1019	244866 7 PU1019	244856 9 FU1019
A PARALLEL SEPARATION SYSTEM	A PARALLEL SEPARATION SYSTEM	A PARALLEL SEPARATION SYSTEM	A PARALLEL SEPARATION SYSTEM	A PARALLEL SEPARATION SYSTEM	A PARALLEL SEPARATION SYSTEM	A PARALLEL SEPARATION SYSTEM	A PARALLEL SEPARATION SYSTEM	A PARAILEL SEPARATION SYSTEM
A PARALLEL SEPARATION SYSTEM - SENSORS	A PARALLEL SEPARATION SYSTEM - SENSORS	A PARALLEL SEPARATION SYSTEM - SENSORS	A PARALLEL SEPARATION SYSTEM - SENSORS	A PARALLEL SEPARATION SYSTEM - SENSORS	A PARALLEIL SEPARATION SYSTEM - ADJUSTABLE RESTRICTORS	A PARALLEL SEPARATION SYSTEM - ADJUSTABLE RESTRICTORS	A PARALLEL SEPARATION SYSTEM ADJUSTABLE RESTRICTORS	SEPARATION SYSTEM - ADJUSTABLE RESTRICTORS
Filed	 	Filed.	E S	78 20	Filled	E C	Filed	E O O
2	m V	Č.	Z	'n	[]]	F	Ž	c C
29/10/2012	22/10/2012	01/10/2012	28/09/2012	18/09/2012	22/19/2012	28/09/2012	28/09/2012	27/09/2012
201180018011.7	11763152.3	13/638676	8483/DELNP/2012 30/03/2031	2013-602536	11763151.5	2013-502535	9486/DELNP/2012 30/03/2031	13/637744
30/03/2031	30/03/2031	30/03/2031	30/03/2031	30/03/2031	30/03/2031	30/03/2031	30/03/2031	30/03/2031
		<a href="http://www.google.com/<br">parants?vid=USPAT>					:	</a
GH8SAB	GHBSAB	GHBSAB	GHBSAB	GHBSAB	GHBSAB	GH8SAB	вухв	СНВЅАВ

284593	275630	273135	273134	265551	265660	245958	245958	245958	245968	
unde	2 PU1435	PU1034CI	PU091140	PU0720CI	PU0720CI	5 PU1034	6 PU1034	3 PU1034	4 PU1034	
Chromatography column modules with valves	STACKABLE CHROMATOGRAPHY COLUMN MODULES AND FLOW CONTROL BLOCKS	A PARALLEL ASSEMBLY OF CHROMATOGRAPY COLUMN MODULES	PACKING OF CHROMATOGRAPHY COLUMNS	PACKING SYSTEM AND METHOD FOR CHROMATOGRAPHY COLUMNS	PACKING SYSTEM AND METHOD FOR CHROMATOGRAPHY COLUMNS	A PARALLEL ASSEMBLY OF CHROMATOGRAPHY COLUMN MODULES	A PARALLEL ASSEMBLY OF CHROMATOGRAPHY COLUMN MODULES	A PARALLEL ASSEMBLY OF	A PARALLEL ASSEMBLY OF CHROMATOGRAPHY COLUMN MODULES	
				PRE-STERILIZED CHROMATOGRAP HY COLUMN	PRE-STERILIZED	PARALLEL ASSEMBLY - MODULAR COLUMN CONCEPT	PARALLEL ASSEMBLY - MODULAR COLUMN CONCEPT	PARALLEL ASSEMBLY - MODULAR COLUMN CONCEPT	PARALLEL ASSEMBLY MODULAR COLUMN CONCEPT	
Rated to	Filed	Filed	Filed	Tilled	Filed	Filed	Filed	Filed	Filed	
830	¥ O	US	CS CS	US	S	ট	US S	O Z	m O	
To be filed Dec 2015	WO 06/07/2015	29/05/2014	07/03/2014	09/11/2012	09/11/2012	04/04/2013	30/11/2012	30/11/2012	20/11/2012	
TBD	EP2015/065311	14/290367	14/201175	19/672832	13/672819	2013-513139	13/701251	201180026967.1	11790092.8	
		01/06/2031	20/12/2030	05/03/2028	05/03/2028	01/06/2031	01/06/2031	01/06/2031	01/06/2031	
		i≺a href=http://www.google.com/ patents?vid=USPAT>	</a 	<a href="http://www.google.com/<br">patents?vid=USPAT>	<a href="http://www.google.com/<br">patents?vid=USPAT>		<a <br="" http:="" www.google.com="">patents/vid=USPAT>			
GHBSAB	GHBSAB	онвеле	GHBSAB	GHESAB	CHBSAB	GHESAB	ЗАЗВНВ	GHESAB	днаѕ _м в	
L		<u> </u>	<u> </u>	<u> </u>	<u> </u>	<u> </u>	P/	ATENT		

173782	173706	173706	173706	173706	173706	173706	173705	173657	173651	173651	
8 PU9951	11 PU\$820	10 PU9820	9 PU9820	8 PU9820	6 PU9820	5 PU9820	8:987d S	7 PU0241	6 PU0235	2 PU0235	
A METHOD FOR ANION EXCHANGE ADSORPTION ON MATRICES CARRYING MIXED MODE LIGANDS	FÖRFARANDE FÖR SEPARATION PÅ KATJONBYTARE	METHOD FOR SEPARATION ON CATION EXCHANGERS	METHOD FOR SEPARATION ON CATION EXCHANGERS	METHOD FOR SEPARATION ON CATION EXCHANGERS	Cation exchanger requiring elevated elution (on strength	METHOD FOR SEPARATION ON CATION EXCHANGERS	METHOD FOR THE QUANTITATIVE RELEASE OF NATURAL OR RECOMBINANT PROTEINS, POLYPEPTIDES OR PEPTIDES	POST-MODIFICATION OF A	MACROPOROUS CROSS-LINKED POLYMER PARTICLES	MACROPOROUS CROSS-LINKED POLYMER PARTICLES	
A METHOD FOR ANION EXCHANGE	CATION EXCHANGER REQUIRING ELEVATED ELUTION ION STRENGTH	A METHOD FOR IMMUNOASSAYING BACTERIAL IGG BINDING PROTEINS	AGAROSE GRAFTING	MACROPOROUS DIVINYL	MACROPOROUS DIVINYL						
Issued	ksued	Issued	ssued	Issued	Issued	issued	issued	is sued	issued	Issued	
ਰੋ	Çĕ rn	00	70	DE .	ā	Ç	S	C C	D _m	÷	
22/11/2000	16/06/1999	16/06/1999	16/05/1939	16/06/1999	16/06/1999	16/06/1999	15/02/2001	25/05/2004	27/05/2003	27/05/2003	
5051957	1094899	1094899	1094899	69905720.5	4643006	2334980	6796486	7048658	80932013.9	4523408	
					!			:			
22/11/2020	16/06/2019	16/06/2019	16/06/2019	16/06/2019	16/06/2019	18/06/2019	14/05/2019	08/05/2023	27/05/2023	27/05/2023	
	_						<a http:="" www.googi<br="">href=http://www.googi e.com/patents?vid=U \$PAT6706496>67064 86	<a href="http://www.google.com/patents?vid=U<br">spAT7045858>70488			
GHBSAB	GHBSAB	GHBSAB	GHBSAB	GHBSAB	днв Заверена	GHBSAB	GHBSAB	GHBSAB	GHBSAB	GHBSAB	
		<u> </u>	:				P/	ATENT			

£

Pubsist Amethod For Amich	173989	173989	173989	173989	173989	173989	173989	173989	173989	173989	173989	173782	173782	173782	173782	
A METHOD FOR ANION EXCHANGE ADSORPTION ON A METHOD FOR ANION A METHOD FOR ANION A METHOD FOR ANION EXCHANGE ADSORPTION ON EXCHANGE ADSORPTION ON A METHOD FOR ANION EXCHANGE ADSORPTION ON EXCHANGE AC'YS EXCHANGE ADSORPTION EXCHANGE ADSORPTION ON EXCHANGE ADSORPTION	6 PU951618	14 20951618	13 20951618	12 PU951618	11 PU951618	10 PU951618	9 PU951818	8 20961618	4 PU951618	2 20051618	1 2095:618	<u>।</u> १८६९७५	12 PU9951	11 PU9951	10 PU9951	
NION Issued PR 22/11/2000 6:0046250.1 22/11/2020 NION Issued FR 22/11/2000 1235748 22/11/2020 NION Issued GB 22/11/2000 1235748 22/11/2020 Issued US 16/09/2002 6:702943 22/11/2020 Issued AJ 06/11/1996 7:9290 06/11/2016 Issued CA 06/11/1996 05/73353 06/11/2016 Issued GB 06/11/1996 05/73353 06/11/2016 Issued GB 06/11/1996 05/73353 06/11/2016 Issued GB 06/11/1996 05/73353 06/11/2016 Issued SE 06/11/1996 05/73353 06/11/2016	IGG SEPARATION MEDIUM	PROTEIN A-CYS	PROTEIN A-CYS	PROTEIN A-CYS	PROTEIN A-CYS	PROTEIN A-CYS	PROTEIN A-CYS	PROTEIN A-CYS	NOVEL PROTEIN A VARIANT	INDUSTRIAL INCOME THE REPORT OF THE REPORT O	PROTEIN A-CYS	METHOD FOR ANION-EXCHANGE ADSORPTION AND ANION- EXCHANGERS	A METHOD FOR ANION EXCHANGE ADSORPTION ON MATRICES CARRYING MIXED MODE LIGANDS	A METHOD FOR ANION EXCHANGE ADSORPTION ON MATRICES CARRYING MIXED MODE LIGANDS	A METHOD FOR ANION EXCHANGE ADSORPTION ON MATRICES CARRYING MIXED MODE LIGANDS	
DE 22/11/2000 60046250.1 22/11/2020 FR 22/11/2000 1236748 22/11/2020 GB 22/11/2000 1236748 22/11/2020 US 16/09/2002 6702943 22/11/2020 AU 06/11/1996 709290 06/11/2016 CA 06/11/1996 2236900 06/11/2016 CH 06/11/1996 0873353 06/11/2016 GB 06/11/1996 0873353 06/11/2016 GB 06/11/1996 0873353 06/11/2016 SE 06/11/1996 0873353 06/11/2016 SE 06/11/1996 0873353 06/11/2016 SE 06/11/1996 0873353 06/11/2016 US 09/06/1997 6399750 06/11/2016	RPROTEIN A-CYS	COUPLING	RPROTEIN A-CYS	RPROTEIN A-CYS	COUPLING	COUPLING	COUPLING			RPROTEIN A-CYS	COUPLING	A METHOD FOR ANION	A METHOD FOR ANION EXCHANGE	A METHOD FOR ANION EXCHANGE	A METHOD FOR ANION EXCHANGE	
22/11/2000 60046250.1 22/11/2020 22/	Issued	Issued	Ssued	issued	Issued	tssued	Issued	ssued	Issued	Issued	ssued	Issued	kss	Issued	lssued	
00 60046250.1 22/11/2020 00 1235748 22/11/2016 00 06/11/2016 00 06/11/2016 00 08/13353 26/11/2016 00 08/13353 26/11/2016 00 08/11/2016 00 08/11/2016 00 08/11/2016	US	S M	Z	E	ଜୁ	퓼	DE.	ç	ŧ	Ç _A	A	CS.	<u>G</u>	Ŧ	D	
0.1 22/11/2020 22/11/2020 22/11/2020 22/11/2020 22/11/2020 06/11/2016 06/11/2016 06/11/2016 06/11/2016 06/11/2016 06/11/2016 06/11/2016	09/06/1997	06/11/1996	06/11/1996	06/11/1396	06/11/1996	06/11/1996	06/11/1996	06/11/1996	06/11/1996	06/11/1996	06/11/1996	16/09/2002	22/11/2000	22/11/2000	22/11/2000	
	6399750	0873353	0873353	0873353	0873353	0873353	69629127.4	0873353	4117903	2236900	709290	6702943	1235748	1235748	60046250.1	
	06/11/2016	06/11/2016	06/11/2016	06/11/2016	06/11/2016	06/11/2016	06/11/2016	06/11/2016	06/11/2016	06/11/2016	06/11/2016	22/11/2020	22/11/2020	22/11/2020	22/11/2020	
4 - 6 -																
GHBSAB	GHBSAB	GHBSAB	GHBSAB	GHBSAB	GHBSAB	GHBSAB	GHBSAB	GHBSAB	GHBSAB	GHBSAB	GHBSAB	GHBSAB			GHBSAB	

174007	174007	174007	174007	173998	173997	173997	173997	173997	173997	
g PU961674	4 PU961674	2 PU961674	1 PU981674	4 PU951657	6 PUB61656	10 PU961656	9 20961656	8 PU961656	4 PU961656	
PROCESS FOR THE PRODUCTION OF A POROUS CROSS-LINKED POLYSACCHARIDE GEL	PROCESS FOR THE PRODUCTION OF A POROUS CROSS-LINKED POLYSACCHARIDE GEL	PROCESS FOR THE PRODUCTION OF A POROUS CROSS-LINKED POLYSACCHARIDE GEL	PROCESS FOR THE PRODUCTION OF A POROUS CROSS-LINKED POLYSACCHARIDE GEL	POLYHYDROXY POLYMERS SUBSTITUTED WITH STYRYL ETHER GROUPS AND GELS AND SURFACES PREPARED FROM THEM	PROCESS FOR CHROMATOGRAPHIC SEPARATION OF PEPTIDES AND NUCLEIC ACID, AND NEW HIGH AFFINITY ION EXCHANGE MATRIX TRIS-ANIEX	TRIS-ANION EXCHANGE	TRIS-ANION EXCHANGE	TRIS-ANION EXCHANGE	TRIS-ANION EXCHANGE	
HIGH FLOW AGAROSE	HIGH FLOW AGAROSE	HIGH FLOW AGAROSE	HIGH FLOW AGAROSE	STYRYL ETHERS	TRIS-ANIEX	TRIS-ANIEX	TRIS-ANIEX	TRIS-ANIEX	TRIS-ANIEX	
Ssued	Issued	benss	Issued	Sauced	issued	benssi	Issued	ssued	Issued	
2	- Fi	Ç	AU	GS.	Ç,	GB	THE RE	DE	5	-
07/04/1997	07/04/1997	07/04/1997	07/04/1997	11/05/1999	29/12/1998	14/02/1997	14/02/1997	14/02/1997	14/02/1997	
E261992	4081143	2251050	726086	6255395	6090288	0888157	0888157	69729182.0	4422797	
07/04/2017	07/04/2017	07/04/2017	07/04/2017	15/07/2018	14/02/2017	14/02/2017	14/02/2017	14/02/2017	14/02/2017	
				<a href="http://www.googl<br">e.com/patients/vid=U sPAT6255385>62553 85	ca href=http://www.googl e.com/patents?vid=U SPAT6090289>60902 88					
GHBSAB	GHBSAB	GHBSAB	GHBSAB	GHBSAB	GHBSAB	GHBSAB TEN	GHBSAB	GHBSAB	GHBSAB	

\$2.00° \$2.000

174007	174007	174007	174007	174007	174007	174007	174007	174007	17.4007	
18 PU961674	17 PU961674	16 PU961674	15 PU961674	14 PU961674	13 PU961674	12 PU961674	11 PU961674	10 PU961674	9 PU961674	
PROCESS FOR THE PRODUCTION OF A POROUS CROSS-LINKED POLYSACCHARIDE GEL	PROCESS FOR THE PRODUCTION OF A POROUS CROSS-LINKED POLYSACCHARIDE GEL	PROCESS FOR THE PRODUCTION OF A POROUS CROSS-LINKED POLYSACCHARIDE GEL	PROCESS FOR THE PRODUCTION OF A POROUS CROSS-LINKED POLYSACCHARIDE GEL	PROCESS FOR THE PRODUCTION OF A POROUS CROSS-LINKED POLYSACCHARIDE SEL	PROCESS FOR THE PRODUCTION OF A POROUS CROSS-LINKED POLYSACCHARIDE GEL	PROCESS FOR THE PRODUCTION OF A POROUS CROSS-LINKED POLYSACCHARIDE GEL	PROCESS FOR THE PRODUCTION OF A POROUS CROSS-LINKED POLYSACCHARIDE GEL	PROCESS FOR THE PRODUCTION OF A POROUS CROSS-LINKED POLYSACCHARIDE GEL	PROCESS FOR THE PRODUCTION OF A POROUS CROSS-LINKED POLYSACCHARIDE GEL	
HIGH FLOW AGAROSE	HIGH FLOW AGAROSE	HIGH FLOW AGAROSE	HIGH FLOW AGAROSE	HIGH FLOW AGAROSE	HIGH FLOW AGAROSE	MIGH FLOW AGAROSE	HIGH FLOW AGAROSE	HIGH FLOW AGAROSE	HIGH FLOW AGAROSE	
is sued	37 28 20 30 30	ssued	issued	issued	is sued	is used	Issued	issued	Ssued	
===	m	G G	 77 73	ms.	<u> </u>	C m		Ğ.	90 FR	
07/04/1997	07/04/1997	07/04/1997	07/04/1987	07/04/1997	07/04/1997	07/04/1997	07/04/1997	07/04/1997	07/04/1897	
69707BE2004	0892816	0892615	0892815	2217413	0892815	69728141.6	0892815	0892815	0892815	
07/04/2017	07/04/2017	07/04/2017	7102/2017	07/04/2017	07/04/2017	07/04/2017	07/04/2017	07/04/2017	07/04/2017	
GHSS8HO	GHBSAB	GHBSAB	GHBSAB	GH8SAB	GHBSAB	GHBSAB	GHBSAB PA	GHBSAB TENT	GHBSAB	

garii Januari Januari

174024	174023	174023	174023	174023	174023	174023	174023	174023	174022	174022	174007	174007	
1 PU971735	5 PU971734	14 PU971734	13 PU971734	10 PU971734	8 PU971734	7 PU971734	6 PU971734	2 PU971734	2 PU971732	14 PU971732	7 PU861674	19 PU961674	
PARTIAL ACTIVATION	PROCESS FOR INTRODUCING A	PROCESS FOR INTRODUCING A FUNCTIONALITY	PROCESS FOR INTRODUCING A	LOCK/LID MATRIX	ADSORPTION/SEPARTION METHOD AND A MEDIUM FOR ADSORPTION/ SEPARATION	AN ADSORPTION/SEPARTION METHOD AND A MEDIUM FOR ADSORPTION/ SEPARATION	PROCESS FOR THE PRODUCTION OF A POROUS CROSS-LINKED POLYSACCHARIDE GEL	PROCESS FOR THE PRODUCTION OF A POROUS CROSS-LINKED POLYSACCHARIDE GEL					
SURFACE	LID ACTIVATION	LID ACTIVATION	LID ACTIVATION	LID ACTIVATION	LID ACTIVATION	LID ACTIVATION	LID ACTIVATION	LID ACTIVATION	EBA BEADS WITH	EBA BEADS WITH EXTENDERS	HIGH FLOW AGAROSE	HIGH FLOW AGAROSE	
Issued	issued	benss	issued	issued	Issued	Issued	lssued	Issued	issued	Issued	tssued	beuted	
AU	S	(n)	<u></u>	SB	Ti Zi	ä	오	ħ	C.	က္ဆ	Č.	Z	_
04/03/1998	14/03/2000	04/03/1998	04/03/1998	04/03/1998	04/03/1998	04/03/1998	04/03/1998	04/03/1998	13/03/2000	03/02/1998	11/05/1999	07/04/1997	
729313	6426315	0966488	0966488	0966488	0966488	69836126.1	0966488	4368424	6428707	1003599	6602980	0892815	
04/03/2018	04/03/2018	04/03/2018	04/03/2018	04/03/2018	04/03/2018	04/03/2018	04/03/2018	04/03/2018	03/02/2018	03/02/2018	16/04/2019	07/04/2017	
	<a http:="" patents?vid="U<br" www.gcogle.com="">SPAT6426315>64263								64287		<a href="http://www.google.com/patents?vid=U<br">SPAT6602990>65029		
GHBSAB	GHBSAB	GHBSAB	GHBSAB	GHBSAB	GHBSAB	GHBSAB	GHBSAB	GHBSAB	GHBSAB	GHBSAB P/	GHBSAB ATENT	онв с на с на с на с на с на с на с на с на на с на на с на на с на на с на на с н с н е е н е е н е е е е е е е е е е е е е	

174673	174073	174073	174073	174048	174048	174029	174029	174029	174029	174029	174029	174029	174024	174024	174024	
3 PU0044	4 PU0044	5 PU0044	6 PU0044	12 PU0008	4 PU0008	4 50971767	12 PU971767	10 PU971767	9 PU971767	7 PU971767	6 PU971767	2 PU971767	7 PU971735	4 PU971735	2 PU971735	
ADSORPTION METHOD AND LIGANDS	A METHOD OF PRODUCING IGG	A METHOD OF PRODUCING IGG	COATED POLYMER ARTICLE AND	COATED POLYMER ARTICLE	MATRICES FOR SEPARATION AND SEPARATION EXPLOITING SAID MATRICES	PARTIAL ACTIVATION	MATRICES FOR SEPARATION AND SEPARATION EXPLOITING SAID MATRICES									
HIST CATION EXCHANGE	HSL CATION EXCHANGE	HSL CATION EXCHANGE	HSL CATION EXCHANGE	IGG-PREPARATION	IGG-PREPARATION	SOURCE	SOURCE	SOURCE	SOURCE	SOURCE	SOURCE	SOURCE	LID BEADS WITH NEUTRAL	SURFACE	LID BEADS WITH NEUTRAL	
Issued	Issued	Filed	issued	issued i	issued	ssued	ssued	Issued	Issued	issued	Issued	ssued	ssued	Issued	ssued	
٨٥	Š	m m	ঠ	US	28	S	E	G G	77	DE.	유	Ä	Us	Ę,	Ç _A	
16/12/2002	11/12/2002	09/12/2002	16/07/2001	09/12/2002	29/03/2001	22/12/1999	22/06/1998	22/06/1998	22/06/1998	22/06/1998	22/06/1998	22/06/1998	24/01/2000	04/03/1998	04/03/1998	
2001283945	2412586		5306568	8895379	PI0109740-7	6429028	1015107	1015107	1015107	69832502.8	1015107	4156675	6572766	4135812	2281846	
		01962857.7														
16/07/2021	16/07/2021	16/07/2021	16/07/2021	27/10/2021	06/01/2025	22/06/2018	22/06/2018	22/06/2018	22/06/2018	22/06/2016	22/06/2018	22/06/2018	04/03/2018	04/03/2018	04/03/2016	
				<a href="http://www.google.com/patents?vid=U<br">SPAT6835379>68363		<a http:="" nref="http://www.googli/e.com/patents?vid=U<br" www.googli="">SPAT6420028>64200							<a href="http://www.google.com/patents?vid=U<br">SPAT6572766>65727 66			
GHBSAB	GHBSAB	GHBSAB	GHBSAB	GHBSAB	GHBSAB	GHBSAB	GHBSAB	GHBSAB	GHBSAB	GHBSAB	GHBSAB	GHBSAB	GHBSAB PATENT	GHBSAB	GHBSAB	

Z....

174103	174103	174103	174103	174097	174097	174097	174097	174097	174073	
9 PU0081	8 PU0081	6 PU008:	# PU0061	2 PU0074	10 PU0074	9 PU0074	8 PU0074	7 PU0074	7 Pu0044	
METHOD OF PRODUCING POROUS SPHERICAL PARTICLES	METHOD OF PRODUCING POROUS SPHERICAL PARTICLES	METHOD OF PRODUCING POROUS SPHERICAL PARTICLES	METHOD OF PRODUCING POROUS SPHERICAL PARTICLES	A METHOD FOR ANION- EXCHANGE ADSORPTION AND THIOETHER ANION-EXCHANGERS HIGH SALT LIGANDS	A METHOD FOR ANION- EXCHANGE ADSORPTION AND MIXED MODE THIOETHER ANION EXCHANGERS THAT CAN BE USED IN THE METHOD	A METHOD FOR ANION- EXCHANGE ADSORPTION AND MIXED MODE THIOETHER ANION EXCHANGERS THAT CAN BE USED IN THE METHOD	A METHOD FOR ANION- EXCHANGE ADSORPTION AND MIXED MODE THIOETHER ANION EXCHANGERS THAT CAN BE USED IN THE METHOD	A METHOD FOR ANION- EXCHANGE ADSORPTION AND MIXED MODE THIOETHER ANION EXCHANGERS THAT CAN BE USED IN THE METHOD	ADSORPTION METHOD AND	
SPINNING DISK METHOD	SPINNING DISK METHOD	SPINNING DISK METHOD	SPINNING DISK METHOD	HIGH SALT LIGANDS	HIGH SALT LIGANDS	HIGH SALT LIGANDS	HIGH SALT LIGANDS	HIGH SALT LIGANDS	HSL CATION EXCHANGE	
Issued	pensa	Issued	issued	issued.	issued.	is sued	issued	penssi	Issued	
오	m m	Ğ	CA	<u> </u>	<u>ග</u>	70	D _m	G	CS.	
29/11/2000	29/11/2000	29/11/2000	29/11/2000	10/09/2002	22/11/2000	22/11/2000	22/11/2000	22/11/2000	20/12/2002	
1240497	1240497	5000059	2392811	7879244	1235749	1235749	80045558.0	4814467	7214321	
29/11/2020	29/11/2020	29/11/2020	29/11/2020	31/03/2026	22/11/2020	22/11/2020	22/11/2020	22/11/2020	17/02/2024	
				<a href="http://www.gcogle.com/patents?vid=U<br">SPAT7879244>78792 44					<a href="hitp://www.google.com/patents?vid=U<br">spA17214321>72143 21	
GHBSAB	GHBSAB	GHBSAB	GHBSAB	GHBSAB	OHBSAB	GHBSAB	İ	GHBSAB PATENT	GHBSAB	

digg.

174104	174104	174103	174103	174103	174103	174103	174103	174103	174103	174103	
4 PU0080	3 PU0080	7 PU0081	17 PU0081	16 PU0081	15 PU0081	14 PU0081	13 PU0081	12 PU0081	11 PU0081	10 PU0081	
METHOD AND DEVICE FOR PRODUCING A COHERENT LAYER OF EVEN THICKNESS OF LIQUID OR MELT ON A ROTATING DISK	METHOD AND DEVICE FOR PRODUCING A COMERENT LAYER OF EVEN THICKNESS OF LIQUID OR MELT ON A ROTATING DISK	METHOD OF PRODUCING POROUS SPHERICAL PARTICLES	METHOD OF PRODUCING POROUS SPHERICAL PARTICLES	METHOD OF PRODUCING POROUS SPHERICAL PARTICLES	METHOD OF PRODUCING POROUS SPHERICAL PARTICLES	METHOD OF PRODUCING POROUS SPHERICAL PARTICLES	METHOD OF PRODUCING POROUS SPHERICAL PARTICLES	METHOD OF PRODUCING POROUS SPHERICAL PARTICLES	METHOD OF PRODUCING POROUS SPHERICAL PARTICLES	METHOD OF PRODUCING PORCUS SPHERICAL PARTICLES	
SPINNING DISK DEVICE	SPINNING DISK DEVICE	SPINNING DISK METHOD	SPINNING DISK METHOD	SPINNING DISK METHOD	SPINNING DISK METHOD	SPINNING DISK METHOD	SPINNING DISK METHOD	SPINNING DISK METHOD	SPINNING DISK METHOD	SPINNING DISK METHOD	
Issued	lssued.	Ssueo.	Issued	seuec	Seussi	issued	Issued	Issued	Issued	Ssued	
£	w m	US	S	ž.	Œ	=	် ကို	T P	ES.	O _E	
29/11/2000	29/11/2000	16/09/2002	29/11/2009	29/11/2000	29/11/2000	29/11/2000	29/11/2000	29/11/2000	29/11/2000	29/11/2000	
1233833	1233833	6941097	1240497	1240497	1240497	1240497	1240497	1240497	1240497	60029368.2	
29/11/2020	29/11/2020	06/10/2021	29/11/2020	29/11/2020	29/11/2020	29/11/2020	29/11/2020	29/11/2020	29/11/2020	29/11/2020	
		<a href="http://www.google.com/patents?vid=U<br">SPAT6841097>68410									
GHBSAB	GHBSAB	GHBSAB	GHBSAB	GHBSAB	GHBSAB	GHBSAB	GHBSAB P	GHESAB ATEN	GHBSAB VT	GHESAB	

174104	174104	174104	174104	174104	174104	174104	174104	
15 PU0080	12 PU0080	11 Pub080	10 PU0080	0800Nd 6	7 PU0080	6 PU0080	5 PU0080	
METHOD AND DEVICE FOR PRODUCING A COHERENT LAYER OF EVEN THICKNESS OF LIQUID OR MELT ON A ROTATING DISK	METHOD AND DEVICE FOR PRODUCING A COMERENT LAYER OF EVEN THICKNESS OF LIQUID OR MELT ON A ROTATING DISK	METHOD AND DEVICE FOR PRODUCING A COHERENT LAYER OF EVEN THICKNESS OF LIQUID OR MELT ON A ROTATING DISK	METHOD AND DEVICE FOR PRODUCING A COHERENT LAYER OF EVEN THICKNESS OF LIQUID OR MELT ON A ROTATING DISK	METHOD AND DEVICE FOR PRODUCING A COHERENT LAYER OF EVEN THICKNESS OF LIQUID OR MELT ON A ROTATING DISK	METHOD AND DEVICE FOR PRODUCING A COHERENT LAYER OF EVEN THICKNESS OF LIQUID OR MELT ON A ROTATING DISK	METHOD AND DEVICE FOR PRODUCING A COHERENT LAYER OF EVEN THICKNESS OF LIQUID OR MELT ON A ROTATING DISK	METHOD AND DEVICE FOR PRODUCING A COHERENT LAYER OF EVEN THICKNESS OF LIQUID OR MELT ON A ROTATING DISK	
SPINNING DISK DEVICE	SPINNING DISK DEVICE	SPINNING DISK DEVICE	SPINNING DISK DEVICE	SPINNING DISK DEVICE	SPINNING DISK DEVICE	SPINNING DISK DEVICE	SPINNING DISK DEVICE	
ssued	beness	is sued	ssued	issued	is succession	issued	issued	
Ş	(s m	Z	=	G G	뭇	0,	<u></u>	_
29/11/2000	29/11/2000	29/11/2000	29/11/2000	29/11/2000	29/11/2000	29/11/2000	29/11/2000	
2394369	1233833	1233833	1233833	1233833	1233835	60015597.8	1233833	
29/11/2020	29/11/2020	29/11/2020	29/11/2020	29/11/2020	29/11/2020	29/11/2020	29/11/2020	
Gнезав	GHBSAB	GHESAB	Снвяле	СНВЅАВ	GH8SA8	GHBSSAB PATENT	CHBSAB	

174104	174104	174104	174104	174104	174104	174104	174104	
S	2	200	<u> </u>	90	ග්	. S	कं	
22 PU0080	21 PU0080	20 PU0090	0800Nd 61	PU0080	18 PU0080	23 PU0080	16 PU0080	
METHOD AND DEVICE FOR PRODUCING A COHERENT LAYER OF EVEN THICKNESS OF LIQUID OR MELT ON A ROTATING DISK	METHOD AND DEVICE FOR PRODUCING A COHERENT LAYER OF EVEN THICKNESS OF LIQUID OR MELT ON A ROTATING DISK	METHOD AND DEVICE FOR PRODUCING A COHERENT LAYER OF EVEN THICKNESS OF LIQUID OR MELT ON A ROTATING DISK	METHOD AND DEVICE FOR PRODUCING A COHERENT LAYER OF EVEN THICKNESS OF LIQUID OR MELT ON A ROTATING DISK	METHOD AND DEVICE FOR PRODUCING A COHERENT LAYER OF EVEN THICKNESS OF LIQUID OR MELT ON A ROTATING DISK	METHOD AND DEVICE FOR PRODUCING A COHERENT LAYER OF EVEN THICKNESS OF LIQUID OR MELT ON A ROTATING DISK	METHOD AND DEVICE FOR PRODUCING A COHERENT LAYER OF EVEN THICKNESS OF LIQUID OR MELT ON A ROTATING DISK	METHOD AND DEVICE FOR PRODUCING A COHERENT LAYER OF EVEN THICKNESS OF LIQUID OR MELT ON A ROTATING DISK	
SPINNING DISK DEVICE	SPINNING DISK DEVICE	SPINNING DISK DEVICE	SPINNING DISK DEVICE	SPINNING DISK DEVICE	SPINNING DISK DEVICE	SPINNING DISK DEVICE	SPINNING DISK DEVICE	
Issued	is sued	Decress:	benssi	ssued	penss	ssued	Issued	
CS CS	999 	0	Ö	£	Ç,	77	ซี	
02/11/2004	02/11/2004	02/11/2004	02/11/2004	02/11/2004	21/08/2002	29/11/2000	29/11/2000	
1502854	1502654	1502654	60042502.9	1502654	6843427	1233833	4993154	
29/11/2020	29/11/2020	29/11/2020	29/11/2020	29/11/2020	25/07/2021	29/11/2020	29/11/2020	
					<a href="http://www.google.com/patents?vid=U<br">SPAT6843427>68434 27			
GHBSAB	GHBSAB	GHBSAB	GHBSAB	GHBSAB	онвсав	GHBSAB PATENT	GHBSAB	

174844	174134	174134	174134	174134	174134	174:21	174121	174105	174105	174105	174104	
3 PU0160	9 PU0115	12 PU0115	10 PU0115	8 PU0115	2 PU0115	4 PI.9767	2 PL9767	9 PU0085	4 PU0085	3 PU0085	14 PU0080	
GENERATION OF ION EXCHANGER MEDIA	ISOLATION OF DNA MOLECULES	MOLECULES MOLECULES	ISOLATION OF PLASMID DNA MOLECULES	MOLECULES MOLECULES	MOLECULES MOLECULES	VON WILLEBRAND FACTOR (VWF) CONTAINING PREPARATION PROCESS FOR PREPARATIONS CONTAINING PREPARATIONS AND USE OF SUCH PREPARATIONS	VON WILLEBRAND FACTOR (VWF) CONTAINING PREPARATION PROCESS FOR PREPARING VWF- CONTAINING PREPARATIONS AND USE OF SUCH PREPARATIONS	METHOD FOR MIXED MODE	A METHOD FOR MIXED MODE ADSORPTION AND MIXED MODE ADSORBENTS	A METHOD FOR MIXED MODE ADSORPTION AND MIXED MODE ADSORBENTS	METHOD AND DEVICE FOR PRODUCING A COHERENT LAYER OF EVEN THICKNESS OF LIQUID OR MELT ON A ROTATING DISK	
SCAFFOLD FOR HSL- PREPARATION	PLASMID SELECT LIGANDS	PLASMID SELECT LIGANDS	PLASMID SELECT LIGANDS Issued	PLASMID SELECT LIGANDS	PLASMID SELECT LIGANDS	WWF-MULTIMER	VWF-MULTIMER	STOCHASTIC HSL	STOCHASTIC HSL	STOCHASTIC HSL	SPINNING DISK DEVICE	
issued	issued	issued	issued	lssued	Issued	Issued	Issued	losued	issued	issued	Issued	
ΑU	Ç,	75	D _E	ซึ่	G G	<u>ස</u>	8	us	Ç _A	È	CS.	-
12/09/2002	25/09/2003	15/04/2002	15/04/2002	15/04/2002	12/04/2002	14/12/1998	11/12/1996	19/06/2003	17/12/2001	17/12/2001	15/12/2004	
2002334542	6916919	1379645	60236789.1	4081376	2377447	0934748	6531577	7008542	2431012	2002235786	7341202	
12/09/2022	15/04/2022	15/04/2022	15/04/2022	15/04/2022	12/04/2022	14/12/2018	11/12/2018	08/08/2022	17/12/2021	17/12/2021	25/07/2021	
	<a http:="" www.googi<br="">e.com/patents?vid≠U SPA16916919>69169						<a href="http://www.googi<br">e.com/patents?vid=U SPAT6531577>65315	<a href="http://www.googi<br">href=http://www.googi e.com/patents?vid=U SPAT7008542>70085			734120202>734120202>734120202>734120202>73412000000000000000000000000000000000000	
GHBSAB	GHBSAB	GHBSAB	GHBSAB	CHESAS	GHBSAB	GH8SAB	CHBSAB	GHBSAB	GHBSAB PAT	GHBSAB ENT	GHBSAB	

174932	174932	174910	174909	174844	174844	174844	174844	174844	174844	174844	174844	174844	174844	174844	174844	174844	174844	
4 PU0215	1 PU0215	3 PU0195	3 PU0201	5 PU0160	9 Puo160	8 PU0160	18 PU0160	17 PU0160	16 PU0160	15 PU0160	14 PU0160	13 PU0160	12 PU0160	11 PU0160	10 PU0160	7 PU0160	4 PU0160	
A MUTATED IMMUNOGLOBULIN- BINDING PROTEIN	A MUTATED IMMUNOGLOBULIN- BINDING PROTEIN	SEPARATION METHOD	METHOD OF PRODUCING HIERARCHICAL POROUS BEADS	GENERATION OF ION EXCHANGER MEDIA	GENERATION OF ION EXCHANGER MEDIA	GENERATION OF ION EXCHANGER MEDIA	GENERATION OF ION EXCHANGER MEDIA	GENERATION OF ION EXCHANGER MEDIA	GENERATION OF ION EXCHANGER MEDIA	GENERATION OF ION EXCHANGER MEDIA	EXCHANGER MEDIA	GENERATION OF ION EXCHANGER MEDIA	GENERATION OF ION EXCHANGER MEDIA	GENERATION OF ION EXCHANGER MEDIA	GENERATION OF ION EXCHANGER MEDIA	GENERATION OF ION EXCHANGER MEDIA	GENERATION OF ION EXCHANGER MEDIA	
CIP-STABLE PROTEIN A- LIGAND	CIP-STABLE PROTEIN A-	CATION-PI INTERACTION BASED CHROMATOGRAPHY	HIERARCHICAL PORE STRUCTURES IN BEADS USING TEMPLATING PARTI	SCAFFOLD FOR HSL- PREPARATION	SCAFFOLD FOR HSL- PREPARATION	PREPARATION	PREPARATION	PREPARATION	PREPARATION	PREPARATION	PREPARATION	PREPARATION	SCAFFOLD FOR HSL- PREPARATION	PREPARATION	PREPARATION	SCAFFOLD FOR HSL- PREPARATION	PREPARATION	
lesued	Issued	Issued	IS Support	Issued	Issued	Issued	Issued	Issued	Issued	Issued	ksued	Issued	Issued	Issued	Issued	lssued d	Issued	
ΑU	Ž	US.	င် တ	S	CS.	N	co m	2	C	7	GB	ק	es S	E E	£	Ğ	Ç	
20/03/2003	20/03/2003	21/06/2004	30/06/2004	12/03/2004	10/03/2004	11/02/2004	12/09/2002	12/09/2002	12/09/2002	12/09/2002	12/09/2002	12/09/2002	12/09/2002	12/09/2002	12/09/2002	12/09/2002	12/09/2002	
2003217119	10-1067181	8138306	7074335	ZL02817837.8	7067059	531094	1425092	1425092	1425092	1425092	1425092	1425092	1425092	60224685.7	1425092	4188632	2460355	
20/03/2023	20/03/2023	11/01/2025	21/07/2023	12/09/2022	26/04/2023	12/09/2022	12/09/2022	12/09/2022	12/09/2022	12/09/2022	12/09/2022	12/09/2022	12/09/2022	12/09/2022	12/09/2022	12/09/2022	12/09/2022	
		<a href="http://www.google.com/patents?vid=U<br">SPAT8138306>81383 06																

£

174932	174932	174932	174932	174932	174932	174932	174932	174932	174932	174932	174932	174932	
10 PU0215	21 PU0215	20 PU0215	19 PU0216	18 PU0215	17 PU0215	16 PU0215	15 PU0215	14 PU0215	13 PU0215	9 PU0215	8 PU0215	5 PU0215	
A MUTATED IMMUNOGLOBULIN- BINDING PROTEIN	MUTANT PROTEINA MUTATED RAMUNOGLOBULIN-BINDING PROTEIN	MUTANT PROTEINA MUTATED IMMUNOGLOBULIN-BINDING PROTEIN	MUTANT PROTEINA MUTATED RAMUNOGLOBULIN-BINDING PROTEIN	MUTANT PROTEINA MUTATED IMMUNOGLOBULIN-BINDING PROTEIN	MUTANT PROTEINA MUTATED INMMUNOGLOBULIN-BINDING PROTEIN	MUTANT PROTEINA MUTATED INAMUNOGLOBULIN-BINDING PROTEIN	MUTANT PROTEINA MUTATED IMMUNOGLOBULIN-BINDING PROTEIN	MUTANT PROTEINA MUTATED IMMUNOGLOBULIN-BINDING PROTEIN	MUTANT PROTEINA MUTATED IMMUNOGLOBULIN-BINDING PROTEIN	A MUTATED IMMUNOGLOBULIN- BINDING PROTEIN	A MUTATED IMMUNOGLOBULIN- BINDING PROTEIN	A MUTATED IMMUNOGLOBULIN- BINDING PROTEIN	
CIP-STABLE PROTEIN A-	CIP-STABLE PROTEIN A- LIGAND	CIP-STABLE PROTEIN A- LIGAND	CIP-STABLE PROTEIN A- LIGAND	CIP-STABLE PROTEIN A- LIGAND	CIP-STABLE PROTEIN A-	CIP-STABLE PROTEIN A- LIGAND	CIP-STABLE PROTEIN A- LIGAND	CIP-STABLE PROTEIN A- LIGAND	CIP-STABLE PROTEIN A- LIGAND	CIP-STABLE PROTEIN A- LIGAND	CIP-STABLE PROTEIN A-	CIP-STABLE PROTEIN A-	
is subsection of the section of the	ssued	Issued	Issued	penss	lssued	periss	fssued	Senso	Issued	lssued	issued	Issued	
C.	rg m	Z	<u> </u>	- 3	GB GB	Ŋ	m Ø	<u> </u>	ç £	Ť	Z	္အ	
20/09/2064	20/03/2003	20/03/2003	20/03/2003	20/03/2003	20/03/2003	20/03/2003	20/03/2003	20/03/2903	20/03/2003	20/03/2003	20/03/2003	20/03/2003	
7834158	1485407	1485407	1485407	1485407	1485407	1485407	1485407	80327608.7	1485407	4391830	255084	2479896	
21/02/2025	20/03/2023	20/03/2023	20/03/2023	20/03/2023	20/03/2023	20/03/2023	20/03/2023	20/03/2023	20/03/2023	20/03/2023	20/03/2023		
<a href="http://www.google.com/patents?vid=U<br">SPAT7834158>7834158													
GHBSAB	GHBSAB	GHBSAB	GHBSAB	GHBSAB	GHBSAB	GHBSAB	GHBSAB	GHBSAB P/	GHBSAB ATEN	GHBSAB	GHBSAB	GHBSAB	

174972	174943	174943	174943	174943	174932	174932	174932	174932	174932	174932	174932	174932	174932	174932	
1 PU0264	6 PU0225	8 Pu0225	4 PU0225	5 PU0225	92 US DIV	31 PU0215	30 PU0215	29 PU0215	PU0215- 28 US CON2	PU0215 27 CN Div5	22 PU0215	11 PU0215- US CON	12 PU0215	6 PU0215	
CHROMATOGRAPHIC TWO-	MANUFACTURE OF POLYSACOHARIDE BEADS	MANUFACTURE OF POLYSACCHARIDE BEADS	MANUFACTURE OF POLYSACCHARIDE BEADS	MANUFACTURE OF POLYSACCHARIDE BEADS	A MUTATED IMMUNOGLOBULIN- BINDING PROTEIN	A MUTATED IMMUNOGLOBULIN-	A MUTATED IMMUNOGLOBULIN- BINDING PROTEIN	A MUTATED IMMUNOGLOBULIN- BINDING PROTEIN	MUTANT PROTEINA MUTATED IMMLINOGLOBULIN-BINDING PROTEIN	A MUTATED IMMUNOGLOBULIN- BINDING PROTEIN					
2-PHASE PREPARATION OF LID BEADS	OLYCOL ADDITION IN POLYSACCHARIDE BEAD PREPARATION	GLYCOL ADDITION IN PREPARATION	GLYCOL ADDITION IN POLYSACCHARIDE BEAD PREPARATION	GLYCOL ADDITION IN POLYSACCHARIDE BEAD PREPARATION	CIP-STABLE PROTEIN A- LIGAND	CIP-STABLE PROTEIN A. LIGAND	CIP-STABLE PROTEIN A- LIGAND	CIP-STABLE PROTEIN A- LIGAND	CIP-STABLE PROTEIN A- LIGAND	CIP-STABLE PROTEIN A- LIGAND	CIP-STABLE PROTEIN A- LIGAND	CIP-STABLE PROTEIN A- LIGAND	CIP-STABLE PROTEIN A.	CIP-STABLE PROTEIN A- LIGAND	
Ssued	benss	Issued	ssued	Filed	Filed.	Issued	beussi	Filed.	THE CO.	Issued	tssued	Issued	Filed	issued	
Çi,	ç G	US	Ç	m	CS.	Š	ž	ž	CS S	2	X	US.	m	Q Z	2
23/02/2005	25/10/2004	21/10/2004	23/09/2004	06/09/2004	04-SEP-15	01/11/2012	01/11/2012	18/10/2012	05/06/2012	29/11/2011	29/11/2010	08/10/2010	10/03/2008	23/09/2004	
7208093	4874525	7341682	2480313			10-1307714	10-1307651			ZL201110407 855.2	10-1307700	8198404		ZL03806793.5	
				63721217.2	14/645617			9070/DELNP/ 2012	13/488562				08004374.8		
11/05/2024	17/04/2023	08/10/2024	17/04/2023	17/04/2023		20/03/2023	20/03/2023	20/03/2023	20/03/2023	20/03/2023	20/03/2023	21/02/2025	20/03/2023	20/03/2023	
<a http:="" patents?vid="U<br" www.google.com="">SPAT7208093>72080		<a href="http://www.google.com/patents?vid=U<br">SPAT7341682>73416										<a href="http://www.google.com/patents?vid=U<br">SPAT8198404>81984			
GHBSAB	GHBSAB	GHBSAB	GHESAB	GHBSAB	GHBSAB	GHBSAB	GHBSAB	GHBSAB	GHBSAB	GHBSAB	GHBSAB	GHBSAB PATENT	GHBSAB	GHBSAB	

175206	175206	175206	175206	175206	175206	175158	175084	175084	176049	175038	174972	174972	
8 PU03100	15 PU03100	13 PU03100	12 PU03100	11 PU03100	10 PU03100	5 200366	4 PU0326	3 PU0326	3 Pu02103	3 PU0297	10 PU0264	5 PU0264	
PURIFICATION OF	PURIFICATION OF	PURIFICATION OF IMMUNOGLOBULINS	PURIFICATION OF IMMUNOGLOBULINS	PURIFICATION OF IMMUNOGLOBULINS	PURIFICATION OF IMMUNOGLOBULINS	MATRIX FOR SEPARATION OF POLYETHERS AND METHOD OF SEPARATION	A METHOD OF PREPARING MULTI MODAL ANION-EXCHANGE LIGANDS	METHOD OF PREPARING MULTI- MODAL ANION-EXCHANGE LIGANDS	USE OF UREA VARIANTS AS	ISOLATION OF ANTISENSE	CHROMATOGRAPHIC TWO- LAYER PARTICLES	CHROMATOGRAPHIC TWO:	
SULPHONAMIDES	SULPHONAMIDES	SULPHONAMIDES	SULPHONAMIDES	SULPHONAMIDES	SULPHONAMIDES	HYDROGEN BOND OF PEG	SYNTHESIS OF ANION - EXCHANGE LIGANDS USING HOMOCYSTEINE THIOL	SYNTHESIS OF ANION EXCHANGE LIGANDS USING HOMOCYSTEINE	LIGAND 1250 TO IGG BINDING POCKET	IMAC-ISOLATION OF ANTISENSE OLIGONUCLEOTIDES	2-PHASE PREPARATION OF LID BEADS	2-PHASE PREPARATION OF LID BEADS	
fssued	Issued	Ssued	issued	issued	issued	issued	Issued	benssi	Issued	Issued	Issued	Issued	
Š		<u>င့</u>	Æ	DE .	웃	55	ç G	US.	CS.	C%	68	JP	
21/06/2006	12/05/2006	12/05/2006	12/05/2006	12/05/2006	12/05/2006	21/07/2009	05/09/2005	29/08/2005	18/04/2005	19/05/2005	27/02/2005	27/02/2006	
ZL200480038 282.9	1697416	1697416	1697416	60200401304 0.0	1697416	8092682	4629660	7320754	7645903	7368561	1558927	4424669	
21/12/2024	21/12/2024	21/12/2024	21/12/2024	21/12/2024	21/12/2024	26/09/2025	05/03/2024	26/04/2023	25/01/2026	28/09/2024	18/08/2023	18/08/2023	
						<a http:="" patents?vid="U<br" www.google.com="">SPAT8092682>80926		<a href="http://www.google.com/patents?vid=U<br">SPAT7320754>7320754	<a href="http://www.google.com/patents?vid=U<br">SPAT7645903>76469	<a href="http://www.google.com/patents?vid=U<br">SPAT7368561>73685			
GHBSAB	GHESAB	GHBSAB	GHBSAB	GHSSAB	GHBSAB	GHBSAB	GHBSAB	GHBSAB	GHBSAS PA	GHBSAB ATENT	GHBSAB	GHBSAB	

Emm. Emm.

175221	175220	175220	175220	175220	175220	175220	175220	175220	175220	175206	175206	
4 PU0407	7 PU0406	3 PUQ406	5 PU0406	11 PU0406	4 PU0406	14 PU0406	13 PU0406	6 PU0408	10 PU0406	PU03100- 5 US DIV	3 PU03100	
PLASMID PURIFICATION	ANTIBODY PURIFICATION	ANTIBODY PURIFICATION	ANTIBODY PURIFICATION	ANTIBODY PURIFICATION	ANTIBODY PURIFICATION	ANTIBODY PURIFICATION	ANTIBODY PURIFICATION	ANTIBODY PURIFICATION	ANTIBODY PURIFICATION	PURIFICATION OF	PURIFICATION OF IMMUNOGLOBULINS	
PLASMID SEPARATION ON SEPHACRYL	MAB PURIFICATION AND LEAKAGE REMOVAL ON HSL	MAB PURIFICATION AND LEAKAGE REMOVAL ON HSL	MAB PURIFICATION AND LEAKAGE REMOVAL ON HSL	MAB PURIFICATION AND LEAKAGE REMOVAL ON HSL	MAB PURIFICATION AND LEAKAGE REMOVAL ON	MAB PURIFICATION AND LEAKAGE REMOVAL ON HSL	MAB PURIFICATION AND LEAKAGE REMOVAL ON HSL	MAB PURIFICATION AND LEAKAGE REMOVAL ON HSL	MAB PURIFICATION AND LEAKAGE REMOVAL ON HSL	SULPHONAMIDES	SULPHONAMIDES	
issued	issued	issued	issued	issued	Issued	lestred	Issued	Issued	ssued	issued	ssued	
S	Š	ģ	è	ž	C S	င္ဟ	D D	Ç	27	CS CS	÷ G	
16/08/2006	28/08/2006	28/08/2006	27/08/2006	25/08/2006	16/08/2006	24/07/2008	24/07/2006	06/07/2006	28/06/2006	22/02/2010	23/06/2006	
8093373	ZL200580006 267.0	4776615	2005217348	10-1149969	7385040	1718668	60200501622 0.8	2552823	257665	8685248	4739233	
					,							
26/09/2028	24/02/2025	24/02/2025	24/02/2025	24/02/2025	24/03/2025	24/02/2025	24/02/2025	24/02/2025	24/02/2025	01/12/2027	21/12/2024	
<a href="http://www.google.com/patents?vid=U<br">SPATE093373>60933					73850					<a href="http://www.googlenref=http://www.googlenref=http://www.googlenref=U<br">e.com/patents?vid=U SPAT6685248>86652 48		
GH8SAB	GHBSAB	GHBSAB	GHBSAS	GHESAB	GHBSAB	GHBSAB	GHBSAB	GHBSAB	GHBSAB PATE	GHBSAB NT	GHBSAB	

175284	175284	175284	175284	175280	175260	175260	175260	175260	175237	175237	175237	175237	
10 PU0450	7 PU0450	9 PU0450	2 PU0450	PU0235CI	7 PU0429	3 PU0429	4 PU0429	8 PU0429	3 PU0418	10 PU0418	9 PU0418	8 PU0418	
METHOD OF PREPARING A CHROMATOGRAPHY MATRIX	METHOD OF PREPARING A CHROMATOGRAPHY MATRIX	METHOD OF PREPARING A CHROMATOGRAPHY MATRIX	METHOD OF PREPARING A	METHOD OF PRODUCING MACROPOROUS CROSS-LINKED POLYMER PARTICLES	SEPARATION MATRIX AND METHOD OF PURIFICATION	METHOD OF PURIFICATION	SEPARATION MATRIX AND METHOD OF PURIFICATION	SEPARATION MATRIX AND METHOD OF PURIFICATION	A METHOD FOR CHROMATOGRAPHIC PURIFICATION				
HFA BY CHEMICAL MODIFICATION OF THE AGAROSE	HEA BY CHEMICAL MODIFICATION OF THE AGAROSE	HFA BY CHEMICAL MODIFICATION OF THE AGAROSE	HFA BY CHEMICAL MODIFICATION OF THE AGAROSE	DIVINYL ETHERS	AROMATIC SULPHONAMIDES	SULPHONAMIDES	AROMATIC	AROMATIC SULPHONAMIDES	PEG ADDITIVE	PEG ADDITIVE	PEG ADDITIVE	PEG ADDITIVE	
issued	issued	Filed	ssued	panss	issued	issued	issued	File G	issued	issued	Issued	Issued	
Z	Ş	m m	S	CS.	2	ਹੋ	Ç,	m U	ซึ่	GB GB	T)	Om Om	
27/02/2007	19/02/2007	15/02/2007	13/10/2004	09/08/2004	25/12/2006	22/12/2006	13/12/2006	24/11/2006	02/10/2006	15/09/2006	15/09/2006	15/09/2006	
264448	2577822		7396467	7146264	ZL200580020 972.6	4890453	8114280		4831697	1729867	1729867	60200802437 3.9	
		05787430.7						05754914.9	-				
21/09/2025	21/09/2025	21/09/2025	08/03/2025	27/05/2023	22/06/2025	22/06/2025	23/01/2028	22/06/2025	31/03/2025	31/03/2025	31/03/2025	31/03/2025	
			<a href="http://www.google.com/patents?vid=U<br">SPAT7396467>73964	<a http:="" patents?vid="U" spat7148264="" www.google.com="">71482			<a http:="" patents?vid="U<br" www.google.com="">SPAT8114280>81142						
GHBSAB	GHBSAB	GHBSAB	GHBSAB	GHBSAB	GHBSAB	GHBSAB	GHBSAB	GHBSAB	GHBSAB PA	GHBSAB TEN	GHBSAB T	GHBSAB	



175294	175294	175294	175294	175294	175294	175294	175284	175284	175284	175284	175284	175284	
7 PU0460	11 PU0460	3 PU0460	4 PU0480	5 PU0460	6 PU0460	10 PU0460	11 PU0450	5 PU0450	6 PU0450	8 PU0450	4 PU0450	12 PU0450	
ANTIBODY PURIFICATION TECHNIQUE	A PROCESS FOR THE PURIFICATION OF ANTIBODIES	A PROCESS FOR THE PURIFICATION OF ANTIBODIES	PROCESS FOR THE PURIFICATION OF ANTIBODIES	A PROCESS FOR THE PURIFICATION OF ANTIBODIES	A PROCESS FOR THE PURIFICATION OF ANTIBODIES	A PROCESS FOR THE PURIFICATION OF ANTIBODIES	METHOD OF PREPARING A	METHOD OF PREPARING A CHROMATOGRAPHY MATRIX	METHOD OF PREPARING A CHROMATOGRAPHY MATRIX	METHOD OF PREPARING A	METHOD OF PREPARING A CHROMATOGRAPHY MATRIX	METHOD OF PREPARING A CHROMATOGRAPHY MATRIX	
MAB PURIFICATION ON MULTIMODAL CATION EXCHANGER FROM FEED	MAB PURIFICATION ON MULTIMODAL CATION EXCHANGER FROM FEED	MAB PURIFICATION ON MULTIMODAL CATION EXCHANGER FROM FEED	MAB PURIFICATION ON MULTIMODAL CATION EXCHANGER FROM FEED	MAB PURIFICATION ON MULTIMODAL CATION EXCHANGER FROM FEED	MAB PURIFICATION ON MULTIMODAL CATION EXCHANGER FROM FEED	MAB PURIFICATION ON MULTIMODAL CATION EXCHANGER FROM FEED	HFA BY CHEMICAL MODIFICATION OF THE AGAROSE	HFA BY CHEMICAL MODIFICATION OF THE AGAROSE	HFA BY CHEMICAL MODIFICATION OF THE AGAROSE	HFA BY CHEMICAL MODIFICATION OF THE AGAROSE	HFA BY CHEMICAL MODIFICATION OF THE AGAROSE	HFA BY CHEMICAL MODIFICATION OF THE AGAROSE	
ssued	Issued	Issued	issued	ssued	issued.	issued	issued	Issued	TT (3) (4)	issued	issued	issued.	
9	X D	S	US	AU	8	Ž	<u>X</u>	æ	00 Xi	2	Ħ	2	
28/05/2006	25/08/2006	25/08/2006	16/08/2006	08/07/2006	05/07/2006	04/07/2006	22/03/2007	22/03/2007	21/03/2007	20/03/2007	20/03/2007	27/02/2007	
ZL200580006 276.X	10-1150050	4848356	7750129	2005216847	2552639	257694	10-1215171	2005287430	O-9835150 Id	ZL200580031 649.9	5122958	2367517	
25/02/2025	25/02/2025	25/02/2025	26/06/2025	25/02/2025	25/02/2025	25/02/2025	21/09/2025	21/09/2025	36-0	21/09/2025	21/09/2025	21/09/2025	
			<a href="http://www.google.com/patents?vid=U<br">SPAT7750129>77501										
GHBSAB	GHBSAB	CH8SA8	GHBSAB	GHBSAB	GHBSAB	GHBSAB	СНВЗАВ	СНВЗАВ	GHBSAB P	CHBSAB ATEN	GHBSAB T	GHBSAB	

Same Same

175314	178314	175311	175311	175311	175311	175311	175311	175311	175311	175311	175311	175311	175311	175311	175311	175311	175311	175311	
10 PU0474	3 PU0474	11 PU0469	8 PU0469	3 PU0469	6 PU0469	4 PU0469	10 PU0469	12 PU0469	5 PU0469	20 PU0469	19 PU0489	18 PU0469	17 PU0469	16 PU0469	15 PU0469	14 PU0469	13 PU0469	7 PU0469	
PURIFICATION OF	PURIFICATION OF	A METHOD OF ANTIBODY PURIFICATION	PURIFICATION	A METHOD OF ANTIBODY PURIFICATION	A METHOD OF ANTIBODY PURIFICATION	METHOD OF ANTIBODY PURIFICATION	A METHOD OF ANTIBODY PURIFICATION	PURIFICATION	A METHOD OF ANTIBODY PURIFICATION	PURIFICATION	A METHOD OF ANTIBODY PURIFICATION	PURIFICATION	PURIFICATION	A METHOD OF ANTIBODY PURIFICATION	A METHOD OF ANTIBODY PURIFICATION	PURIFICATION	PURIFICATION	A METHOD OF ANTIBODY PURIFICATION	
AGAROSE MATRIX FOR AMGEN	AGAROSE MATRIX FOR	MAB ON MULTIMODAL ANIONEXCHANGER	ANIONEXCHANGER	MAB ON MULTIMODAL ANIONEXCHANGER	MAB ON MULTIMODAL ANIONEXCHANGER	MAB ON MULTIMODAL	MAB ON MULTIMODAL ANIONEXCHANGER	ANIONEXCHANGER	ANIONEXCHANGER	MAB ON MULTIMODAL ANIONEXCHANGER	MAB ON MULTIMODAL ANIONEXCHANGER	MAB ON MULTIMODAL ANIONEXCHANGER	MAB ON MULTIMODAL ANIONEXCHANGER	MAB ON MULTIMODAL ANIONEXCHANGER	ANIONEXCHANGER	ANIONEXCHANGER	MAB ON MULTIMODAL ANIONEXCHANGER	MAB ON MULTIMODAL ANIONEXCHANGER	
Filed	is sued	Filed	lssued	Issued	Filed	Issued	Issued	benss	Issued	Issued	Issued	issued	ssued	Issued	Issued	Issued	Issued	Issued	
2	<u>C</u>	À	2	÷	20	S	Ž	22	Ã	<u></u>	S m	Z	=	00	77	DE	오	Ş	
16/05/2007	22/12/2005	20/04/2007	20/04/2007	20/04/2007	19/04/2007	13/04/2007	10/04/2007	09/04/2007	05/04/2007	30/03/2007	30/03/2007	30/03/2007	30/03/2007	30/03/2007	30/03/2007	30/03/2007	30/03/2007	27/03/2007	
	8728828		ZL200580036 075.4	5064225		7714112	260429	2389552	2005296351	1807205	1807205	1807205	1807205	1807205	1807205	60200503831 8.1	1807205	2582113	
3653/DELNP/ 2007		10200770090 33			Pi0518207-7														
12/12/2025	10/11/2028	21/10/2025	21/10/2025	21/10/2025		25/10/2025	21/10/2025	21/10/2025	21/10/2025	21/10/2025	21/10/2025	21/10/2025	21/10/2025	21/10/2025	21/10/2025	21/10/2025	21/10/2025	21/10/2025	
	<a href="http://www.gcogi<br">e.com/patents?vid=U SPAT8728828>67288 28					<a href="http://www.google.com/patents?vid=U<br">SPAT7714112>77141													
GHBSAB	GHBSAB	GHBSAB	GHBSAB	GHBSAB	GHBSAB	GHBSAB	GHBSAB	GHBSAB	GHBSAB	GHBSAB	GHBSAB	GHBSAB	GHBSAB	GHESAB PAT	GHBSAB EN	GHBSAB T	GHBSAB	GHBSAB	

188432	188432	188432	183132	183132	183132	183132	163132	175314	175314	175314	175314	
8 PU0554	4 PU0554	3 PU0554	3 PU0530	11 PU0530	10 PU0530	9 PU0530	8 PU0530	8 PU0474	5 500474	7 900474	6 500474	
PROCESS FOR CROSS-LINKING CELLULOSE ESTER MEMBRANES	PROCESS FOR CROSS-LINKING	PROCESS FOR CROSS-LINKING CELLULOSE ESTER MEMBRANES	REGENERATION OF A	REGENERATION OF A CHROMATOGRAPHY MATRIX	REGENERATION OF A CHROMATOGRAPHY MATRIX	REGENERATION OF A CHROMATOGRAPHY MATRIX	REGENERATION OF A CHROMATOGRAPHY MATRIX	PURIFICATION OF IMMUNOGLOBULINS	PURIFICATION OF	PURIFICATION OF	PUBLEICATION OF	
PROCESS FOR CROSS- LINKING CELLULOSE ESTER MEMBRANES SIP - LS - BIOPROCESS DISPOSABLES	PROCESS FOR CROSS- LINKING CELLULOSE ESTER MEMBRANES SIP - LS - BIOPROCESS DISPOSABLES	PROCESS FOR CROSS- LINKING CELLULOSE ESTER MEMBRANES SIP - LS - BIOPROCESS DISPOSABLES	MABSELECT OP PROTOCOL SIP - LS - BIOPROCESS CHROMATOGRAPHY MEDIA	MABSELECT CIP PROTOCOL SIP - LS - BIOPROCESS CHROMATOGRAPHY MEDIA	MABSELECT OF PROTOCOL SIP - LS - BIOPROCESS CHROMATOGRAPHY MEDIA	MABSELECT OF PROTOCOL SIP - LS - BIOPROCESS CHROMATOGRAPHY MEDIA	MABSELECT OP PROTOCOL SIP - LS - BIOPROCESS CHROMATOGRAPHY MEDIA	AGAROSE MATRIX FOR AMGEN	AGAROSE MATRIX FOR AMGEN	AGAROSE MATRIX FOR AMGEN	AGAROSE MATRIX FOR AMGEN	
Issued	ଞ୍ଚ ଓଡ଼େ ଓଡ଼େ	is sued	penss	ssued	Ssued	issued	Respect	issued	issued	Issued	issued	
D m		S	' ö	Ti di	င္ပ	m m	m	2	Ť	Ş	AU	
29/01/2008	29/01/2008	25/01/2008	21/11/2007	19/09/2007	19/09/2007	19/09/2007	19/09/2007	14/06/2007	13/06/2007	05/06/2007	05/06/2007	
1924345	5143732	8496123	5148484	1885-468	1885488	1685488	1885488	ZL200580043 050.7	5787461	2586603	2005317279	
24/07/2026	24/07/2026	12/04/2029	22/05/2026	22/05/2028	22/05/2026	22/08/2026	22/05/2026	12/12/2025	12/12/2025	12/12/2025	12/12/2025	
126	126	<a http:="" patents?vid="U<br" www.google.com="">SPAT8496123>84961	126	328	726	026	928	028	025	025	025	
GHBSAB	CHBSAB	GHBSAB	GHBSAB	GHBSAB	GHBSAB	СНВSAB	GHESAB PAT	GHBSAB EN	GHBSAB	GHBSAB	GHBSAB	

Second Second

PATENT
REEL: 062019 FRAME: 0257

192352	192352	192352	191817	19:817	191817	191817	191817	186432	188432	
14 PU0541	13 PU0541	12 PU0541	6 PU0573	7 PU0573	3 PU0573	9 PU0573	4 Pu0573	10 PU0554	9 PU0554	
(1,2,3) TRIAZOLO(1,5- a)PYRIMIDINE DERIVATIVES AS CHROMATOGRAPHIC ADSORBENT FOR THE SELECTIVE ADSORPTION OF IGG	(1,2.3) TRIAZOLO(1,5- a)PYRIMIDINE DERIVATIVES AS CHROMATOGRAPHIC ADSORBENT FOR THE SELECTIVE ADSORPTION OF IGG	(1,2,3) TRIAZOLO(1,5- a)PYRIMIDINE DERIVATIVES AS CHROMATOGRAPHIC ADSORBENT FOR THE SELECTIVE ADSORPTION OF IGG	MANUFACTURE OF CHROMATOGRAPHY MATRICES	MANUFACTURE OF CHROMATOGRAPHY MATRICES	MANUFACTURE OF CHROMATOGRAPHY MATRICES	MANUFACTURE OF CHROMATOGRAPHY MATRICES	MANUFACTURE OF CHROMATOGRAPHY MATRICES	PROCESS FOR CROSS-LINKING CELLULOSE ESTER MEMBRANES	PROCESS FOR CROSS-LINKING CELLULOSE ESTER MEMBRANES	
ORGA SIP - LS - BIOPROCESS CHROMATOGRAPHY MEDIA	ORGA SIP - LS - BIOPROCESS CHROMATOGRAPHY MEDIA	ORG A SIP · LS · BIOPROCESS CHROMATOGRAPHY MEDIA	SIP - LS - BIOPROCESS CHROMATOGRAPHY MEDIA VINYL SULPHONATE COUPLING	SIP - LS - BIOPROCESS CHROMATOGRAPHY MEDIA VINYL SULPHONATE COUPLING	SIP - LS - BIOPROCESS CHRCMATOGRAPHY MEDIA VINYL SULPHONATE COUPLING	SIP - LS - BIOPROCESS CHROMATOGRAPHY MEDIA VINYL SULPHONATE COUPLING	SIP - LS - BIOPROCESS CHROMATOGRAPHY MEDIA VINYL SULPHONATE COUPLING	PROCESS FOR CROSS- LINKING CELLULOSE ESTER MEMBRANES SIP - LS - BIOPROCESS DISPOSABLES	PROCESS FOR CROSS- LINKING CELLULOSE ESTER MEMBRANES SIP - LS - BIOPROCESS	
Benss	lssued	is sued	Filed	issued	Issued	Issued	Issued	is Seried	Issued	
<u>ဂ</u>	D D	THE COLUMN TO TH	m m	2	' 5	2	GS.	ဂ္ဂ ဂ	T 20	
17/12/2007	17/12/2007	17/12/2007	14/03/2008	28/02/2008	21/02/2008	31/01/2008	22/01/2008	29/01/2008	29/01/2008	
1899342	60200603942 7.6	1899342		ZL200680031	5069239	262571	8858800	1924345	1924345	
			06784126.2							
29/06/2026	29/06/2026	29/06/2026	30/08/2026	30/08/2026	30/08/2026	30/08/2026	22/11/2026	24/07/2026	24/07/2026	
							<a http:="" patents?vid="U<br" www.google.com="">SPAT8858800>88588			
GHBSAB	GHBSAB	онекав	СНВЗАВ	GHBSAB	GHBSAB	GHBSAB	GHBSAB	GHBSAB PATENT	GHBSAB	

195316 195316	चे इ इ इ इ इ इ इ इ	193313	193312	193312	193312	193312	193312	193312	193312	193312	192352	
7 PU0547	10 PU0547	4 PU0547	3 PU0512	6 PU0512	8 PU0512	13 PU0512	12 PU0512	11 PU0512	10 PU0512	9 PU0512	5 PU0541	
METHOD OF PREPARING A SEPARATION MATRIX	METHOD OF PREPARING A SEPARATION MATRIX	METHOD OF PREPARING A SEPARATION MATRIX	METHOD OF STERILIZATION	METHOD OF STERILIZATION	METHOD OF STERILIZATION	METHOD OF STERILIZATION	METHOD OF STERILIZATION	METHOD OF STERILIZATION	METHOD OF STERILIZATION	METHOD OF STERILIZATION	[1, 2, 4] TRIAZOLO [1, 5-A] PYRIMIDINE DERIVATIVES AS CHROMATOGRAPHIC ADSORBENT FOR THE SELECTIVE ADSORPTION OF IGG	
HFA NO. 2 WITHOUT COMPACT SIP - LS - BIOPROCESS CHROMATOGRAPHY MEDIA	HFA NO. 2 WITHOUT COMPACT SIP - LS - BIOPROCESS CHROMATOGRAPHY MEDIA	HEA NO. 2 WITHOUT COMPACT SIP - LS - BIOPROCESS CHROMATOGRAPHY MEDIA	SEPARATION SYSTEMS WATER STERILIZATION	SIP - LS - BIOPROCESS SEPARATION SYSTEMS WATER STERILIZATION	SIP - LS - BIOPROCESS SEPARATION SYSTEMS WATER STEPILIZATION	SIP - LS - BIOPROCESS SEPARATION SYSTEMS WATER STERILIZATION	SIP - LS - BIOPROCESS SEPARATION SYSTEMS WATER STERILIZATION	SIP - LS - BIOPROCESS SEPARATION SYSTEMS WATER STERILIZATION	SIP - LS - BIOPROCESS SEPARATION SYSTEMS WATER STERILIZATION	SEPARATION SYSTEMS WATER STERILIZATION	ORG A SIP - LS - BIOPROCESS CHROMATOGRAPHY MEDIA	
Ssued	Filed	issued	issued	issued	benssi	Issued	Seued	lssued	penssi	issued	issued	
\$	Ž	C _S	รับ	9	S	æ	Z	္ထ	D D	T)	CS.	
20/11/2007	13/11/2007	31/10/2007	07/09/2007	08/09/2007	28/08/2007	17/08/2007	17/08/2007	17/08/2007	17/08/2007	17/08/2007	17/08/2009	
2609093		8309709	5021610	ZL200680007 268.1	7682510	1855729	1855729	1855729	60200603903 0.0	1855729	7625839	
	8702/DELNP/											
28/06/2026	28/06/2026	20/09/2028	06/03/2026	06/03/2026	06/03/2026	06/03/2026	06/03/2026	96/03/2026	06/03/2026	06/03/2026	29/08/2026	
		<a http:="" www.googi<br="">href=http://www.googi e.com/patents?vid=U SPAT8309709>83097			<a http:="" patents?vid="U<br" www.google.com="">SPAT7682510>76825						ref=http://www.googl e.com/patents?vid=U SPAT7625838>76258 38	
GHBSAB	GAS3HO	GHBSAB	GHBSAB	GHBSAB	GHBSAB	GHBSAB	GHBSAB	GHBSAB	GHBSAB	GHBSAB \TEN	GHBSAB	

195752	195752	195752	195752	195752	195752	195752	195752	195752	193313	193313	199319	193313	193313	193313	193313	
10 PU0583	2 PU0563	6 PU0583	3 PU0583	7 PU0583		11 PU0583	5 PU0583	8 PU0583	8 PU0547	5 PU0547	3 PU0547	11 PU0547	6 PU0547	9 PU0547	12 PU0547	
CHROMATOGRAPHY LIGAND	CHROMATOGRAPHY LIGAND	CHROMATOGRAPHY LIGAND	CHROMATOGRAPHY LIGAND	CHROMATOGRAPHY LIGAND	CHROMATOGRAPHY LIGAND	CHROMATOGRAPHY LIGAND	CHROMATOGRAPHY LIGAND	CHROMATOGRAPHY LIGAND	METHOD OF PREPARING A SEPARATION MATRIX							
ASTAIRE LIGAND	ASTAIRE LIGAND	ASTAIRE LIGAND	ASTAIRE LIGAND	ASTAIRE LIGAND	ASTAIRE LIGAND	ASTAIRE LIGAND	ASTAIRE LIGAND	ASTAIRE LIGAND	HFA NO. 2 WITHOUT COMPACT SIP - LS - BIOPROCESS CHROMATOGRAPHY MEDIA	HFA NO. 2 WITHOUT COMPACT SIP - LS - BIOPROCESS CHROMATOGRAPHY MEDIA	HFA NO. 2 WITHOUT COMPACT SIP - LS - BIOPROCESS CHROMATOGRAPHY MEDIA	HFA NO. 2 WITHOUT COMPACT SIP - LS - BIOPROCESS CHROMATOGRAPHY MEDIA	HFA NO. 2 WITHOUT COMPACT SIP - LS - BIOPROCESS CHROMATOGRAPHY MEDIA	HFA NO. 2 WITHOUT COMPACT SIP - LS - BIOPROCESS CHROMATOGRAPHY MEDIA	HFA NO. 2 WITHOUT COMPACT SIP - LS - BIOPROCESS CHROMATOGRAPHY MEDIA	
benssi	ssued	Filed	lsssped	issued	Filed	issued	issued	Filed	ssued	benss	Ssued	penss	Filed	FI EEC	issued	
줆	Ğ	88	Ç	S	2	잗		- 1	9	2	t	Ã	<u> </u>	171 13	22	
20/04/2007	20/04/2007	19/04/2007	13/04/2007	12/04/2007	10/04/2007	09/04/2007	05/04/2007	30/03/2007	07/01/2008	06/01/2008	06/01/2008	04/01/2008	04/01/2008	17/12/2007	14/12/2007	
10-1243601	4831436		7867784	2583578		2396246	2005296352		ZL200680024	2006266529	5058159	10-1326438			2411081	
		P10518216-6			2647/DELNP/ 2007	-		05796563.4					Pi0612720-7	06747969.1		
21/10/2025	21/10/2025		15/05/2027	21/10/2025	21/10/2025	21/10/2025	21/10/2025	21/10/2025	28/06/2026	28/06/2026	28/05/2025	28/06/2026		28/06/2026	28/06/2026	
			<a http:="" patents?vid="U<br" www.google.com="">SPAT7867784>78677					_								
GHBSAB	GHBSAB	GHBSAB	GHBSAB	GHBSAB	GHBSAB	GHBSAB	GHBSAB	GHBSAB	GHBSAB	GHBSAB	GASSBHG	GHBSAB	GHBSAB	GHBSAB PATENT	GHBSAB	

220860	216196	216196	216195	199796	139796	139796	195752	195752	195752	195752	
3 PU06100	PU0215CI 3 P2-CON	PU0215C:	PU0215CI	5830nd -5830nd	4 PU0595	1 PU0595	PU0583	4 US CON	13 PU0583	12 PU0583	
SEPARATION MATRIX FOR VIRAL	MUTANT PROTEIN	MUTANT PROTEIN	PROTEIN LIGANDS	ACTIVATED SOLID SUPPORT AND	ACTIVATED SOLID SUPPORT AND	ACTIVATED SOLID SUPPORT AND	CHROMATOGRAPHY LIGAND	CHROMATOGRAPHY LIGAND	CHROMATOGRAPHY LIGAND	CHROMATOGRAPHY	
AFFIFLU SUPHATED	PROTEASE STABILITY SURE	PROTEASE STABILITY	PROTEASE STABILITY	ACTIVATED SOLID SUPPORT AND METHOD SIP - LS - BIOPROCESS CHROMATOGRAPHY MEDIA	ACTIVATED SOLID SUPPORT AND METHOD SIP - LS - BIOPROCESS CHROMATOGRAPHY MEDIA	ACTIVATED SOLID SUPPORT AND METHOD (SIP - LS - BIOPROCESS CHROMATOGRAPHY MEDIA	ASTAIRE LIGAND	ASTAIRE LIGAND	ASTAIRE LIGAND	ASTAIRE LIGAND	
is successive desired.	Filed	Issued	issued		71 (6) (2)	SS Ded	<u> </u>	issued	issued	issued	
Sign 1	S	C Ø	C C	C.	ni V	co m	C.	<u>~</u>	25	9	
26/03/2009	14/01/2013	29/03/2009	27/02/2006	06/06/2012	08/05/2008	29/11/2005	17/11/2014	04/01/2011	19/03/2010	20/04/2007	
8481298		8354510	7709209	8648146		529145		8895710	2541429	ZL200580036	
	13/740793				06816717.8		14/542816				
25/06/2028	20/03/2023	24/01/2024	24/01/2024	22/11/2026	22/11/2026	29/11/2025	21/10/2025	19/07/2026	21/10/2025	21/10/2025	
ca href=http://www.googl e.com/patents?vid=U \$PA18481298>84812 98	<a href="http://www.google.com/patents?vid=U<br">SPAT>	<a href="http://www.googi<br">href=http://www.googi e.com/patents?vid=U SPAT6354510>83545 10	-ca href=http://www.goog! e.com/patents?vid=U SPAT7708209>77092	<a href="http://www.google.com/patents?vid=U<br">SPAT8648146>86481				<a href="http://www.google.com/patents?vid=U<br">SPAT8895710>88957			
GHBSAB	GHBSAB	GHBSAB	GHBSAB	GH8SA8	GHBSAB	GH8SAB	GHBSAB PAT	CHBSAB	CHBSAB	GHBSAB	

messi.

225428	220862	220662	220662	220662	220662	220662	220662	220662	220862	
3 PU0719	PU08101- 13 US CON	11 US DW	10 PU06101	7 PU06101	3 PU06101	6 PU08101	8 PU06101	9 Pu06101	5 PU06:101	
CROSS-LINKED CELLULOSE	CHROMATOGRAPHY LIGAND COMPRISING DOMAIN C FROM STAPHYLOCOCCUS AUREUS PROTEIN A FOR ANTIBODY ISOLATION	CHROMATOGRAPHY LIGAND COMPRISING DOMAIN C FROM STAPHYLOCOCCUS AUREUS PROTEIN A FOR ANTIBODY ISOLATION	CHROMATOGRAPHY LIGAND COMPRISING DOMAIN C FROM STAPHYLOCOCCUS AUREUS PROTEIN A FOR ANTIBODY ISOLATION	CHROMATOGRAPHY LIGAND COMPHISING DOMAIN C FROM STAPHYLOCCOCUS AUREUS PROTEIN A FOR ANTIBODY ISOLATION	CHROMATOGRAPHY LIGAND COMPRISING DOMAIN O FROM STAPHYLOCOCCUS AUREUS PROTEIN A FOR ANTIBODY ISOLATION	CHROMATOGRAPHY LIGAND COMPRISING DOMAIN C FROM STAPHYLOCOCCUS AUREUS PROTEIN A FOR ANTIBODY ISOLATION	CHROMATOGRAPHY LIGAND COMPRISING DOMAIN C FROM STAPHYLOCOCCUS AUREUS PROTEIN A FOR ANTIBODY ISOLATION	CHROMATOGRAPHY LIGAND COMPRISING DOMAIN C FROM STAPHYLOCOCCUS AUREUS PROTEIN A FOR ANTIBODY ISOLATION	CHROMATOGRAPHY LIGAND COMPRISING DOMAIN C FROM STAPHYLOCOCCUS AUREUS PROTEIN A FOR ANTIBODY ISOLATION	
LIGHTLY CROSS-LINKED CELLULOSE MEMBRANES	DOMAIN C AS AFFINITY LIGAND	DOMAIN C AS AFFINITY								
Filed	Filed	Riscued	gstred	Filed	ssued	T) (B) (C)	Tilled.	Filed	ssued	
US .	C _S	C	5	2	S	Ç	m	2	À	
16/07/2009	27/01/2014	27/07/2012	27/03/2009	27/03/2009	26/03/2009	25/03/2009	20/03/2009	13/03/2009	06/03/2009	
		8772447	5945539		8329860				2007300751	
12/523323	14/164519			20078003626		2664530	07806849.9	1675/DENP/2		
07/02/2028	27/09/2027	27/09/2027	27/09/2027	27/09/2027	17/07/2028	27/09/2027	27/09/2027	27/09/2027	27/09/2027	
#=http://www.googl om/patents?vid=-U AT>	<a href="http://www.google.com/patents?vid=U<br">SPAT>	<a href="http://www.google.com/patents?vid=U<br">SPAT8772447>87724 47			<a href="nttp://www.googi<br">e.com/patents?vid=U SPAT8329860>83298					
GHBSAB	GHBSAB	GHBSAB	GHBSAB	онвs/AB	GHBSAB	снвсав	GHBSAB	GHBSAB DATENT	GHBSAB	
wents 1988:22:04		J	<u> </u>	<u> </u>		L		PATENT		

228759	226759	228025	228025	228025	228025	228025	228025	227325	226197	226197	226197	226197	226197	226197	226197	225428	225428	225428
6 PU0795	5 PU0795	8 PU0786	6 PU0786	5 PU0786	3 PU0786	7 PU0786	9 PU0788	3 PU0760	3 PU0736	4 PU0736	9 PU0736	8 PU0736	7 PU0736	6 PU0736	5 PU0736	4 PU0719	7 PU0719	6 PU0719
STERILIZATION METHOD	STERILIZATION METHOD	SEPARATION MATRIX	SEPARATION MATRIX	SEPARATION MATRIX	SEPARATION MATRIX	SEPARATION MATRIX	SEPARATION MATRIX	POLYMER TWO PHASE SYSTEM	PURIFICATION OF	PURIFICATION OF IMMUNOGLOBULINS	MAUNOGLOBULINS	PURIFICATION OF IMMUNOGLOBULINS	PURIFICATION OF	PURIFICATION OF IMMUNOGLOBULINS	PURIFICATION OF	CROSS-LINKED CELLULOSE	CROSS-LINKED CELLULOSE MEMBRANES	GROSS-LINKED CELLULOSE
STERILIZATION METHOD FOR READY-TO-PROCESS COLUMNS	STERILIZATION METHOD FOR READY-TO-PROCESS COLUMNS	THIN LID BEADS	THIN LID BEADS	THIN LID BEADS	THIN LID BEADS	THIN LID BEADS	THIN LID BEADS	GENERAL PARTITION	SULFAMIDE LIGANDS	SULFAMIDE LIGANDS	SULFAMIDE LIGANDS	SULFAMIDE LIGANDS	SULFAMIDE LIGANDS	SULFAMIDE LIGANDS	SULFAMIDE LIGANDS	CELLULOSE MEMBRANES	LIGHTLY CROSS-LINKED CELLULOSE MEMBRANES	CELLULOSE MEMBRANES
Issued	Filed	Issued	issued	Issued	Filed	Filed	Issued	penss	Issued	Filed	Issued	Issued	Issued	issued	issued	Filed	issued	Issued
AT	ā	۵ŗ	S	Ç	US	m	٩U	S	US.	灵	유	G G	DE.	7	щ	m	ਰਿ	2
18/02/2010	15/02/2010	25/01/2010	18/01/2010	18/01/2010	06/01/2010	15/12/2009	01/12/2009	03/12/2009	30/09/2009	28/08/2009	19/08/2009	19/08/2009	19/08/2009	19/08/2009	19/08/2009	19/08/2009	07/08/2009	06/08/2009
2162990		5643642	ZL200880100 334.9	2693334			2008279841	8268915	9044740		2129461	2129461	60200803850 1.5	2129461	2129461		5420424	ZL200880004 229.5
	2010-523101				12/667873	08794090.4				5537/DELNP/ 2009					:	08715706.1		
27/08/2028	27/08/2028	22/07/2028	22/07/2028	22/07/2028	22/07/2028		22/07/2028	06/05/2029	20/10/2029	20/03/2028	20/03/2028	20/03/2028	20/03/2028	20/03/2028	20/03/2028	07/02/2028	07/02/2028	07/02/2028
					<a href="http://www.goog/<br">e.com/patents?vid=U SPAT>			<a href="http://www.google.com/patents?vid=U<br">SPAT8288915>82689 15	9044740>40									
GHBSAB	GHBSAB	GHBSAB	GHBSAB	CHE	GHBSAB	GHBSAB	GHBSAB		GHBSAB	GHBSAB	GHBSAB	GHBSAB	GHBSAB	GHBSAB	онв в в	GHBSAB	GHBSAB	GHBSAB

233127	233127	233127	233127	233127	233127	230795	230795	230795	226759	228759	228759	228759	228759	228759	226759	
6 PU0836	5 PU0836	4 PU0836	3 PU0838	8 PU0836	7 PU0836	8 PU07123	7 PU07123	6 PU07123	3 PU0795	14 PU0795	13 PU0795	11 PU0795	:0 PU0795	8 PU0795	7 PU0795	
CHROMATOGRAPHY MEDIUM	CHROMATOGRAPHY MEDIUM	CHROMATOGRAPHY MEDIUM	CHROMATOGRAPHY MEDIUM	CHROMATOGRAPHY MEDIUM	CHROMATOGRAPHY MEDIUM	METHOD FOR STERILIZATION OF CHEMICALLY ACTIVATED SOLID SUPPORT MATERIALS	METHOD FOR STERILIZATION OF CHEMICALLY ACTIVATED SOLID SUPPORT MATERIALS	METHOD FOR STERILIZATION OF CHEMICALLY ACTIVATED SOLID SUPPORT MATERIALS	STERILIZATION METHOD	STERILIZATION METHOD	STERILIZATION METHOD	STERILIZATION METHOD	STERILIZATION METHOD	STERILIZATION METHOD	STERILIZATION METHOD	
HIGHLY HYDROPHOBIC LID MEDIUM	HIGHLY HYDROPHOBIC LID	MEDIUM HIGHLY HYDROPHOBIC LID	MEDIUM	MEDIUM	MEDIUM	STERILIZATION METHOD FOR ACTIVATED SOLID SUPPORT MATERIALS	STERILIZATION METHOD FOR ACTIVATED SOLID SUPPORT MATERIALS	STERILIZATION METHOD FOR ACTIVATED SOLID SUPPORT MATERIALS	STERILIZATION METHOD FOR READY-TO-PROCESS COLUMNS	STERILIZATION METHOD FOR READY-TO-PROCESS COLUMNS	STERILIZATION METHOD FOR READY-TO-PROCESS COLUMNS	STERILIZATION METHOD FOR READY-TO-PROCESS COLUMNS	STERILIZATION METHOD FOR READY-TO-PROCESS COLUMNS	STERILIZATION METHOD FOR READY-TO-PROCESS COLUMNS	STERILIZATION METHOD FOR READY-TO-PROCESS COLUMNS	
Filed	lssued	FI Be d	issued	Filed	Filed	issued	benss	Issued	Semec	Issued	Issued	Issued	Issued	lssued	Issued	
Ş	A	S S	Ģ	Z	m	GB	30	Om m	CS	<u> </u>	Г	6	Ti Zi	DE C	웃	
21/10/2010	21/10/2010	20/10/2010	19/10/2010	29/09/2010	24/09/2010	26/05/2010	26/05/2010	26/05/2010	19/02/2010	18/02/2010	18/02/2010	18/02/2010	18/02/2010	18/02/2010	18/02/2010	
	2009238686		5643747			2237604	2237604	60200802375 4.9	9101677	2182990	2182990	2182990	2182990	60200800620 6.6	2182990	
20098011497		12/988707		6864/DELNP/ 2010	09735164.7									-		
21/04/2029	21/04/2029	21/04/2029	21/04/2029	21/04/2029		27/08/2028	27/08/2028	27/08/2028	26/01/2029	27/08/2028	27/08/2028	27/08/2028	27/08/2028	27/08/2028	27/08/2028	
		<a http:="" www.goog!<br="">href=http://www.goog! e.com/patents?vid=U SPAT>							<a http:="" patents?vid="U<br" www.google.com="">SPAT9101677>91016							
GHBSAB	GHBSAB	GHBSAB	CHBSAB	CHBSAB	GHBSAB	GHBSAB	GHBSAB	GHBSAB	GHBSAB	GHBSAB	GHBSAB	GHBSAB P	GHBSAB ATEN	GHBSAB T	GHBSAB	

Action Section 1

237953	237953	237953	237963	237953	237309	237268	237268	237268	237268	237268	237268	237268	234277	
8 PU07141	9 PU07141	4 PU07141	7 PU07141	10 PU07141	5 PU0902	4 PU0901	7 PU0901	6 PU0901	3 20090:	: 06U/d 5	9 PU0901	8 PU0901	4 PU0863	
PREPARATION OF POLYSACCHARIDE BEADS	PREPARATION OF POLYSACCHARIDE BEADS	PREPARATION OF POLYSACCHARIDE BEADS	PREPARATION OF POLYSACCHARIDE BEADS	PREPARATION OF POLYSACCHARIDE BEADS	AFFINITY CHROMATOGRAPHY MATRIX	SEPARATION METHOD USING SINGLE POLYMER PHASE SYSTEMS	SEPARATING METHOD ADOPTING SINGLE POLYMER SYSTEM	SEPARATION METHOD USING SINGLE POLYMER PHASE SYSTEMS	SEPARATION MEDIUM FOR CHROMATOGRAPHY OF VARIOUS BIOMOLECULES					
PREPARATION OF POLYSACCHARIDE BEADS	PREPARATION OF POLYSACCHARIDE BEADS	PREPARATION OF POLYSACCHARIDE BEADS	PREPARATION OF POLYSACCHARIDE BEADS	PREPARATION OF POLYSACCHARIDE BEADS	MONOMERIC AND DIMERIC PROTEIN A MATRIX	ONE POLYMER TWO	ONE POLYMER TWO	ONE POLYMER TWO	ONE POLYMER TWO	ONE POLYMER TWO	ONE POLYMER TWO	ONE POLYMER TWO	CHARGE REPULSION LID	
โรรและ	Filed	Filed	Filed.	Filed	Issued	penss	Issued	Filed	issued	T B C	Filed	F	Tillion a	
AU	CA	in a	ž	2	2	C.S.	2	<u>S</u>	ভি	ÅU	Ž	m m	. G	_
20/10/2009	09/10/2009	30/09/2009	23/09/2009	25/04/2007	11/07/2011	26/09/2011	06/07/2011	30/06/2011	29/06/2011	15/08/2011	08/06/2011	23/05/2011	20/02/2013	
2008244684			- 		ZL201080004 708.4	91 15 51 01	ZL201080004 367.7		5785098	i i				
	2683642	08741857.0	6121/DELNP/ 2009	20071009870				2748807		2010203836	4301/DELNP/ 2011	10729364.9	12/988707	
21/04/2028	21/04/2028	21/04/2026	21/04/2028	25/04/2027	11/01/2030	02/08/2032	07/01/2030	07/01/2030	07/01/2030	07/01/2030	07/01/2030	07/01/2030	04/06/2029	
						href=http://www.googl e.com/patents?vid=U SPAT915181>91151 61								
GHBSAB	GHBSAB	GHBSAB	GHBSAB	GHESAB	SHESAB	GHESAB	GHBSAB	GHSSAB	GHBSAB	GHBSAB	GHBSAB PATE	GHBSAB NT	GHBSAB	

Etitt

249970	249970	249964	249964	249964	249964	249964	249302	247076	246627	242394	242394	242394	237953	237953	237953	
5 PU1097	4 PU1097	7 PU1082	6 PU1082	3 PU1082	5 PU1062	4 PU1082	7 PU1061	3 PU1044	7 PU1053	8 PU0992	4 PU0992	3 PU0992	5 PU07141	6 PU07141	3 PU07141	
AFFINITY CHROMATOGRAPHY MATRIX	AFFINITY CHROMATOGRAPHY MATRIX	AFFINITY CHROMATOGRAPHY MATRIX	AFFINITY CHROMATOGRAPHY MATRIX	AFFINITY CHROMATOGRAPHY MATRIX			AFFINITY CHROMATOGRAPHY	METHOD FOR STORAGE AND STABILIZATION OF A TARGET SUBSTANCE	CHROMATOGRAPHY METHOD AND MEDIA USED THEREFORE	SEPARATION MATRICES	SEPARATION MATRICES	SEPARATION MATRICES	PREPARATION OF POLYSACCHARIDE BEADS	PREPARATION OF POLYSACCHARIDE BEADS	PREPARATION OF POLYSACCHARIDE BEADS	
N28A FOR INCREASED	N28A FOR INCREASED	H138S	H16S	H 1885	H18S	H 1888	P571 PROTEIN APROTEIN Z	STABILIZATION AND STORAGE METHOD	NEW IEF LID BEADS	HYDROPHOBIC LIGANDS ON BASE MATRIX	ON BASE MATRIX	HYDROPHOBIC LIGANDS ON BASE MATRIX	PREPARATION OF POLYSACCHARIDE BEADS	PREPARATION OF POLYSACCHARIDE BEADS	PREPARATION OF POLYSACCHARIDE BEADS	
File od	Filed	Issued	Filed	Filed	Filed	Filed	Issued	Filed	Filed	Filed	Filed	Issued	Issued	issued	Issued	
2	m m	US	ğ	2	2	m m	CS.	S	S	CS.	2	Çi O	<u>ဂ</u>	ซิ	U.S	
04/06/2013	30/05/2013	05/09/2013	19/06/2013	19/06/2013	04/06/2013	30/05/2013	29/05/2013	01/02/2013	09/01/2013	12/04/2012	11/04/2012	22/03/2012	26/10/2009	23/10/2009	23/10/2009	
		9187555					8859726					5826180	ZL200880013	5457335	8137563	
4937/DELNP/ 2013	11850413.3		2013-546072	20118006111 5.6	4935/DELNP/ 2013	11850306.9		13/813800	13/809179	13/501623	20108004690 1.4					
19/12/2031	19/12/2031	19/12/2031	19/12/2031	19/12/2031	19/12/2031	19/12/2031	28/11/2031	26/04/2031	28/06/2031	08/10/2030	08/10/2030	08/10/2030	21/04/2028	21/04/2028	21/04/2028	
							<a href="http://www.googi<br">e.com/patents?vid=U SPAT8859726>88597 26 >	<a href="http://www.google.com/patents?vid=U<br">SPAT>	<a http:="" patents?vid="U<br" www.google.com="">SPAT>	<a http:="" patents?vid="U" spat="" www.google.com="">		-			<a href="http://www.google.com/patents?vid=U<br">SPAT6137563>8137563	
GHBSAB	GHBSAB	GHBSAB	GHBSAB	GHBSAB	GHBSAB	GHBSAB	GHBSAB	GHBSAB	GHBSAB	GHBSAB	GHBSAB	GHBSAB	GHBSAB	GHBSAB	GHBSAB	

256479	256479	256479	256079	256079	258079	258079	256079	256079	253288	12 33 32 32 50 60	249970	249970	249970	
6 PU1178	4 PU1178	5 PU1178	3 PU1168	8 PU1166	4 PU1166	6 PU166	5 PU1166	7 PU1166	1 PU0583CI	3 PU11:01	7 PU1097	6 PU1097	3 PU1097	
METHOD FOR PURIFICATION OF CLEAVED PRO-INSULIN	CLEAVED PRO-INSULIN	METHOD FOR PURIFICATION OF CLEAVED PRO-INSULIN	PLASMA PROTEIN FRACTIONATION BY SEQUENTIAL POLYACID PRECIPITATION	PLASMA PROTEIN FRACTIONATION BY SEQUENTIAL POLYACID PRECIPITATION	PLASMA PROTEIN FRACTIONATION BY SEQUENTIAL POLYACID PRECIPITATION	PLASMA PROTEIN FRACTIONATION BY SEQUENTIAL POLYACID PRECIPITATION	PLASMA PROTEIN FRACTIONATION BY SEQUENTIAL POLYACID PRECIPITATION	PLASMA PROTEIN FRACTIONATION BY SEQUENTIAL POLYACID PRECIPITATION	CHROMATOGRAPHY LIGAND	AFFINITY CHROMATOGRAPHY MATRIX	AFFINITY CHROMATOGRAPHY	AFFINITY CHROMATOGRAPHY MATRIX	AFFINITY CHROMATOGRAPHY	
WITH LID BEADS	INSULIN PURIFICATION WITH LID BEADS	INSULIN PURIFICATION WITH LID BEADS	PLASMA PROTEIN FRACTIONATION BY SEQUENTIAL POLYACID PRECIPITATION	PLASMA PROTEIN FRACTIONATION BY SEQUENTIAL POLYACID PRECIPITATION	PLASMA PROTEIN FRACTIONATION BY SEQUENTIAL POLYACID PRECIPITATION	PLASMA PROTEIN FRACTIONATION BY SEQUENTIAL POLYACID PRECIPITATION	PLASMA PROTEIN FRACTIONATION BY SEQUENTIAL POLYACID PRECIPITATION	PLASMA PROTEIN FRACTIONATION BY SEQUENTIAL POLYACID PRECIPITATION	ASTAIRE LIGANO	PROTEIN ZETA HEXAMER	N28A FOR INCREASED	N28A FOR INCREASED	N28A FOR INCREASED	
Filed	Filed	Filed.	Fi ie d	Filed	Tiled.	Filed	T E C	Ties ed	Tile d	File Cd.	Filed	Filed	Filed	
ŧ	щ	2	<u>^</u>	S.	2	Z	m m	Z Z	US	CS.	US,	ğ	2	
26/03/2014	14/03/2014	11/03/2014	03/04/2014	17/03/2014	14/03/2014	24/02/2014	17/02/2014	13/02/2014	13/06/2011	16/05/2014	20/06/2013	19/06/2013	19/06/2013	
2014-533247	12837180.4	1846/DELNP/ 2014	2012309202	14/345302	20128004493	1365/DELNP/ 2014	12832274.0	621197	13/158780	14/358821	13/996023	2013-546071	20118006111 4.1	
28/09/2032	28/09/2032	28/09/2032	14/09/2032	14/09/2032	14/09/2032	14/09/2032	14/09/2032	14/09/2032	21/10/2025	28/11/2032	19/12/2031	19/12/2031	19/12/2031	
									<a href="http://www.google.com/patents?vid=U</td"><td><a http:="" patents?vid="U" spat="" www.google.com=""></td><td>ca href=http://www.googl e.com/patents?vid=U SPAT></td> >	<a http:="" patents?vid="U" spat="" www.google.com="">	ca href=http://www.googl e.com/patents?vid=U SPAT>			
GHBSAB	GHBSAB	GHBSAB	GHBSAB	GHBSAB	GHBSAB	GHBSAB	GHBSAB	GHBSAB	GHBSAB	GHBSAB DAT	GHBSAB ENT	GHBSAB	GHBSAB	

Sam.

263006	263006	260072	257846	257846	257846	256626	256626	256626	256626	256626	256591	256591	258591	256591	256479	256479	
4 PU1288	5 PU1288	3 PU1208	6 PU1217	5 PU1217	4 PU1217	4 PU1227	5 PU1227	3 PU1227	7 PU1227	6 PU1227	3 PU12107	5 PU12107	6 PU12107	4 PU12107	3 PU1178	7 PU1178	
MULTIMODAL ANION EXCHANGE MATRICES	MULTIMODAL ANION EXCHANGE MATRICES	METHOD FOR ENDOTOXIN REMOVAL	AFFINITY CHROMATOGRAPHY MATRIX	AFFINITY CHROMATOGRAPHY MATRIX	AFFINITY CHROMATOGRAPHY MATRIX	SEPARATION METHOD AND SEPARATION MATRIX	SEPARATION METHOD AND SEPARATION MATRIX	SEPARATION METHOD AND SEPARATION MATRIX	SEPARATION METHOD AND SEPARATION MATRIX	SEPARATION METHOD AND SEPARATION MATRIX	METHOD FOR CLEANING OF PACKED BED CHROMATOGRAPHY COLUMNS	METHOD FOR CLEANING OF PACKED BED CHROMATOGRAPHY COLUMNS	METHOD FOR CLEANING OF PACKED BED CHROMATOGRAPHY COLUMNS	METHOD FOR CLEANING OF PACKED BED CHROMATOGRAPHY COLUMNS	CLEAVED PRO-INSULIN	METHOD FOR PURIFICATION OF	
NEW ADHERE LIGAND VARIETIES	NEW ADHERE LIGAND VARIETIES	CAPTO CORE FOR ENDOTOXIN REMOVAL	DOUBLE MUTATIONS	DOUBLE MUTATIONS	DOUBLE MUTATIONS	CATION EXCHANGERS	COPOLYMER GRAFTED CATION EXCHANGERS	COPOLYMER GRAFTED CATION EXCHANGERS	CATION EXCHANGERS	COPOLYMER GRAFTED CATION EXCHANGERS					WITH LID BEADS	INSULIN PURIFICATION	
Filed	Filled	Filed	Filled	Filed	Tilled	Filed	Filed	Filed	Filed	E C	Filed	Fled	Filed	Filed	Filed	Filed	
m	Z	US.	ਰੋ	E G	Ç,	S	TJ.	Ç,	ডি	Z	2	ç. O	US SU	m T	S	US	
22/04/2015	20/04/2015	22/08/2014	22/09/2014	19/09/2014	15/09/2014	24/10/2014	23/10/2014	22/10/2014	21/10/2014	16/10/2014	12/06/2015	11/06/2015	03/06/2015	26/05/2015	08/04/2014	31/03/2014	
13854329.3	3308/DELNP/ 2015	14/380477	2015-503160	13767846.2	14/385336	20138002176 4.2	13781240.0	14/396207	2015-508919	3671/DELNP/ 2014	20138006531 8.1	2015-547894	14/649227	13862375.6	20128004775 1.8	14/348634	
11/11/2033	11/11/2033	27/02/2033	26/03/2033	26/03/2033	26/03/2033	22/04/2033	22/04/2033	22/04/2033	22/04/2033	22/04/2033	12/12/2033	12/12/2033	12/12/2033	12/12/2033	28/09/2032	26/09/2032	
					<a href="http://www.google.com/patents?vid=U<br">SPAT>			<a href="http://www.googi<br">e.com/patents?vid=U SPAT>			_		<a e.com="" href="http://www.googl" patents?vid="U" spat="">			<a href="http://www.google.com/patents?vid=U<br">SPAT>	
GHBSAB	GHBSAB	GHBSAB	GHBSAB	GHBSAB	GHBSAB	GHBSAB	GHBSAB	GHBSAB	GHBSAB	GHBSAB	GHBSAB	GHBSAB	GHBSAB P /	GHBSAB ATEN	GHBSAB T	GHBSAB	

Same Same

280060	278661	278543	274839	273810	272178	268770	266175	263627	263627	263627	263627	263627	263627	263627	263006	263006	263006	
	3 PU1457	2 PU1481	2 PU1411	2 PU1428	2 PU1377	2 PU1359	2 PU1328	9 PU10122	8 PU10122	5 PU10122	3 PU10122	6 PU10122	7 PU10122	4 PU10122	3 PU1288	6 PU1288	7 PU1288	
METHOD FOR CHROMATOGRAPHY	MILITATED IMMUNOGLOBULIN- BINDING POLYPEPTIDES	BINDING POLYPEPTIDES	SEPARATION MATRICES FOR PURIFICATION OF BIOLOGICAL PARTICLES	CHROMATOGRAPHY METHOD	STABILIZATION OF FERMENTED BEVERAGES	METHOD FOR PRODUCTION OF A CHROMATOGRAPHY MATERIAL	BINDING POLYPEPTIDES	POLYPEPTIDE	MANUNCGLOBULIN G FC REGION	IMMUNOGLOBULIN G FC REGION	IMMUNOGLOBULIN G FC REGION BINDING POLYPEPTIDE	IMMUNOGLOBULIN G FC REGION BINDING POLYPEPTIDE	MMUNOGLOBULIN G FC REGION	IMMUNOGLOBULIN G FC REGION BINDING POLYPEPTIDE	MATRICES MATRICES	MULTIMODAL ANION EXCHANGE MATRICES	MULTIMODAL ANION EXCHANGE	
CHROMATOGRAPHY NEW PLASMAPROCESS	PROTEIN A AFFINITY MEDIA	PROTEIN LAFFINITY MEDIA	Salt ligand		CSS adsorber PVP	Agarose RPC Octylglycidylether Peptide Purification Reversed Phase Chromatography (RPC)	PROTEIN A AFFINITY MEDIA	POLYPEPTIDE	POLYPEPTIDE	POLYPEPTIDE	POLYPEPTIDE	РОГАБЕЬЛЮЕ	POLYPEPTIDE	POLYPEPTIDE	VARIETIES	NEW ADHERE LIGAND VARIETIES	NEW ADHERE LIGAND VARIETIES	
	Filed.	E ed.	Filled	Filed	Filed	Filed	Filed	Filed	Sense	Filed	F) 	Issued	Filed	Filed	Filed	Filed	File ea	
က္ထ	<u>\$</u>	So	₩o	ĕo	₩C	wo	WO.	щ	US	S	ซั	m	Ž	Ç	S	ਚਿ	6	
10/04/2015	16/11/2015	11/12/2015	18/02/2015	04/06/2015	26/11/2014	09/10/2014	08/07/2014	19/08/2015	11/10/2012	07/09/2012	04/09/2012	27/08/2012	16/08/2012	13/08/2012	12/05/2015	08/05/2015	06/05/2015	
									9175067			2544785						
1506113.8	EP2015/0766	EP2015/0793 87	SE2015/0501	EP2015/0625 00	SE2014/0514 07	SE2014/0511 94	SE2014/0508 72	15181524.8		20118001284 4.2	2012-556471		7165/DELNP/ 2012	2789738	20138005912	2015-541741	14/441129	
10/04/2035								07/03/2031	07/03/2031	07/03/2031	07/03/2031	07/03/2031	07/03/2031	07/03/2031	11/11/2033	11/11/2033	11/11/2033	
									</a 								<a href="http://www.google.com/patents?vid=U<br">SPAT>	
GHBSAB	GHBSAB	онвsав	GHBSAB	GHBSAB	GHESAB	GHBSAB	GHBSAB	GHBSAB	GHBSAB	GHBSAB	GHESAB	GHBSAB	GHBSAB	GHBSAB PAT	GHBSAB EN	GHBSAB _	GHBSAB	

235690	235690	280060A	278543A	278543A	266175A	282540	282161	280957	280722	
3 PU0882	4 PU0882	\	2 PU1482	1 PU1482	2 PU1330	2		<u> </u>	1 PU1509	
MICROTITRE PLATE	MICRO TITRE PLATE	CHROMATOGRAPHY	BINDING POLYPEPTIDES	BINDING POLYPEPTIDES	BINDING POLYPEPTIDES	BINDING POLYPEPTIDES	MANUFACTURING PROCESS FOR POLYSACCHARIDE BEADS	A SEPARATION MATRIX AND A METHOD OF SEPARATING ANT BODIES	SANITIZATION METHOD FOR AFFINITY CHROMATOGRAPHY MATRICES	
ADSORPTION ISOTHERM PREDICTOR PLATES	PREDICTOR PLATES	PLASMAPROCESS	PROTEIN L AFFINITY	PROTEIN L AFFINITY	PROTEIN A AFFINITY				PROTEIN A AFFINITY MEDIA	
Fled	Filed	Filed	Filed	Filed	Filed	Filed	11 24	Filed	Filed	
S	щ.	98	wo	SE	₩°	<u>پ</u>	က္ဆ	G E	င္တ	
35/04/2011	10/03/2011	10/04/2015	11/12/2015	17/12/2014	10/07/2014	16/11/2015	04/06/2015	28/08/2015	03/03/2015	
13/122585	09820838.6	1506117.9	EP2015/0793 89	1451564-7	SE2014/0508 82	EP2015/0766	1509677.9	1515339.8	1503578.5	
07/10/2029	07/10/2029	10/04/2035					04/08/2035	28/08/2035	03/03/2035	
<a href="http://www.goog/<br">href=http://www.goog/ e.com/patents?vid=iU SPAT>										
GH8SAB	GHBSAB	GHBSAB	GHBSAB	GHBSAB	GHBSAB	GHBSAB	GHBSAB	GHBSAB	GHBSAB	
	Ca href=http://www.googl spat> 3 PU0882 MICRO TITRE PLATE PREDICTOR PLATES Filed US 05/04/2011 13/122585 07/10/2029 SPAT> ADSORPTION ISOTHERM 6.com/paients?vid=U Withated immunodiohulin binding PROTEIN A AFFINITY	4 PU0882 MICRO TITRE PLATE PREDICTOR PLATES Filed EP 10/03/2011 09820838.6 07/10/2029	A 1 CHROMATOGRAPHY PLASMAPROCESS Filed GB 10/04/2015 1506117.9 10/04/2036 17/10/2029 10/	A 2 PU1482 MINDING POLYPEPTIDES MEDIA Filed WO 11/12/2015 EP2015/0793 A 1 PU1482 BINDING POLYPEPTIDES CHROMATOGRAPHY NEW PLASMAPROCESS Filed WO 11/12/2015 89 A 1 PU0882 MICRO TITRE PLATE ADSORPTION ISOTHERM PREDICTOR PLATES Filed EP 10/03/2011 1506117.9 10/04/2036 07/10/2029 10/04/2036 07/10/2029 Aref=http://www.google.com/paients?vid=U 3 PU0882 MICRO TITRE PLATE ADSORPTION ISOTHERM A AFFINITY Filed US 05/04/2011 13/122585 07/10/2029 PAT> Mil/tated immunoclobuilin binding PREDICTOR PLATES Filed US 05/04/2011 13/122585 07/10/2029 SPAT>	1 PU1482 BINDING POLYPEPTIDES MEDIA Filed SE 17/12/2014 1451564-7 1451564-	AUTATED IMMUNOGLOBULIN- MEDIA ME	MUTATED MMUNOGLOBULIN- Filed WO 16/11/2015 42	1 MANUFACTURING PROCESS FOR Field GB 04/06/2015 1508677.9 04/06/2035 POLYSACCHARIDE BEADS Field GB 04/06/2015 EP2015/0766 EP2015/0766 2 SINDING POLYPEPTIDES MUTATED MANUNCGLOBULIN- PROTEIN A AFFINITY Filed WO 16/11/2015 42 MCDIFIED KAPPA LIGHT CHAIN- MEDIAN M	A SEPARATING METHOD OF SEPARATING METHOD OF SEPARATING ANTIBODIES MANUFACTURRING PROCESS FOR Filed GB 28/08/2015 1515339 8 28/08/2035	AFEMITY CHROMATOGRAPHY PROTEIN A AFFMITY Filed GB 2009/2015 1503578.5 0303/2035

e frank

SUB-SCHEDULE 2.1.1(a)(ii) GE Healthcare Bio-Sciences AB and GE Healthcare BioProcess R&D AB Trademarks and trademark applications



TRADENARK	COUNTRY	REGISTRATION/
BioProcess	France	422222
BioProcess	France Canada	1333276
	Canada Australia	TMA339545
BIOPROCESS	7 7 8 8 9 9 9 11 12	437376
BIOPROCESS	Japan	2199350
BioProcess	French Polynesia	1333276
CAPTO	Japan	5504322
CAPTO	Russian Federation	469964
CAPTO	Singapore	T1113201C
CAPTO	Turkey	201177705
CAPTO	Korea - Republic of (South)	400943510
CAPTO	Argentina	2077557
CAPTO	CTM	3952017
CAPTO	India	1303076
CAPTO	Mexico	884800
CAPTO	United States of America	3112443
CAPTO	Brazîl	827033133
CAPTO	Argentina	2077559
CAPTO	Norway	241795
CAPTO	Switzerland	P-529471
CAPTO	Brazil	827033125
CAPTO	Mexico	868175
CAPTO	Canada	TMA677895
CAPTO	New Zealand	716546
CAPTO	China	4215291
CAPTO	China	4215272
CAPTO	Australia	1015276
DROP DESIGN	Canada	TMA318300
DROP DESIGN (NEG)	Denmark	VR196800362
DROP DEVICE	Denmark	VR196800361
DROP DEVICE	Norway	74427
DROP DEVICE	Sweden	122445
DROP DEVICE	Hong Kong	199608656
DROP DEVICE	Singapore	T9504241Z
DROP DEVICE	Turkey	200127130
DROP DEVICE	Singapore	T9504239H
DROP DEVICE	Australia	660580
DROP DEVICE	Belarus	7811
DROP DEVICE		, 012
(POSITIVE)	Finland	54129
GAMMABIND	Germany	1134833
GAMMABIND	Japan	2307218
GAMMABIND	United States of America	1511384
GAMMABIND	United Kingdom	1337491
GAMMABIND	Benelux	440932
GAMMABIND	France	1454529
MABSELECT	Cuba	20060721
MABSELECT	СТМ	10386662
MABSELECT	Saudi Arabia	65717
MABSELECT	Japan	4378549
<u>-</u>	4n	10110010

MABSELECT	Japan	4904336
MABSELECT	Kazakhstan	5958
MABSELECT	Ukraine	16348
MABSELECT	Australia	857391
MABSELECT	China	1696054
MABSELECT	China	1981906
MABSELECT	Switzerland	P-487623
MABSELECT	United States of America	2606880
MABSELECT	Saudi Arabia	64776
MABSELECT	Norway	214969
MABSELECT	Canada	TMA576496
MABSELECT	Venezuela	P258532
MABSELECT	Saudi Arabia	65349
MABSELECT	Canada	TMA325547
MABSELECT	Venezuela	P258531
MABSELECT SURE	United States of America	3121281
MABSELECT SURE	CTM	4028353
MABSELECT XTRA	United States of America	3165701
MABSELECT XTRA	CTM	4029096
MABTRAP	Norway	
MAbTrap	China	211073
MABTRAP	Australia	1747815
MABTRAP	11300700710	867456
	Switzerland	P-493790
MAbTrap	Taiwan	1026255
MAbTrap	United States of America	1586594
MABTRAP	Israel	147249
MABTRAP	Brazil	823706249
MABTRAP (STYLISED)	Japan	4582706
MBPTRAP	Argentina	2194842
MBPTRAP	Chile	822102
MBPTRAP	Mexico	982549
MBPTRAP	Brazil	828947937
MBPTRAP	Venezuela	P288895
MBPTRAP	Argentina	2187106
MBPTRAP	Venezuela	P288892
MBPTRAP	Canada	TMA735027
MBPTRAP	Venezuela	P288894
MBPTRAP	Brazil	828948046
MBPTRAP	Venezuela	P288893
MONO P	CTM	3476281
MONO P	United States of America	4777271
MONO P	Japan	2013615
MONO P	Japan	Appl. No. 1255663
MONO P	CTM	14231518
MONO P	WIPO	1255663
MONO Q	Japan	Appl. No. 1255662
MONO Q	CTM	14231567
MONO O	WILDO	9.3000000
MONO Q	WIPO	1255662
MONO Q MONO Q MONO Q	WIPO Japan United States of America	1255662 2013616 4777286

MONO Q	United States of America	1311779
MONO S	United States of America	1311778
MONO S	United States of America	4777285
MONO S	CTM	3485687
MONO S	Japan	Appl. No. 1255661
MONO S	CTM	14231401
MONO S	WIPO	1255661
MONOBEADS	Norway	211629
MONOBEADS	Taiwan	993671
MONOBEADS	Japan	2096424
MONOBEADS	China	1740081
MONOBEADS	Australia	868686
MONOBEADS	Argentina	2621661
MONOBEADS	India	999687
MONOBEADS	Switzerland	P-490431
MONOBEADS	Mexico	710689
MONOBEADS	Canada	575449
MONOBEADS	Brazil	823706192
MONOBEADS	Israel	147254
MONOBEADS	CTM	2140945
MONOBEADS	Korea - Republic of (South)	539801
PREDICTOR	Japan	5179047
PREDICTOR	China	6262366
PREDICTOR	China	6262365
PREDICTOR	CTM	6241822
PREDICTOR	United States of America	3697805
READY TO PROCESS	France	63463253
READYTOPROCESS	United States of America	3537591
READYTOPROCESS	Canada	TMA826259
READYTOPROCESS	Germany	30670702
READYTOPROCESS	Japan	5099577
SEPHACEL	Ireland	91985
SEPHACEL	Finland	53259
SEPHACEL	France	1403557
SEPHACEL	Denmark	VR196800608
SEPHACEL	Kosovo	Appl. No. 1933
SEPHACEL	Canada	TMA175235
SEPHACEL	Cuba	2002-0478
SEPHACEL	Norway	73010
SEPHACEL	Sweden	122348
SEPHACEL	Japan	914233
SEPHACEL	Germany	848449
SEPHACEL	Australia	254543
SEPHACEL	United Kingdom	908489
SEPHACEL	United States of America	4055424
SEPHACRYL	CTM	3346952
SEPHACRYL	Switzerland	P-358878
SEPHACRYL	Australia	223499
SEPHACRYL	China	850021
SEPHACRYL	Japan	886159
SEPHACRYL	Canada	TMA169949
	Server F. F. W. W. M. W.	· 1417-1.2.2.2.2.2.2.2.2.2.2.2.2.2.2.2.2.2.2.2



SEPHACRYL	Norway	83727
SEPHACRYL	United States of America	942529
SEPHACRYL	Brazil	814294006
SEPHADEX	India	516533
SEPHADEX	Norway	53469
SEPHADEX	Denmark	VR195901979
SEPHADEX	Argentina	2578214
SEPHADEX	Portugal	249097
SEPHADEX	United Kingdom	788337
SEPHADEX	Spain	1271007
SEPHADEX	Italy	1256283
SEPHADEX	Austria	43730
SEPHADEX	Canada	45750 TMA119497
SEPHADEX	Finland	35720
SEPHADEX	United States of America	2752292
SEPHADEX	Reavil	814294022
SEPHADEX	Sweden	115437
SEPHADEX	Argentina	2601644
SEPHADEX	Ireland	2001044
SEPHADEX	Switzerland	2P-302053
SEPHADEX	France	
SEPHADEX	Israel	1304612 21709
SEPHADEX	Japan	709762
SEPHADEX	China	850035
SEPHADEX	Australia	250793
SEPHADEX	Germany	750175
SEPHADEX	New Zealand	730173
SEPHADEX	Benelux	72726 83837
SEPHADEX	French Polynesia	1304612
SEPHAROSE	Brazil	814294014
SEPHAROSE	Australia	
SEPHAROSE	China	482650 850048
SEPHAROSE	Japan	1960742
SEPHAROSE	United States of America	832512
SEPHAROSE	India	516535
SEPHAROSE	Cuba	4762002
SEPHAROSE	CIM	3399731
SEPHAROSE	Switzerland	P-341236
SEPHAROSE	Canada	TMA155718
SEPHAROSE	Norway	68277
SOURCE	United States of America	2006485
SOURCE	CTM	3476298
STREAMLINE	United States of America	1937434
STREAMLINE	CTM	
STREAMLINE	Japan	3498111 3047349
STREAMLINE	Japan Japan	3047349 3077300
SUPERDEX	Japan Japan	3077300 2245801
SUPERDEX	Japan	2341445
SUPERDEX	CTM	2341445 3344462
SUPERDEX	United States of America	
SUPEROSE	Argentina	1793147
wor nowall	ता हुण्यामार्थ	2546272

SUPEROSE	Canada	TMA323094
SUPEROSE	Mexico	708125
SUPEROSE	New Zealand	170047
SUPEROSE	United States of America	1811757
SUPEROSE	CTM	2129120
SUPEROSE	Japan	2015930
SUPEROSE	Australia	482649





15 DU0823	232368 11 DU0823 COLUMN	232368 8 DU0823 THEREOP	232368 4 DU0823 COLLUMN	232368 3 DU0823 COLUMN	OMORNO	224973 1 DUOTUA COLUMN CHROMA	2 D.40766	2 DJ0787 2 DJ0766 2 DJ0766	2 DU0768 2 DU0767 2 DU0766 1 DU0704	2 DU0768 2 DU0768 2 DU0767 2 DU0766	6 DU0573 1 DU0768 2 DU0768 2 DU0767 2 DU0766 1 DU0704	4 DU0673 6 DU0873 1 DU0768 2 DU0768 2 DU0768 2 DU0767	5 DU0873 4 DU0673 6 DU0573 1 DU0768 2 DU0768 2 DU0768 1 DU0766	3 DUBE73 5 DU0573 4 DU0673 6 DU0673 7 DU0768 2 DU0768 2 DU0768 2 DU0769	2 DU0673 3 DU0673 5 DU0673 4 DU0673 6 DU0673 7 DU0768 2 DU0768 2 DU0768 1 DU0768	1 DU0673 2 DU0673 3 DU0673 4 DU0673 4 DU0673 6 DU0673 2 DU0768 2 DU0768 2 DU0768
OF OF	ТОСКАРНҮ	CHROMATOGRAPHY COLUMN AND PART KROMA THEREOF NN OC	COLUMN ASSEMBLY NN OC	COLUMN ASSEMBLY NN OC		TOGRAPHY	FOR TOGRAPHY TOGRAPHY	TOGRAPHY TOGRAPHY	TOGRAPHY TOGRAPHY TOGRAPHY	TOGRAPHY TOGRAPHY TOGRAPHY TOGRAPHY TOGRAPHY	TOGRAPHY TOGRAPHY TOGRAPHY TOGRAPHY TOGRAPHY	TOGRAPHY TOGRAPHY TOGRAPHY TOGRAPHY TOGRAPHY TOGRAPHY	TOGRAPHY TOGRAPHY TOGRAPHY TOGRAPHY TOGRAPHY TOGRAPHY TOGRAPHY	TOGRAPHY TOGRAPHY TOGRAPHY TOGRAPHY TOGRAPHY TOGRAPHY TOGRAPHY	TOGRAPHY TOGRAPHY TOGRAPHY TOGRAPHY TOGRAPHY TOGRAPHY TOGRAPHY TOGRAPHY	TOGRAPHY TOGRAPHY TOGRAPHY TOGRAPHY TOGRAPHY TOGRAPHY TOGRAPHY TOGRAPHY
KROMATOGRAFIKOLO	KROMATOGRAFIKOLO	KROMATOGRAFIKOLO	KROMATOGRAFIKOLO NN OCH DEL D-RAV Issued	KROMATOGRAFIKOLO NN OCH DEL D-RAV (Issued	de se	CHROMATOGRAPHY CCLUMN	TOGRAPHY TOGRAPHY									
m S	m M	S O	US.	US	MM		U _S	<u>8</u> %	हा है है	LS LS EX	Co So So Ed N	S S S S S	C S S S E E N C E			
26/n8/2018	26/08/2008	27/08/2008	25/08/2008	25/08/2008	12/01/2007		20/12/2007	20/12/2007	20/12/2007	05/07/2007 20/12/2007 20/12/2007 20/12/2007	18/01/2007 05/07/2007 20/12/2007 20/12/2007 20/12/2007	18/01/2007 18/01/2007 05/07/2007 20/12/2007 20/12/2007	18/01/2007 18/01/2007 18/01/2007 05/07/2007 20/12/2007 20/12/2007	16/01/2007 16/01/2007 18/01/2007 18/01/2007 98/01/2007 20/12/2007 20/12/2007	16/01/2007 16/01/2007 16/01/2007 18/01/2007 18/01/2007 20/12/2007 20/12/2007	19/07/2006 16/01/2007 16/01/2007 18/01/2007 18/01/2007 18/01/2007 20/12/2007 20/12/2007
000982813-	000992813- 0004	ZL2008301 35786.1	D600580	D600579	000651344		D629979	C1569008	0869980 0869900 0869900	000764122 0001 0639990 0639979	208203 000764122 0001 0639990 0639979		<u> </u>			
58/08/20143	26/08/2033	27/05/2018	22/09/2013	22/09/2023	12/01/2032		14/06/2025	13/05/2022	14/06/2025 13/06/2022 14/06/2025	05/07/2032 14/08/2025 13/05/2025	05/07/2032 14/06/2025 14/06/2025	18/01/2017 05/97/2032 14/06/2025 13/05/2022	18/01/2032 18/01/2017 18/01/2017 05/07/2032 14/08/2025 14/08/2025	18/01/20223 16/01/2032 18/01/2017 18/01/2017 05/07/2032 05/07/2032 14/06/2025 14/06/2025	16/10/2024 18/01/2023 18/01/2032 18/01/2017 18/01/2025 14/06/2025	19/07/2031 16/10/2024 16/10/2023 16/01/2032 16/01/2032 16/01/2032 14/06/2025 14/06/2025
			http://www.google.com/patents?vid=L SPATD900580	http://www.google.com/patents?vid=L			D639979</a 	<a hre="http://www.googie.com/pstents?vid=<br">USPATD569008>D559008 <a hre="http://www.googie.com/pstents?vid=<br">http://www.googie.com/pstents?vid= USPATD639979>D839979	- - - - - USPATID639980-26338980-4/a> - - - USPATID639980-25638980-4/a> - - USPATID669008-25658008-4/a> - - - - USPATID669078-2658008-4/a> - USPATID669078-2658008-2668078-4/a> - USPATID669978-25038973-4/a> USPATID669978-25038973-4/a>	D639980 D659008 D659008 D839073 D839073	 da href=ittp://www.googie.com/patents?vid=USPATD539980>D639886 da href=ittp://www.googie.com/patents?vid=USPATD569008>D558088 da href=http://www.googie.com/patents?vid=USPATD569078>D538079 da USPATD639978>D538979 USPATD639978>D538979 	D639980 <a com="" patents?vid="USPATD659000\$-D659008</a"> <a com="" patents?vid="USPATD659001\$-D659008</a"> D839098 D839979	ea href=ntp://www.google.com/patents?vid= USPATD639980>D639980 ea href=htp://www.google.com/patents?vid= USPATD669009>D659008 ea href=htp://www.google.com/patents?vid= USPATD6399719>D839979	-ca -ca USPATD601912>D601912 USPATD601912>D601912 48 href=htp://www.google.com/patents?vid= -ca USPATD609980>D60986 48 href=htp://www.google.com/patents?vid= -ca href=htp://www.google.com/patents?vid= USPATD60987B>D0098-com/patents?vid= USPATD60987B>D0098-com/patents?vid= USPATD60987B>D0098-com/patents?vid=	<a href="http://www.google.com/patents?vid=<br">USPATD601912>D601912 <a href="http://www.google.com/patents?vid=<br">USPATD509980>D639880 <a href="http://www.google.com/patents?vid=<br">USPATD569008>D558008 <a href="http://www.google.com/patents?vid=<br">USPATD639978>D538979 <a href="http://www.google.com/patents?vid=<br">USPATD639978>D538979 <a href="http://www.google.com/patents?vid=<br">USPATD639978>D538979	<a href="http://www.google.com/patents?vid=<br">USPATD601912>D601912 <a href="http://www.google.com/patents?vid=<br">USPATD609980>D639880 <a href="http://www.google.com/patents?vid=<br">USPATD669908>D65908 <a href="http://www.google.com/patents?vid=<br">USPATD669008>D65908 <a href="http://www.google.com/patents?vid=<br">USPATD66978>D65908 <a href="http://www.google.com/patents?vid=<br">USPATD66978>D65908 <a href="http://www.google.com/patents?vid=<br">USPATD66978>D65908 <a href="http://www.google.com/patents?vid=<br">USPATD66978>D65908 <a href="http://www.google.com/patents?vid=<br">USPATD66978>D65908 <a href="http://www.google.com/patents?vid=<br">USPATD66978>D65908
GHBSAB	GHBSAB	GHBSAB	GHBSAB	GHBSA8	GHBSA8		GHESAB	GHESAB GHESAB	ļ							





PATENT

APPENDICES

Appendix A	Business Transfer Agreement
Appendix 1.1	Equity Guarantee
Appendix 1.2	Board resolution of Instrumentarium AB approving the Business Transfer
Appendix 2.1	Shareholders resolution of BioProcess approving the Business Transfer
Appendix 2.2	Board resolution of BioProcess approving the Business Transfer
Appendix 2.3	Shareholders resolution of Bio-Sciences approving the Business Transfer
Appendix 2.4	Board resolution of Bio-Sciences approving the Business Transfer
Appendix 2.5	Shareholders resolution of Instrumentarium AB approving unconditional shareholder contribution to BioProcess
Appendix 3.1A	Board resolution of Instrumentarium AB approving the unconditional shareholder contribution
Appendix 3.1B	Unconditional shareholder contribution document
Appendix 4.1	CP Satisfaction Letter
Appendix 6.1	Intellectual Property Licence Agreement
Appendix 6.2	Research and Development Agreement
Appendix 6.3	Intellectual Property Licence Agreement (Shared IPR)
Appendix 6.4	Intra-Group Shared Services Agreement

This CLOSING AGENDA (the "Closing Agenda") is dated 30 December 2015 (the "Closing Date") and made between:

- (1) **GE Healthcare BioProcess R&D AB**, Reg. No. 556707-7366, a limited liability company incorporated under the laws of Sweden, and having its registered office at 751 84 Uppsala ("BioProcess"); and
- (2) **GE Healthcare Bio-Sciences AB**, Reg. No. 556108-1919, a limited liability company incorporated under the laws of Sweden, and having its registered office at 751 84 Uppsala ("Bio-Sciences").

Each of the Seller and the Purchaser is hereinafter referred to as a "Party" and, jointly, as the "Parties".

BACKGROUND

- A. The Seller and the Purchaser have entered into a business transfer agreement on 18

 December 2015 (the "Business Transfer Agreement") Appendix A, under which the
 Seller has agreed to sell, and the Purchaser has agreed to purchase the Chromatography
 Media Business.
- B. Capitalized terms used but not otherwise defined herein shall have the same meaning ascribed to them in the Business Transfer Agreement and, unless otherwise provided for hereinafter, all references to a Clause are references to the relevant Clause of the Business Transfer Agreement.
- C. The Parties have convened at the offices of Mannheimer Swartling Advokatbyrå AB, Norrlandsgatan 21, Stockholm, on this day to consummate the Business Transfer and to take the actions prescribed and required for the Closing under the Business Transfer Agreement.

NO.	CLAUSE	ACTION/DELINERY
1.	ACTIONS	PRECEDING CLOSING
1.1	N/A	It was acknowledged that GE Medical Systems Information Technologies Inc had made an equity guarantee in favour of Instrumentarium AB, Appendix 1.1.
1.2	N/A	It was acknowledged that the board of Instrumentarium AB had approved the Business Transfer, <u>Appendix 1.2</u> .
2.		AUTHORITY
2.1	N/A	It was acknowledged that the general meeting of shareholders in BioProcess had approved the Business Transfer, <u>Appendix 2.1</u> .
2.2	N/A	It was acknowledged that the board of BioProcess had approved the Business Transfer, <u>Appendix 2.2</u> . The board resolutions also contain authorisations to act on behalf of BioProcess.

NO	CLAISE	ACHONDELIVERY
2.3	N/A	It was acknowledged that the general meeting of shareholders in Bio-Sciences had approved the Business Transfer, <u>Appendix 2.3</u> .
2.4	N/A	It was acknowledged that the board of Bio-Sciences had approved the Business Transfer, <u>Appendix 2.4</u> . The board resolutions also contain authorisations to act on behalf of Bio-Sciences.
2.5	N/A	It was acknowledged that the general meeting of shareholders in Instrumentarium AB had approved the unconditional shareholder contribution from Instrumentarium AB to BioProcess set out in item 3.1 below, <u>Appendix 2.5</u>
3.	UNCONDI TO BIOPR	TIONAL SHAREHOLDER CONTRIBUTION FROM INSTRUMENTARIUM ABOCESS
3.1	N/A	It was acknowledged that Instrumentarium AB made an unconditional shareholder contribution to BioProcess, Appendix 3.1A (Board minutes) and 3.1B (contribution document).
4,	CONDITIC	ONS PRECEDENT
4.1	4	The Parties acknowledged that each Condition Precedent has been fully satisfied or waived as further set out in the CP Satisfaction Letters duly executed by the Parties, Appendix 4.1.
5.	PRE-CLOS	ING ACTIONS
5.1	3.2	The Parties acknowledged that the Seller has delivered to the Purchaser details of the Seller's Bank Account (as defined below) in due time pursuant to Clause 3.2 of the Business Transfer Agreement.
6.	CLOSING.	ACTIONS UNDER THE BUSINESS TRANSFER AGREEMENT
	Miscellaneo	
6.1	F	The Parties acknowledged that the Intellectual Property Licence Agreement had been duly signed and executed by the Parties, <u>Appendix 6.1</u> .
6.2	Œ	The Parties acknowledged that the Research and Development Agreement had been duly signed and executed by the Parties, <u>Appendix 6.2</u> .
6.3	F	The Parties acknowledged that the Intellectual Property Licence Agreement (Shared IPR) had been duly signed and executed by the Parties, <u>Appendix 6.3</u> .
6.4	F	The Parties acknowledged that the Intra-Group Shared Services Agreement had been duly signed and executed by the Parties, <u>Appendix 6.4</u> .

NO	61.01.51	ACCETON/DELEVERY				
	Payment of	the Purchase Price and Closing Certificate				
6.5	3.1	The Purchaser paid the Purchase Price of SEK 65,731,000,000 (Sixty Five Billion Seven Hundred Thirty-one Million Swedish krona) in immediately available funds to the following bank account held by Bio-Sciences (the "Seller's Bank Account"): Bank: Danske Bank Sweden Account number: SE9812000000012410104673 SWIFT: DABASESX				
6.6	N/A	Bio-Sciences confirmed the receipt of the Purchase Price of SEK 65,731,000,000 (Sixty Five Billion Seven Hundred Thirty-one Million Swedish krona).				
6.7	3.2	The Parties acknowledged that the payment of the Purchase Price has been made in due time pursuant to Clause 3.2 of the Business Transfer Agreement.				
6.8	5.2.1	BioProcess and Bio-Sciences agreed that this Closing Agenda shall be deemed to be the Closing Certificate referred to in Clause 5.2.1 of the Business Transfer Agreement.				
	Notification of block of access					
6.9	7.2.10	The Parties confirmed that a notification was sent to GE Healthcare Bio-Sciences Corp. attention Amit Barkan, administrator of Magic and Wipro GE Healthcare Private Limited, attention Jayakrishnan, KG, administrator of ConDoc and Aptrix, confirming that the Purchaser, effective as of the Closing Date, has the right to block Bio-Sciences' access to the Transferred Intellectual Property in said systems.				
30 U 30 V.,	Consummation of Closing					
6.10	N/A	The Parties confirmed that Closing has been duly and fully completed in accordance with the Business Transfer Agreement.				
	Governing law and disputes					
6.11	N/A The Parties agreed and acknowledged that Clause 9.6 (Governing law and disputes the Business Transfer Agreement shall apply to this Closing Agenda.					

IN WITNESS WHEREOF, this Closing Agenda has been signed in two (2) originals, of which the Parties have taken one (1) each.

Date: Signed and released on 30 December 2015

GE HEALTHCARE BIOPROCESS R&D AB

Name: Cárolina Hammarqvist, p.p.a

Date: Signed and released on 30 December 2015

GE HEALTHCARE BIO-SCIENCES AB

Name: Jan Erneberg, p.p.a

Yb	
Business Transfer Agreement	
dated 18 December 2015	
	onnon-
GE Healthcare Bio-Sciences AB	
and	
GE Healthcare BioProcess R&D AB	
Transfer of Chromatography Media Business	
a section of the desired graphs of the desired as the desired of the desired as the desired of the desired as the desired of t	



TABLE OF CONTENTS

1.	DEFINITIONS AND INTERPRETATION	4
2.	SALE AND PURCHASE	6
3.	PURCHASE PRICE AND PAYMENT	7
	CONDITIONS PRECEDENT	
5.	CLOSING	9
	REPRESENTATIONS AND WARRANTIES	
7.	COVENANTS	.13
8.	INDEMNIFICATION	. 17
9.	MISCELLANEOUS	. 20

SCHEDULES

Schedule F(a)	Intellectual Property Licence Agreement (Chromatography Media Business)
Schedule F(b)	Research and Development Agreement
Schedule F(c)	Intellectual Property Licence Agreement (Shared IPR)
Schedule F(d)	Intra-Group Shared Services Agreement
Schedule 1.1 C	Chromatography Media Business
Schedule 1.1 PS	Pro Forma Financial Statements
Schedule 2.1.1(a)	Transferred Intellectual Property Rights
Schedule 2.1.1(b)	Assumed Contracts
Schedule 2.1.1(c)	Shared Contracts



This Business Transfer Agreement is dated 18 December 2015 and made between:

- (1) GE Healthcare Bio-Sciences AB, Reg. No. 556108-1919, a limited liability company incorporated under the laws of Sweden; and having its registered office at 751 84 Uppsala ("Bio-Sciences"); and
- (2) GE Healthcare BioProcess R&D AB, Reg. No. 556707-7366, a limited liability company incorporated under the laws of Sweden; and having its registered office at Björkgatan 30, 751 84 Uppsala, (the "Purchaser").

Capitalized terms shall have the meaning ascribed to them in Clause 1.1 below.

BACKGROUND

- In addition to other business areas, Bio-Sciences conducts the Chromatography Media Business.
- B. Bio-Sciences is interested in divesting the Chromatography Media Business to the Purchaser and the Purchaser is interested in acquiring the Chromatography Media Business. The Business Transfer is carried out within the scope of a current internal reorganisation. The objectives of the internal reorganisation is to (i) increase the protection of the chromatography media business by ring-fencing it from potential third party claims and (ii) start the consolidation of the global IP of the chromatography media business and R&D funding of that IP within a single legal entity.
- C. The core of the Chromatography Media Business consists of the commercial product ownership of the products within the Chromatography Media Business and, accordingly, includes the Transferred Intellectual Property Rights attributable to the products within the Chromatography Media Business (including any additional thereto related Intellectual Property Right) and contracts related to such Transferred Intellectual Property Rights...
- D. The Purchaser will, at least initially, engage Bio-Sciences as its (i) manufacturer, (ii) research and development organization, and (iii) sales and distribution channel. In light thereof and for the sake of clarity, the Chromatography Media Business to be transferred to the Purchaser does not include any employees, fixed assets, real property, leases of premises, or sales contracts with customers.
- E. It is acknowledged that the Parties are companies within the same group of companies but both Parties are of the opinion that this Agreement is made on fair market terms and at arm's length.
- F. Simultaneously when signing this Agreement, Bio-Sciences and the Purchaser have undertaken to enter into the following agreements, all of which will enter into force at the Closing:
 - (a) an Intellectual Property Licence Agreement (Chromatography Media Business), Schedule F(a);
 - (b) a Research and Development Agreement, Schedule F(b);
 - (c) an Intellectual Property Licence Agreement (Shared IPR), Schedule P(c); and
 - (d) an Intra-Group Shared Services Agreement, Schedule F(d).



G. In view of the foregoing, the Parties hereby agree as follows.

1. DEFINITIONS AND INTERPRETATION

1.1 Definitions

- "Affiliate" means with respect to any Person as of any time, (i) any other Person directly or indirectly controlled by or under the common control with that first-mentioned Person and (ii) any other Person(s) directly or indirectly controlling or jointly controlling such first-mentioned Person. For the purposes of this definition, "control" (including, with correlative meaning, the terms "controlling", "controlled by" and "under the common control with") means the possession, directly or indirectly, of the power to direct or cause the direction of management and policies of such Person through the ownership of more than fifty (50) per cent of the voting securities, by contract or otherwise.
- "Agreement" means this business transfer agreement, including any schedules hereto, as it or they may be amended from time to time in accordance with the terms hereof.
- "Ancillary Agreements" means the agreements referred to in item F in the background to this Agreement.
- "Assumed Contracts" is defined in Clause 2.1.1(b).
- "Assumed and Shared Contracts" means those Assumed Contracts that require Third Party Consent and the Shared Contracts, individually or jointly as the case may be.
- "Chromatography Media Business" is defined in Schedule 1.1 C.
- "Business Assets" is defined in Clause 2.1.1.
- "Business Day" means a day (other than a Saturday or Sunday or public holiday) on which banks generally are open for business in Sweden, other than for internet banking services.
- "Business Liabilities" is defined in Clause 2.2.1.
- "Business Transfer" means the transfer of the Business Assets to, and the assumption of the Business Liabilities by, the Purchaser pursuant to this Agreement.
- "Cash" means cash in hand or deposited in a bank, or checks, money orders, marketable securities, short-term instruments and other cash equivalents.
- "Claim" means a claim made by the Purchaser under the Warranties.
- "Closing" means the completion of the Business Transfer and the completion or waiver (if applicable) of the closing actions set forth in Clause 5.2.
- "Closing Date" means 30 December 2015, provided, however, that all the Conditions Precedent have been satisfied or, if applicable, waived prior to such date and otherwise (i) the 6th (5th) Business Day after the date when all the Conditions Precedent have been satisfied or, if applicable, waived or (ii) such later date as the Parties may agree on in writing.
- "Conditions Precedent" means the conditions precedent set forth in Clause 4.

(i)

- "Confidential Information" means any and all information of any kind or nature whatsoever, whether written or oral, including, without limitation, financial information, trade secrets, customer lists and other proprietary business information, regarding the Purchaser, Bio-Sciences or any Affiliate of the Parties, or their respective products or services, which information is not known to the general public or to persons unaffiliated with the Purchaser, Bio-Sciences or any Affiliate of the Parties, as the case may be.
- "Covenants" means the covenants set forth in Clause 7.
- "Encumbrance" means any option, lien, mortgage, pledge, charge, retention of title, or other third party right or security interest of any kind or an agreement, arrangement or obligation to create any of the foregoing.
- "GAAP" means generally accepted accounting principles, such as International Financial Reporting Standards as published by the International Financial Standards Board, (Sw. "god redovisningssed") or any other similar standards.
- "Intellectual Property Rights" means patents, trademarks, registered designs, copyrights and neighbouring rights, including data bases, Know-How and other rights of a similar kind in any part of the world whether registered or not, including applications for the registration of such rights.
- "Know-How" means any trade secrets and confidential and proprietary industrial and commercial information and techniques in any form including, without limitation, drawings, formulae, test results, reports, project reports and testing procedures, instruction and training manuals, tables of operating conditions, lists and particulars of customers and suppliers and market forecasts.
- "Liabilities" means any and all debts, liabilities and obligations, whether accrued or fixed, known or unknown, absolute or contingent, matured or un-matured or determined or determinable.
- "Loss" means all direct and reasonably foreseeable indirect losses, deficits, liabilities, damages, costs and expenses (including reasonable settlement costs and reasonable legal, accounting and other expenses for investigating or defending any actions or threatened actions).
- "Party (-ies)" means Bio-Sciences and the Purchaser, either individually or jointly as the case may be.
- "Person" means any individual, legal entity or any other entity, including any authority.
- "Pro Forma Financial Statements" means the pro forma financial statements enclosed hereto as Schedule 1.1 PS.
- "Purchase Price" is defined in Clause 3.1.
- "Purchaser" is defined in the preamble to this Agreement.
- "Signing Date" means the date of the duly execution of this Agreement by the Parties.
- "Shared Contracts" is defined in Clause 2.1.1(c).
- "Tax Invoice" is defined in Clause 3.3.2(b).



"Third Party Consent" means any necessary approvals from a third party to transfer a contract to the Purchaser under this Agreement and, where relevant after such transfer, sublicense the Intellectual Property Rights back to Bio-Sciences where such sub-license is needed for Bio-Sciences' continued operations.

"Transferred Intellectual Property Rights" is defined in Clause 2.1.1(a).

"Warranties" means all of the representations and warranties made by Bio-Sciences set out in Clause 6.1.

1.2 Interpretation

- 1.2.1 Unless a contrary indication appears, any reference in this Agreement to:
 - (a) a provision of law is a reference to that provision as amended or re-enacted; and
 - (b) the singular includes the plural and vice versa.
- 1.2.2 Clause and schedule headings are for ease of reference only and shall not affect the construction of this Agreement.
- 1.2.3 References to clauses, paragraphs and schedules are references to clauses, paragraphs and schedules to this Agreement unless otherwise stated.

2. SALE AND PURCHASE

2.1 Business Assets

- 2.1.1 On the Closing Date, Bio-Sciences shall sell and transfer and the Purchaser shall purchase and acquire the following assets and rights pertaining to the Chromatography Media Business that are further specified in sub-clauses (a) and (c) in this Clause 2.1.1 (the "Business Assets"):
 - (a) all Intellectual Property Rights listed or described in <u>Schedule 2.1.1(a)</u> (collectively the "Transferred Intellectual Property Rights");
 - (b) all of Bio-Sciences' rights under the contracts listed in <u>Schedule 2.1.1(b)</u> (collectively the "Assumed Contracts") to the extent they are not yet performed or discharged prior to the Closing Date. Notwithstanding the aforesaid, all receivables for license fees (royalties) attributable to time prior to 1 January 2016 shall be excluded (and thus be invoiced by Bio-Sciences);
 - (c) such of Bio-Sciences' rights under the contracts listed in Schedule 2.1.1(c) (collectively the "Shared Contracts") that are attributable to the Chromatography Media Business and to the extent they are not yet performed or discharged prior to the Closing Date.
- 2.1.2 For the avoidance of doubt, no assets or rights other than those specified in sub-clauses (a) through (c) in Clause 2.1.1 are sold or assigned to the Purchaser under this Agreement, and the Parties specifically agree and acknowledge that the Business Transfer does not include:
 - (a) any Cash, fixed assets, inventory or real property;



- (b) any contracts for sale of products or services; and
- (c) any accounts receivable (i.e. accounts receivable invoiced prior to Closing) attributable to the Chromatography Media Business (all such accounts receivable will be retained by Bio-Sciences).

2.2 Business Liabilities

- 2.2.1 On the Closing Date, Bio-Sciences shall sell and transfer and the Purchaser shall purchase and assume the Liabilities pertaining to the Chromatography Media Business that are further specified in sub-clauses (a) through (b) in this Clause 2.2.1 (the "Business Liabilities"):
 - (a) all of Bio-Sciences' Liabilities arising under the Assumed Contracts to the extent they are not yet performed or discharged prior to the Closing Date. Notwithstanding the aforesaid, all payables for license fees (royalties) attributable to time prior to 1 January 2016 shall be excluded (and thus be paid by Bio-Sciences); and
 - (b) all of Bio-Sciences' Liabilities arising under the Shared Contracts that are attributable to the Chromatography Media Business and to the extent they are not yet performed or discharged prior to the Closing Date.
- 2.2.2 For the avoidance of doubt, no Liabilities other than those specified in sub-clauses (a) through (b) in Clause 2.2.1 are accepted and assumed by the Purchaser under this Agreement. It is acknowledged that no employees shall be transferred to the Purchaser and, hence, no Liabilities attributable to employees shall be assumed by the Purchaser.

3. PURCHASE PRICE AND PAYMENT

3.1 Purchase Price

The total purchase price for the Chromatography Media Business consisting of the Business Assets and the Business Liabilities (the "**Purchase Price**") shall be Sixty Five Billion Seven Hundred Thirty-one Million SEK (65,731,000,000).

3.2 Payment of Purchase Price

Subject to Clause 4, the Purchaser shall pay the Purchase Price to Bio-Sciences on the Closing Date. The Purchase Price shall be paid by transfer of immediately available funds, without any set-off, withholding or counterclaim, to the bank account designated by Bio-Sciences.

3.3 VAT

- 3.3.1 The Parties agree and acknowledge:
 - (a) that the Business Transfer constitutes a transfer of business that qualify as a VAT exempt transfer of a going concern in accordance with Chapter 3, Clause 25 of the Swedish VAT Act (Sw. mervärdesskattelagen (1994:200)); and
 - (b) consequently, that VAT will not be levied on the Business Transfer.



- 3.3.2 If the Business Transfer, or any part thereof, is deemed as a taxable transaction from a VAT point of view by the tax authorities:
 - (a) VAT shall be levied on the taxable part of the Business Transfer in accordance with applicable law; and
 - (b) Bio-Sciences shall provide the Purchaser with a valid invoice that (i) specifically states the charged VAT, (ii) meets all requirements imposed by the tax authorities and (iii) meets all further conditions required to allow the Purchaser to obtain applicable tax relief, if available (the "Tax Invoice").
- 3.3.3 Upon receipt of a Tax Invoice, the Purchaser shall pay the VAT amount set out in the Tax Invoice to Bio-Sciences within ten (10) Business Days. For the sake of clarity, the Parties specifically agree and acknowledge that the Purchaser shall be under no obligation to pay any VAT under this Agreement to Bio-Sciences unless provided with a Tax Invoice.

4. CONDITIONS PRECEDENT

4.1 Conditions Precedent to the Purchaser's obligation to Close

The obligation of the Purchaser to proceed to the Closing shall be conditional upon each of the following being satisfied or waived by the Purchaser:

- (i) the performance by Bio-Sciences of all covenants set forth herein that are to be performed by Bio-Sciences prior to or on Closing (in particular the entering into the Ancillary Agreements as referred to in Clause 7.1.2);
- (ii) the Purchaser shall have received all of the items required to be delivered to it pursuant to Clause 5.2; and
- (iii) no order, decision or ruling of a court or regulatory authority shall have been made enjoining the completion of the transactions contemplated hereby.

4.2 Conditions Precedent to Bio-Sciences' obligations to Close

The obligation of Bio-Sciences to proceed to the Closing shall be conditional upon each of the following being satisfied or waived by Bio-Sciences:

- the performance by the Purchaser of all covenants set forth herein that are
 to be performed by the Purchaser prior to or on Closing (such as, without
 limitation, the payment of the Purchase Price);
- (ii) Bio-Sciences shall have received all of the items required to be delivered to it pursuant to Clause 5.2; and
- (iii) no order, decision or ruling of a court or regulatory authority shall have been made enjoining the completion of the transactions contemplated hereby.



4.3 Drop dead date

In the event that not all of the conditions precedent set forth in Clauses 4.1 or 4.2 above have not been satisfied or waived by Bio-Sciences (in relation to the conditions set forth in Clause 4.2) or the Purchaser (in relation to the conditions set forth in Clause 4.1) on or before 31 December 2015 or if the Closing for any other reason has not occurred prior to such date, Bio-Sciences or the Purchaser (as applicable) shall be entitled to terminate this Agreement with immediate effect by giving written notice, provided that such termination will not affect any claims between the Parties arising prior to the date at which this Agreement is terminated (including claims related to a Party's failure to satisfy its conditions to Closing due to a failure to exercise appropriate efforts as required by Clauses 5.2 and 7.1).

5. CLOSING

5.1 Date, time and place

The Closing shall take place on the Closing Date starting at 09.00 (CET) at the Stockholm offices of Mannheimer Swartling Advokatbyrå.

5.2 Closing actions

- 5.2.1 At Closing, each of the Parties shall deliver the other Party the Closing Certificate, confirming that Closing has occurred under this Agreement.
- 5.2.2 At Closing, each of the Parties shall use its reasonable endeavours to take, or cause to be taken, all actions and to do, or cause to be done, all things necessary or desirable under applicable laws and regulations to consummate the Business Transfer, including, without limitation, signing any additional documents or instruments reasonably requested by the other Party.

5.3 Transfer of risk and title

- 5.3.1 Title to the Transferred Intellectual Property Rights shall pass and transfer to the Purchaser at the Closing, whereby it is acknowledged that in relation to certain patents registered outside Sweden certain registration activities may be required in order for the transfer to be enforceable as against third parties. In addition, it is further acknowledged that the community trademarks and community designs the transfer will be enforceable as against third parties only upon the completion of the registration referred to in Clause 7.2.1.
- 5.3.2 The rights and obligations under the Assumed Contracts that are not subject to any Third Party Consent (or which are subject to Third Party Consent but where such consent has been obtained prior to Closing), shall be deemed transferred to and assumed by the Purchaser at Closing.
- 5.3.3 The rights and obligations under the Assumed Contracts that are subject to any Third Party Consent and where such Third Party Consent has not been obtained prior to the Closing Date, shall be deemed not to have been transferred and assumed on the Closing Date but shall only be deemed transferred and assumed if and when such Third Party Consent has been obtained.
- 5.3.4 The rights and obligations under the Shared Contracts shall be deemed not to have been transferred and assumed on the Closing Date but shall only be deemed transferred and



assumed if and when the rights and obligations under such Shared Contracts attributable to the Chromatography Media Business have been separated from the other rights and obligations under such Shared Contracts and necessary Third Party Consent has been obtained.

5.4 Failure to complete Closing

- 5.4.1 If the Purchaser, on the one hand, or Bio-Sciences, on the other hand, fails to materially comply with any of its obligations under Clause 5.2, the non-defaulting Party shall be entitled in its sole discretion to:
 - (a) terminate this Agreement, which, however, shall not prejudice the non-defaulting Party's right to indemnification with respect to the defaults which have occurred and shall not affect this Clause 5.4 or Clause 9, which shall survive such termination;
 - (b) effect the Closing so far as is practicable which, however, shall not prejudice the non-defaulting Party's right to indemnification with respect to the defaults which have occurred; or
 - (c) specify a new date for Closing, which shall be a Business Day no more than five (5) Business Days after the original Closing Date, in which case the provisions of this Clause 5.4 (except for this sub-clause (c)) shall apply to the Closing so deferred.

6. REPRESENTATIONS AND WARRANTIES

6.1 Representations and warranties of Bio-Sciences

Subject to the qualifications and limitations set forth in this Agreement, Bio-Sciences makes the following Warranties to the Purchaser. The Warranties are made on and as of the date hereof and as of Closing.

6.1.1 <u>Authority</u>

- 6.1.1.1 Bio-Sciences has full corporate power and authority to execute and deliver this Agreement and the Ancillary Agreements and each other agreement, document or instrument delivered in connection herewith and to consummate the transactions contemplated hereby and thereby.
- 6.1,1.2 Any documents or instruments executed by Bio-Sciences in connection with this Agreement (including the Ancillary Agreements) have been duly authorised and constitute binding obligations of, and are enforceable against, Bio-Sciences in accordance with their respective terms.
- 6.1.1.3 The execution by Bio-Sciences of this Agreement and any other document or instrument in connection with it, and the performance by Bio-Sciences of its obligations under the Agreement and the consummation of the transaction provided for in this Agreement, do not, and will not, result in a breach of any provision of the articles of association of Bio-Sciences.

1 1/1

6.1.2 Financial

- 6.1.2.1 The Pro Forma Financial Statements include a pro forma profit & loss statement for the period stated therein reflecting an estimate of the financial results of the Chromatography Media Business if such Chromatography Media Business had been a stand-alone business prior to the Closing Date. The Pro Forma Financial Statements have been prepared in good faith by Bio-Sciences with the objective of presenting a fair view of such financial results but both Parties acknowledge that the Pro Forma Financial Statements are proforma and, accordingly, have not been possible to be prepared in accordance with GAAP.
- 6.1.2.2 With the exception of intellectual property matters, which are solely governed by Clause 6.1.4, the Business Assets and the Business Liabilities, together with the services provided by Bio-Sciences under the Ancillary Agreements are sufficient for conducting the Chromatography Media Business materially in the same manner as the Chromatography Media Business was conducted by Bio-Sciences in the twelve (12) months prior to Closing.

6.1.3 Litigation

- 6.1.3.1 There is no order, decree or judgement of any court or any government or agency of Sweden or any foreign country outstanding involving the Chromatography Media Business.
- 6.1.3.2 There is no litigation, investigation, arbitration, or tax proceeding attributable to the Chromatography Media Business pending or, to Bio-Sciences' knowledge, threatened by or against Bio-Sciences that could include the Purchaser or negatively impact the Chromatography Media Business save for the litigation referred to in Clause 7.2.8.

6.1.4 Intellectual Property Rights

- All registered Intellectual Property Rights owned on the Signing Date, or acquired up to and including the Closing Date, by Bio-Sciences and attributable to the Chromatography Media Business are listed in Schedule 2.1.1(a). Bio-Sciences is the sole legal and beneficial owner of all such registered Intellectual Property Rights.
- 6.1.4.2 All, in Bio-Sciences' reasonable opinion, material unregistered Intellectual Property Rights owned by Bio-Sciences and attributable to the Chromatography Media Business are listed (or described) in Schedule 2.1.1(a). Bio-Sciences is the sole legal and beneficial owner of all such unregistered Intellectual Property Rights.
- 6.1.4.3 Save for such rights that are remaining with employees under applicable mandatory laws or national collective bargaining agreements, no Intellectual Property Rights used in the Chromatography Media Business are vested in any former or current employees.
- 6.1.4.4 The Transferred Intellectual Property Rights are not subject to any third party license rights except as granted under the Assumed and Shared Contracts.
- 6.1.4.5 To Bio-Sciences' knowledge, the Know-How included in the Transferred Intellectual Property Rights has been held confidential and duly protected in accordance with good industry practice and no third party has access to such Know-How except under any of the Assumed and Shared Contracts.
- 6.1.4.6 Save as set out in Clause 6.1.3.2 and to Bio-Sciences' knowledge, no third parties have made claims against Bio-Sciences that the Chromatography Media Business (and/or the



- products within the Chromatography Media Business) infringe Intellectual Property Rights of a third party.
- 6.1.4.7 To Bio-Sciences' knowledge and save as set out in Clause 7.2.8, Bio-Sciences has not made any claims against third parties that the Transferred Intellectual Property Rights are being infringed upon by such third party.
- 6.1.4.8 To Bio-Sciences' knowledge, the Transferred Intellectual Property Rights are valid.
- 6.1.5 Agreements
- 6.1.5.1 To Bio-Sciences' knowledge, the Assumed and Shared Contracts have been entered into on fair market terms and on arm's length basis.
- 6.1.5.2 Bio-Sciences is not in default under any Assumed and Shared Contract, nor is, to Bio-Sciences' knowledge, any counterparty to an Assumed and Shared Contract in such default.
- 6.1.5.3 All Assumed Contracts and Shared Contracts are in full force and effect, and, to Bio-Sciences' knowledge, notice for termination of any Assumed Contract or Shared Contracts has not been given or received by Bio-Sciences.
- 6.1.6 No Encumbrances

None of the Business Assets are subject to any Encumbrance.

6.2 Representations and warranties of the Purchaser

The Purchaser represents and warrants as follows below. The representations and warranties are made on and as of the date hereof and as of Closing.

- 6.2.1 Corporate
- 6.2.1.1 The Purchaser has full corporate power and authority to execute and deliver this Agreement and the Ancillary Agreements and each other document or instrument delivered in connection herewith and to consummate the transactions contemplated hereby and thereby.
- 6.2.1.2 Any documents or instruments executed by the Purchaser in connection with this Agreement or any Ancillary Agreement have been (or will at Closing be) duly authorised and constitute binding obligations of, and are enforceable against, the Purchaser in accordance with their respective terms.
- 6.2.1.3 The execution by the Purchaser of this Agreement and any other document or instrument in connection with it, and the performance by the Purchaser of its obligations under this Agreement or any Ancillary Agreement do not, and will not, result in a breach of any provision of the articles of association of the Purchaser.
- 6.2.2 Financing

The Purchaser will on the Closing Date have sufficient cash, available lines of credit or other sources of immediately available funds to enable the Purchaser to make all payments it may be required to make under this Agreement.



7. COVENANTS

7.1 Covenants pending Closing

7.1.1 Conduct of the Chromatography Media Business between the date hereof and the Closing Date

Bio-Sciences undertakes to procure that between the date hereof and the Closing Date, the Chromatography Media Business shall, save as contemplated by this Agreement and except as otherwise agreed in writing by the Purchaser, such consent not to be unreasonably withheld or delayed, carry on the Chromatography Media Business as a going concern in the ordinary course and consistent with past practices with a view to maintaining the Chromatography Media Business as a going concern.

7.1.2 Entering into the Ancillary Agreement

Each of the Parties shall sign and enter into the Ancillary Agreements. The Parties acknowledge that such Ancillary Agreements are conditional upon the Closing occurring under this Agreement.

7.2 Covenants after Closing

7.2.1 Registration of transfer of certain Transferred Intellectual Property Rights

The Parties undertake to use their reasonable endeavours to take any and all actions reasonably required (including signing additional documents) in order to register, as soon as reasonably practical after the Closing Date, the transfer of the Transferred Intellectual Property Rights under applicable laws and regulations, including, without limitation, to register the transfer of the community trademarks and community designs. The Purchaser shall carry the costs for all such registrations and shall promptly upon Bio-Sciences' request reimburse Bio-Sciences for any such reasonable costs incurred by Bio-Sciences.

- 7.2.2 Third Party Consents and split of Shared Contracts
- 7.2.2.1 The Parties undertake to use their reasonable endeavours to obtain, as soon as reasonably practical after the Closing Date, any Third Party Consents and, in case of Shared Contracts implement an effective split of the Shared Contracts between the Parties, whereby the following shall apply:
 - (a) Bio-Sciences shall be the party contacting third parties unless otherwise agreed by the Parties:
 - (b) the Parties shall always keep each other informed of, as well as consult with each other regarding, any negotiations with relevant third parties; and
 - (c) if any transfer fees or similar would be payable to obtain a Third Party Consent, each of the Purchaser and Bio-Sciences shall carry half of all costs for such transfer fees.
- 7.2.2.2 As set out in Clauses 5.3.3 and 5.3.4, immediately upon receipt of a Third Party Consent, the Assumed and Shared Contracts shall be deemed transferred to the Purchaser and, if requested by Bio-Sciences, the Purchaser or the third party, the Parties shall issue a written confirmation of the completion of the transfer of the Assumed and Shared Contract concerned.



- 7.2.2.3 Bio-Sciences shall not have any liability vis-à-vis Purchaser in relation to any non-obtained Third Party Consent provided Bio-Sciences have met its obligations in Clause 7.2.2.1.
- 7.2.3 Interim contract administration
- 7.2.3.1 Until the Third Party Consents have been obtained, and to the extent permitted under the relevant Assumed and Shared Contract, the following shall apply:
 - (a) Bio-Sciences shall, as between the Parties, administer the relevant Assumed and Shared Contract:
 - (b) Bio-Sciences shall perform Bio-Sciences' undertakings under the relevant Assumed and Shared Contract on behalf of the Purchaser and Bio-Sciences shall grant the Purchaser the rights, use and benefits of such Assumed and Shared Contract;
 - (c) all revenues and costs attributable to the relevant Shared Contracts shall be allocated to the Purchaser instead of Bio-Sciences (except for any costs for administering the relevant Assumed and Shared Contracts pursuant to sub-clause (a), which shall be borne by Bio-Sciences); and
 - (d) Bio-Sciences shall use its reasonable endeavours to enforce the relevant Assumed and Shared Contract as directed by the Purchaser through Bio-Sciences.
- 7.2.3.2 Notwithstanding anything to the contrary in Clause 7.2.3.1, until the Third Party Consents have been obtained:
 - (a) any contractual assets, rights, obligations and liabilities arising out of the relevant Assumed and Shared Contracts shall remain with Bio-Sciences in relation to the third parties; and
 - (b) the Purchaser shall be discharged from performing Bio-Sciences' undertakings under, or bearing the relevant costs in relation to, an Assumed and Shared Contract to the extent the associated rights, use or benefits (including revenues) cannot be granted or allocated to the Purchaser.
- 7.2.3.3 In relation to any actual payments to or from third parties under any Assumed and Shared Contract subject to Third Party Consent, the following shall apply until the Third Party Consent has been obtained:
 - (a) Bio-Sciences shall forward any relevant invoices received without undue delay to the Purchaser and the Purchaser shall thereafter pay the invoice amount to Bio-Sciences without undue delay, provided that the Purchaser has no bona fide reasons to withhold payment, in order for Bio-Sciences to procure the payment to the third party;
 - (b) Bio-Sciences shall procure that any invoices in respect of the relevant Assumed and Shared Contract are paid following payment to Bio-Sciences by the Purchaser of such invoice amounts, unless it is possible for the Purchaser to directly pay such invoices to the third parties;
 - (c) if Bio-Sciences is charged any penalty payments due to late payment caused by the Purchaser, the Purchaser shall reimburse Bio-Sciences for such penalty payments;



- (d) the Parties shall use their reasonable endeavours in order to enable the Purchaser to directly receive any payments due from a third party; and
- (e) Bio-Sciences shall procure that any payments received from a third party are forwarded without undue delay to the Purchaser.
- 7.2.3.4 In relation to any VAT (and/or similar sales taxes) in respect of the administration of Assumed and Shared Contracts pursuant to Clause 7.2.3.1(a), the Parties shall use their reasonable endeavours in order to take such actions that are required in order to ensure that VAT does not become a final cost to Bio-Sciences or the Purchaser. If VAT would become a final cost to Bio-Sciences, the Purchaser shall reimburse Bio-Sciences for such cost.
- 7.2.4 Additional contracts and additional Intellectual Property Rights
- 7.2.4.1 The Parties acknowledge that there may be agreements which are exclusively attributable to the Chromatography Media Business but which have not been identified prior to the Signing Date and consequently have not been included in the Assumed Contracts (the "Additional Assumed Contracts") and similarly, also agreements partly attributable to the Chromatography Media Business which have not been identified prior to the Signing Date (the "Additional Shared Contracts").
- 7.2.4.2 Further, there may be other Intellectual Property Rights that are exclusively attributable to the Chromatography Media Business but that were not identified prior to the Signing Date and therefore were not included in the Transferred Intellectual Property Rights but that would have been included had they been identified prior to the Signing Date (the "Additional Intellectual Property Rights").
- 7.2.4.3 The Parties agree that any Additional Assumed Contracts, Additional Shared Contracts or Additional Intellectual Property Rights which may be identified after the Signing Date shall be treated between the Parties based on the following principles:
 - (a) In respect of Additional Assumed Contracts, the Parties shall enter into an amendment of this Agreement for the purposes of effecting the transfer and assumption of any Additional Assumed Contracts;
 - (b) In respect of Additional Shared Contracts, if it would be material to either Party, that the Purchaser assumes responsibility for those parts of an Additional Shared Contract that are attributable to the Chromatography Media Business, the Parties shall (i) use reasonable endeavours to assign, assume, and transfer those rights and liabilities under those contracts that are attributable to the Chromatography Media Business to the Purchaser, through the entering into by the Purchaser of a new agreement with the relevant third parties, thus releasing Bio-Sciences from those rights and obligations or (ii) establish back-to-back arrangements during the remainder of the ordinary term of such Additional Shared Contracts;
 - (c) In respect of Additional Intellectual Property Rights, the Parties shall enter into an amendment of this Agreement for the purposes of transferring such additional items to the Purchaser;

in which case the provisions of Clause 7.2.3 of the Agreement shall apply *mutatis mutandis*; in each case provided that it would not be deemed to be in breach of the relevant Additional Assumed Contract or Additional Shared Contract.

de la

7.2.5 Joint liability for Assumed Contracts and Shared Contracts

Each of the Parties agrees that, where required to complete the transfer of Assumed Contracts and/or Shared Contracts or where specifically requested by a third party to an Assumed Contract and/or Shared Contract, Bio-Sciences shall, jointly with the Purchaser, be liable for and in respect of any and all current or future obligations and liabilities incurred under the Assumed Contracts or Shared Contracts. Each of the Parties agrees that any liability incurred under this Clause 7.2.5 shall be finally settled in accordance with Clause 8.2.3.

7.2.6 Wrong pocketing

Each of the Parties agrees that after the Closing Date, the Purchaser and Bio-Sciences will hold on behalf of the other and will promptly transfer and deliver to the other, from time to time as and when received by them, any payments, cash, cheques, with appropriate endorsements, or other property that each of them may receive on or after the Closing Date which properly belongs to the other Party and will account to the other for all such receipts.

7.2.7 Release of guarantees

The Purchaser shall obtain the release, effective as of Closing, of Bio-Sciences from any guarantee, security, indemnity, bond, letter of comfort or other similar obligations given or incurred by Bio-Sciences to the extent attributable to the Chromatography Media Business.

7.2.8 <u>Litigation</u>

Patent infringement proceedings have been initiated in Canada relating to Canadian patents No. 2394369 and No. 2392611 included in the Transferred Intellectual Property Rights. The litigation concerns ProMetic's manufacturing of agarose beads by a spraying technology. The case is currently pending before a court of first instance and trial will take place in 2016. ProMetic has raised certain invalidity objections in course of the proceedings. Unless the Parties agree otherwise, Bio-Sciences shall remain a party to the litigation post-Closing and the Purchaser shall join such proceedings as a co-party on terms and conditions to be agreed in good faith between the Parties and in in consultation with Canadian counsel representing Bio-Sciences in the litigation.

7.2.9 General assurance

The Parties shall use their reasonable endeavours to take, or cause to be taken, all actions and to do, or cause to be done all things necessary or desirable under applicable laws and regulations to consummate the Business Transfer in the event such need would arise after Closing.

7.2.10 Access to ConDocs, Magic and Aptrix

The Parties undertakes to notify GE Healthcare Bio-Sciences Corp. attention Amit Barkan, administrator of Magic and Wipro GE Healthcare Private Limited, attention Jayakrishnan, KG, administrator of ConDoc and Aptrix that the Purchaser, effective as of Closing, controls the access to the systems ConDoc, Magic and Aptrix respectively, and therefore has the right to block Bio-Sciences access to the Transferred Intellectual Property. Bio-Sciences shall not try to obstruct or circumvent such blocking.



7.2.11 Use of Know How

Bio-Sciences undertakes not to make use of or disclose to any third party any Know-How transferred under this Agreement after the Closing Date, unless and only to the extent permitted under the license agreement referred to in Clause F(a). Bio-Sciences acknowledges and fully accepts that the undertaking by Bio-Sciences in this Clause 7.2.10 has been an essential assumption (Sw. "väsentlig förutsättning") for the Purchaser when entering into this Agreement and when agreeing to pay the agreed Purchase Price.

8. INDEMNIFICATION

8.1 Breach of Warranties

In the event of a breach by Bio-Sciences of any of the Warranties, the Purchaser shall, subject to the qualifications and limitations set forth in this Agreement, as its sole and exclusive remedy, be entitled to a reduction or refund of the Purchase Price in an amount equal to the Losses sustained by the Purchaser. The reduction or refund of the Purchase Price for breach of any of the Warranties shall be made by an amount corresponding to the Losses sustained by the Purchaser.

8.2 Breach of Covenants and other undertakings; Specific indemnities

- 8.2.1 Each Party will indemnify and hold harmless the other Party against and in respect of any and all Losses incurred or suffered by the aggrieved Party that relate to (i) any of the breaching Party's breach of Covenant or other undertaking under this Agreement, and (ii) any misrepresentations and breach of warranties made by the Purchaser.
- 8.2.2 Bio-Sciences will indemnify and hold harmless the Purchaser against and in respect of any and all Losses incurred or suffered by the Purchaser that relate to Bio-Sciences' Liabilities that have not been assumed by the Purchaser under this Agreement.
- 8.2.3 The Purchaser will indemnify and hold harmless Bio-Sciences against and in respect of any and all Losses incurred or suffered by Bio-Sciences that relate to the Business Liabilities assumed by the Purchaser under this Agreement.

8.3 Other Rights and Remedies

The indemnification rights of the Purchaser under this Clause 8 are exclusive and sever the right to any other remedies the Purchaser may have at law or otherwise for misrepresentation, breach of warranty or failure to fulfil any agreement or covenant hereunder. Hence and without limiting the generality of the aforesaid, it is specifically agreed that no remedy whatsoever under the Sale of Goods Act (Sw. Köplagen (1990:931)) or under any other statute, law or legal principle, including (but not limited to) the right to rescind this Agreement, shall be available to the Purchaser except in the case of fraud, gross negligence, wilful misconduct or wilful concealment.

8.4 Limitation of Liability and Recovery

8.4.1 The Purchaser shall not be entitled to a reduction or refund of the Purchase Price unless the aggregated amount of all Claims which could otherwise be validly made under this Clause 8, exceeds SEK 100,000,000, in which case all Losses may be recoverable (i.e., no deductible shall apply once Losses exceed SEK 100,000,000). However, the limitation of liability set forth in this Clause 8.4.1 shall not apply in relation to: (a) a breach of any of

J.

- the Warranties in Clause 6.1.1; or (b) claims arising as a result of any fraud, gross negligence, wilful misconduct or wilful concealment.
- The aggregate liability of Bio-Sciences in respect of all Claims under the Warranties shall in no event exceed an amount corresponding to 20 per cent of the Purchase Price.
 However, the limitation of liability set forth in this Clause 8.4.2 shall not apply in relation to: (a) a breach of any of the Warranties in Clause 6.1.1; or (b) claims arising as a result of fraud, gross negligence, wilful misconduct or wilful concealment.
- No Claim shall entitle the Purchaser to a reduction or refund of the Purchase Price unless notice in writing of any such Claim accompanied by reasonable particulars thereof specifying the nature of the Claim and, as far as practicable, the amount of the Claim (though failure to give prompt notice of the Claim will only adversely impact the Purchaser's ability to recover from Bio-Sciences if, and then only to the extent, such delay actually adversely impacts Bio-Sciences' defence of the Claim), has been given to Bio-Sciences reasonably promptly after the date when the Purchaser became aware of the circumstances giving rise to the Claim, and in any event no later than (a) eighteen (18) months after the Closing Date or, (b) if the Claim relates to Taxes, within ninety (90) days from the date when the Taxes in question have been subject to a final and non-appealable decision by the relevant tax authority or, (c) if the Claim relates to a breach of Clause 6.1.1, five years after the Closing Date.
- 8.4.4 For the purposes of this Agreement, a liability which is contingent shall not constitute a Loss unless and until such contingent liability becomes an actual liability and is due and payable. This provision shall not preclude the Purchaser from submitting a Claim within the relevant period set forth in Clause 8.4.3 subject to a further decision on the issue referred to herein.
- 8.4.5 If any Loss is a tax deductible item, the recoverable Loss shall be reduced by an amount equivalent to any net tax benefits actually achievable by the Purchaser (and also taking into account whether any reduction or refund of the Purchase Price or any indemnification amount will be taxable for the Purchaser).
- 8.4.6 Bio-Sciences shall have no liability if and to the extent that:
 - (a) a Loss occurs as a result of the passing of any legislation not in force at the date hereof, or which takes effect with retroactive effect, or occurs as a result of any increase in the tax rate in force on the date hereof or any change in the generally established practise of the relevant tax authorities; or
 - (b) the Purchaser prior to Closing actually knew of a breach of Warranty; or
 - (c) a Loss is recoverable under an insurance policy or from a third party, provided Bio-Sciences will be responsible for (A) the Purchaser's costs in pursuing such claims for recovery, and (B) any increase in insurance premiums attributable to such recovery under an insurance policy; or
 - (d) a Loss would not have arisen but for an act, omission, (including the mitigation of costs and losses) or transaction carried out by the Purchaser, or persons deriving title from the Purchaser or the Company after the Closing Date, with the direct intent of creating a Claim, or due to a change in practices following Closing.



8.5 No additional warranties or representations

The Parties acknowledge that Bio-Sciences has not made, and the Purchaser has not relied on, any representation or warranty (express or implied) regarding the Business Assets and the Business Liabilities other than the Warranties and furthermore that no action or omission by Bio-Sciences or its representatives shall be construed as implying any other representation or warranty.

8.6 Mitigation of losses

In the event of a misrepresentation, breach of warranty, breach of covenant or breach of any other undertaking under this Agreement, the aggrieved Party shall use its reasonable endeavours to mitigate the losses, damages, costs, and expenses.

8.7 Third Party Claims

- 8.7.1 In the event that the Purchaser becomes aware of any fact or set of circumstances which are likely to give rise to a Third Party Claim, which could result in a Claim, the Purchaser shall, in order to preserve its right to bring a Claim against Bio-Sciences:
 - (i) as soon as reasonably practicable give written notice of it to Bio-Sciences (though failure to give prompt notice of the Third Party Claim will only adversely impact the Purchaser's ability to recover from Bio-Sciences if, and then only to the extent, such delay actually adversely impacts Bio-Sciences' defence of the Third Party Claim);
 - (ii) not make any admission of liability, agree to settle or compromise with any person, body or authority in relation to it, without first obtaining the prior written consent of Bio-Sciences, which consent shall not be unreasonably withheld or delayed:
 - (iii) give Bio-Sciences, or Bio-Sciences' duly authorised representatives, the right, but not the obligation, to conduct and control, through counsel of its choosing, any Third Party Claim (but Bio-Sciences may only exercise the right to take over the defence of the Third Party Claim if Bio-Sciences agrees to accept liability for it and agrees to indemnify the Purchaser in respect of it); and Bio-Sciences may compromise or settle the same, provided that Bio-Sciences shall first consult with the Purchaser in respect of any proposed compromise or settlement, and provided further that Bio-Sciences may only settle or compromise such claim if Bio-Sciences assumes the responsibility for such settlement or compromise. If Bio-Sciences elects not to control or conduct the defence of a Third Party Claim, Bio-Sciences shall still have the right to participate in the defence or prosecution of any Third Party Claim and, at its own expense, to employ counsel of its own choosing for such purpose; and
 - (iv) give reasonable access free of charge to the personnel of the Purchaser access to any relevant premises, accounts, documents and records within its possession and to take copies of them, in order to enable Bio-Sciences, or Bio-Sciences' duly authorised representatives, to examine the basis of, conduct the defence of, or follow the defence of, the Third Party Claim.

11

9. MISCELLANEOUS

9.1 Assignments

Neither Party may, wholly or partly, assign, pledge or otherwise dispose of its rights and/or obligations under this Agreement without the other Party's prior written consent. However, an existing or new floating charge shall not be considered to be in breach of this clause. Except in cases of mergers and demergers completed in accordance with applicable law, the rights and/or obligations under this Agreement may not in any other way be transferred to a third party without the other Party's prior written consent.

9.2 Partial invalidity

If any provision of this Agreement or the application of it shall be declared or deemed void, invalid or unenforceable in whole or in part for any reason, the Parties shall amend this Agreement in order to give effect to, so far as is possible, the spirit of this Agreement. If the Parties fail to amend this Agreement, the provision, which is void, invalid or unenforceable, shall be deemed deleted and the remaining provisions of this Agreement shall continue in full force and effect.

9.3 Interpretation

English language terms used in this Agreement shall be interpreted solely with reference to legal usage, traditions and the laws of Sweden and not with reference to the legal usage, traditions, or laws of any other country.

9.4 Waiver

Neither Party shall be deprived of any right under this Agreement because of its failure to exercise any right under this Agreement or failure to notify the infringing party of a breach in connection with the Agreement. Notwithstanding the foregoing, rules on complaints and limitation periods shall apply.

9.5 Amendments

Any amendment or addition to this Agreement must be made in writing and signed by the Parties to be valid.

9.6 Governing law and disputes

- 9.6.1 The laws of Sweden, excluding its conflict of law principles, govern all matters arising under this Agreement.
- 9.6.2 As the exclusive means of initiating adversarial proceedings to resolve any dispute arising out of this Agreement or its subject matter, either Party may demand that any such dispute be resolved by arbitration:
 - (a) administered by the Arbitration Institute of the Stockholm Chamber of Commerce;
 - (b) in the English language; and
 - (c) using three (3) arbitrators.

The Parties hereby consent to such dispute being so resolved.

- 9.6.3 Any arbitral proceedings pursuant to this Clause 9.6 shall be carried out in Stockholm, Sweden.
- The Parties agree and acknowledge that all arbitral proceedings conducted or initiated with reference to the arbitration clause in this Clause 9.6 will be kept strictly confidential. This confidentiality undertaking shall cover the fact that arbitration has been initiated, all information disclosed in the course of such arbitral proceedings, as well as any decision or award that is made or declared during the proceedings. Information covered by this confidentiality undertaking may not, in any form, be disclosed to any Person without the prior written consent of the other Party. Notwithstanding the foregoing, a Party shall not be prevented from disclosing such information in order to safeguard in the best possible way such Party's rights vis-à-vis the other Party in connection with the dispute, or if such a right exists pursuant to statute, regulation, a decision by an authority, a stock exchange contract or similar.
- 9.6.5 In case this Agreement or any part of it is assigned or transferred to any Person, such Person shall automatically be bound by the arbitration clause in this Clause 9.6.



This Agreement has been signed in two (2) originals, of which Bio-Sciences and the Purchaser have taken one each.

Stockholm 18 December 2015

GE HEALTHCARE BIO-SCIENCES AB

Name: Jan Erneberg, p.p.a

Name: Bo Lundström, p.p.a

Stockholm

18 December 2015

GE HEALTHCARE BIOPROCESS R&D AB

Name: Carolina Hammarqvist, p.p.a

Amendment Agreement
· · · · · · · · · · · · · · · · · · ·
dated 19 June 2017
dated 17 June 2017
GE Healthcare Bio-Sciences AB
and
and
GE Healthcare BioProcess R&D AB
Transfer of Chromatography Media Business

TABLE OF CONTENTS

1.	DEFINITIONS AND INTERPRETATION	. 3
2	INTEGRATED PART AND PREVAILING DOCUMENT	4
3.	SALE AND PURCHASE OF THE ADDITIONAL INTELLECTUAL PROPERTY RIGHTS .	, 4
4.	PURCHASE PRICE	. 4
5	MISCELLANEOUS	Δ

SCHEDULES

Schedule 3.1

Additional Intellectual Property Rights

This Amendment Agreement is dated as set out below 2016 and made between:

- (1) **GE Healthcare Bio-Sciences AB**, Rog. No. 556108-1919, a limited liability company incorporated under the laws of Sweden; and having its registered office at 751 84 Uppsala ("Bio-Sciences"); and
- (2) **GE Healthcare BioProcess R&D AB**, Reg. No. 556707-7366, a limited liability company incorporated under the laws of Sweden; and having its registered office at Björkgatan 30, 751 84 Uppsala, (the "**Purchaser**").

Capitalized terms shall have the meaning ascribed to them in Clause 1.1 below.

BACKGROUND

- A. On 18 December 2015, Bio-Sciences and the Purchaser entered into a Business Transfer (the "BTA") under which the Chromatography Media Business (as defined in the BTA) was transferred to the Purchaser and such transfer was completed on 30 December 2015.
- B. A. Recently, the Parties have identified a number of Additional Intellectual Property Rights (as defined in the BTA) that are exclusively attributable to the Chromatography Media Business and therefore rightfully should have been included in the Business Transfer. The Additional Intellectual Property Rights would have been included in the Business Transfer had they been identified prior to the Closing Date. The Parties note that certain Additional Intellectual Property Rights were acquired by Bio-Sciences from other entities within the Parties' group to be assigned to the Purchaser under this Amendment Agreement. For administrative purposes solely, the Parties acknowledge that the Purchaser will, subsequent to entering into this Amendment Agreement and to the extent permitted under the relevant jurisdictions, be registered as the owner of such Additional Intellectual Property Rights directly, hence, not registering the initial assignment of such Additional Intellectual Property Rights to Bio-Sciences.
- C. In view of the foregoing, the Parties now have agreed to amend the terms of the BTA as follows.

1. DEFINITIONS AND INTERPRETATION

1.1 Definitions

"Additional Intellectual Property Rights" means the additional Transferred Intellectual Property Rights as defined in Clause 7.2.4.2 in the BTA identified by the Parties after the Closing Date.

"Amendment Agreement" means this agreement, including its schedules, and as amended from time to time.

"Amendment Signing Date" means the date of the duly execution of this Amendment Agreement by the Parties.

"Intellectual Property Rights" means patents, trademarks, registered designs, copyrights and neighbouring rights, including data bases, Know-How and other rights of a similar kind in any part of the world whether registered or not, including applications for the registration of such rights.

"Know-How" means any trade secrets and confidential and proprietary industrial and commercial information and techniques in any form including, without limitation, drawings, formulae, test results, reports, project reports and testing procedures, instruction and training manuals, tables of operating conditions, lists and particulars of customers and suppliers and market forecasts.

"Party (-ies)" means Bio-Sciences and the Purchaser, either individually or jointly as the case may be.

"Purchaser" is defined in the preamble to this Amendment Agreement.

2. INTEGRATED PART AND PREVAILING DOCUMENT

This Amendment Agreement shall be an integrated part of the BTA and, thus, any and all provisions in the BTA shall also apply to this Amendment Agreement.

In the event any provisions in the BTA and the Amendment Agreement would be inconsistent or in conflict with each other, the provisions in this Amendment Agreement shall prevail.

3. SALE AND PURCHASE OF THE ADDITIONAL INTELLECTUAL PROPERTY RIGHTS

- 3.1 Effective as of this Amendment Signing Date, Bio-Sciences hereby sells and transfers and the Purchaser purchases and acquires all Intellectual Property Rights listed or described in Schedule 3.1 (collectively the "Additional Intellectual Property Rights").
- Accordingly, all title to and interest in the Additional Intellectual Property Rights shall pass and transfer to the Purchaser on this Amendment Signing Date.
- 3.3 The Additional Intellectual Property Rights shall be deemed to be included by the definition of Transferred Intellectual Property Rights. Thus, and without limitation, Clause 7.2.1 of the BTA shall apply.

4. PURCHASE PRICE

4.1 Purchase Price

The Parties agree and acknowledge that the Purchase Price set out in the BTA and already paid for the Chromatography Media Business shall also be deemed to include full compensation for the Additional Intellectual Property Rights. Hence, no further purchase price shall be payable as regards the Additional Intellectual Property Rights.

5. MISCELLANEOUS

Without limiting the generality of Section 2, the provisions on applicable law, dispute resolution and arbitration shall also apply to this Amendment Agreement and any references to the BTA, shall be deemed to include also a reference to this Amendment Agreement.

This Amendment Agreement has been signed in two (2) originals, of which Bio-Sciences and the Purchaser have taken one each.

Uppsala 19 June 2017

GE HEALTHCARE BIO-SCIENCES AB

Ann-Christine Löfgren

Bo Lundström

Uppsala 19 June 2017

GE HEALTHCARE BIOPROCESS R&D AB

Sofie Stille

Christel Fenge

1. Additional Intellectual Property Rights

1.1 Patents and patent applications

Patents and patent applications listed in Sub-Schedule 3.1 (i).

1.2 Trademarks and trademarks applications

Trademarks and trademarks applications listed in Sub-Schedule 3.1(ii).

SUB-SCHEDULE 3.1.1(a)(i)

GE Healthcare Bio-Sciences AB

and

GE Healthcare BioProcess R&D AB

MI MANNHEIMER SWARTLING WWW.MANNHEIMERSWARTLING.55

Patents and patent applications

								.,		~~~	
219099	219099	219099	219099	219099	174135	174135	174135	174135	174135	174135	Plock(eft#
>	10	7	Os.	4h	ထ	ထ	7	ത	ڻ ن	ω	三)(1)
889011	PU0668	PU0668	PU0668	PU0668	PU0122	PU0122	PU0122	PU0122	PU0122	PU0122	Alf Døglet Number
AXIAL CHROMATOGRAPHY COLUMNS AND METHODS	AXIAL CHROMATOGRAPHY COLUMNS AND METHODS	AXIAL CHROMATOGRAPHY COLUMNS AND METHODS	AXIAL CHROMATOGRAPHY COLUMNS AND METHODS	AXIAL CHROMATOGRAPHY COLUMNS AND METHODS	SCALABLE INLET LIQUID DISTRIBUTION SYSTEM FOR LARGE SCALE CHROMATOGRAPHY COLUMNS	SCALABLE INLET LIQUID DISTRIBUTION SYSTEM FOR LARGE SCALE CHROMATOGRAPHY COLUMNS	SCALABLE INLET LIQUID DISTRIBUTION SYSTEM FOR LARGE SCALE CHROMATOGRAPHY COLUMNS	SCALABLE INLET LIQUID DISTRIBUTION SYSTEM FOR LARGE SCALE CHROMATOGRAPHY COLUMNS	SCALABLE INLET LIQUID DISTRIBUTION SYSTEM FOR LARGE SCALE CHROMATOGRAPHY COLUMNS	SCALABLE INLET LIQUID DISTRIBUTION SYSTEM FOR LARGE SCALE CHROMATOGRAPHY COLUMNS	Title
Issued	Issued	Issued	Issued	Issued	Issued	Issued	Issued	issued	issued	Issued	डेमांस ड
긠	DE	S.	GB	g	GB	뮸	R	Çī Ü	m P	US	Gly
06/02/2009	06/02/2009	14/01/2009	12/07/2007	16/01/2009	10/05/2002	10/05/2002	10/05/2002	10/05/2002	10/05/2002	04/11/2003	Application Date
2081659	502007020292.2	200780027226.9	2440244	5198446	1393058	1393058	1393058	4263490	1393058	7051758	Palent Number
07786120.1	07786120.1	200780027226.9	0713572.6	2009-519857	02740581.0	02740581.0	02740581.0	2002-589789	02740581.0	10/476903	Application Number
17/07/2027	17/07/2027	17/07/2027	12/07/2027	17/07/2027	10/05/2022	10/05/2022	10/05/2022	10/05/2022	10/05/2022	11/04/2023	Expiration Date

225849	225849	225849	225849	225849	220662	220662	220662	219100	219100	219100	219100	219100	219100	219100	219100	219100	219100	219100
13 PU0720	9 PU0720	6 PU0720	4 PU0720	2 PU0720	16 PU06101	15 PU06101	14 PU06101	19 PU0674	18 PU0674	17 PU0674		15 PU0674	13 PU0574	12 US CON	9 PU0674	8 PU0674	5 PU0674	4 PU0674
PACKING SYSTEM AND METHOD FOR CHROMATOGRAPHY COLUMNS	PACKING SYSTEM AND METHOD FOR CHROMATOGRAPHY COLUMNS	PACKING SYSTEM AND METHOD FOR CHROMATOGRAPHY COLUMNS	PACKING SYSTEM AND METHOD FOR CHROMATOGRAPHY COLUMNS	PACKING SYSTEM AND METHOD FOR CHROMATOGRAPHY COLUMNS	CHROMATOGRAPHY LIGAND COMPRISING DOMAIN C FROM STAPHYLOCOCCUS AUREUS PROTEIN A FOR ANTIBODY ISOLATION	CHROMATOGRAPHY LIGAND COMPRISING DOMAIN C FROM STAPHYLOCOCCUS AUREUS PROTEIN A FOR ANTIBODY ISOLATION	CHROMATOGRAPHY LIGAND COMPRISING DOMAIN C FROM STAPHYLOCOCCUS AUREUS PROTEIN A FOR ANTIBODY ISOLATION	CHROMATOGRAPHY COLUMNS, SYSTEMS AND METHODS	CHROMATOGRAPHY COLUMNS, SYSTEMS AND METHODS	CHROMATOGRAPHY COLUMNS, SYSTEMS AND METHODS	CHROMATOGRAPHY COLUMNS, SYSTEMS AND METHODS	CHROMATOGRAPHY COLUMNS, SYSTEMS AND METHODS	CHROMATOGRAPHY COLUMNS, SYSTEMS AND METHODS	CHROMATOGRAPHY COLUMNS, SYSTEMS AND METHODS	CHROMATOGRAPHY COLUMNS, SYSTEMS AND METHODS	CHROMATOGRAPHY COLUMNS, SYSTEMS AND METHODS	CHROMATOGRAPHY COLUMNS, SYSTEMS AND METHODS	CHROMATOGRAPHY COLUMNS, SYSTEMS AND METHODS
Issued	Issued	issued	Issued	Issued	Issued	Issued	Issued	Issued	Issued	Issued	issued	Issued	Issued	Issued	Issued	Issued	Issued	Issued
윴	J.P	CZ	GB	SU	GB	FR	DE	SE	Z	GB B	R	DE	DE	SU	EP	CN	GB	JP
02/09/2009	07/09/2009	09/09/2009	05/03/2008	05/03/2008	20/03/2009	20/03/2009	20/03/2009	05/02/2009	05/02/2009	05/02/2009	05/02/2009	05/02/2009	14/11/2013	04/06/2012	05/02/2009	09/01/2009	12/07/2007	16/01/2009
602008028420.4	5271284	ZL200880007695.9	2447344	8778187	2066419	2066419	602007043885.3	2081660	2081860	2081660	2081660	602007042063.6	202007019578.8	8702983	2081660	ZL200780026819.3	2440243	5133987
08715265.7	2009-552118	200880007695.9	0804089.1	12/042363	07808849.9	07808849.9	07808849.9	07786121.9	07786121.9	07786121.9	07786121.9	07786121.9	202007019578.8	13/487766	07786121.9	200780026819.3	0713570.0	2009-519858
05/03/2028	05/03/2028	05/03/2028	05/03/2028	05/03/2028	27/09/2027	27/09/2027	27/09/2027	17/07/2027	17/07/2027	17/07/2027	17/07/2027	17/07/2027	14/11/2023	16/07/2027	17/07/2027	17/07/2027	12/07/2027	17/07/2027

2000	283827	263627	263627	263627	263627	245274	243604	243604	243604	243604	243604	238835	238835	238835	238835	238835	238835	238635	225849
	7,	<u>i</u> ω	170	<i>د</i> ــ،	10	10	12	<u>-</u>	10	မ	O1	ಹ	12	-:	10	φ	6	4	4
DI 14 04 00	PI110122	PU10122	PU10122	PU10122	PU10122	PU1022	PU09114	PU09114	PU09114	PU09114	PU09114	PU0934	PU0934	PU0934	PU0934	TPO- 9162AMB PU0934	PU0934	PU0934	PU0720
IMMUNOGLOBULIN G FC REGION BINDING	IMMUNOGLOBULÍN G FC REGION BINDING	O CIN	IMMUNOGLOBULIN G FC REGION BINDING	ດ	IMMUNOGLOBULIN G FC REGION BINDING POLYPEPTIDE	METHOD FOR PRODUCTION OF CHROMATOGRAPHY MEDIA	METHOD OF DRY PACKING OF CHROMATOGRAPHY COLUMNS	METHOD FOR DRY PACKING CHROMATOGRAPHY	FILTER HOLDER IN A CHROMATOGRAPHY COLUMN	PACKING SYSTEM AND METHOD FOR CHROMATOGRAPHY COLUMNS									
issued	Issued	Issued	Issued	Issued	Issued	Flied	Issued	Issued	Issued	issued	Issued	issued	Issued	Issued	issued	Issued	issued	Issued	Issued
=	ㅋ	뭇	GB	H	PE	US	GB B	H	DE .	유	CN	Z	DE	GB	FR	P	S	US	R
27/08/2012	27/08/2012	27/08/2012	27/08/2012	27/08/2012	27/08/2012	23/10/2012	19/06/2012	19/06/2012	19/06/2012	19/06/2012	21/06/2012	21/10/2011	21/10/2011	21/10/2011	21/10/2011	01/12/2014	14/11/2011	10/11/2011	02/09/2009
2544785	2544785	2544785	2544785	2544785	602011020461.0		2517000	2517000	2517000	2517000	ZL201080058776.9	2430438	2430438	2430438	2430438	3195931	ZL201080021956.X 201080021956.X	8377296	2121157
11707162.1	11707162.1	11707162.1	11707162.1	11707162.1	11707162.1	13/642937	10839893.4	10839893.4	10839893.4	10839893,4	201080058776.9	10775163.8	10775163.8	10775163.8	10775163.8	2014-006343	201080021956.X	13/319816	08716265.7
07/03/2031	07/03/2031	07/03/2031	07/03/2031	07/03/2031	07/03/2031	20/04/2031	20/12/2030	20/12/2030	20/12/2030	20/12/2030	20/12/2030	10/05/2030	10/05/2030	10/05/2030	10/05/2030	10/05/2020	10/05/2030	10/05/2030	05/03/2028

266175A	266175A	266175A	266175A	266175A	282821	282378	266175	266175	266175	266175	266175	263627	263627	263627	263627	263627
7	ලා .	Ċħ	4-	ယ	.خ.	>	7	တ	თ	4	(.)	20	<u></u>	တ်	17	<u>ත</u>
PU1330	PU1330	PU1330	PU1330	PU1330			PU1328	PU1328	PU1328	PU1328	PU1328	PU10122	PU10122	PU10122	PU10122	PU10122
MUTATED IMMUNOGLOBULIN-BINDING POLYPEPTIDES	MUTATED IMMUNOGLOBULIN-BINDING POLYPEPTIDES	MUTATED IMMUNOGLOBULIN-BINDING POLYPEPTIDES	MUTATED IMMUNOGLOBULIN-BINDING POLYPEPTIDES	MUTATED IMMUNOGLOBULIN-BINDING POLYPEPTIDES	A METHOD AND APPARATUS FOR PACKING A CHROMATOGRAPHY COLUMN	Method and chromatography media	MUTATED IMMUNOGLOBULIN-BINDING POLYPEPTIDES	IMMUNOGLOBULIN G FO REGION BINDING POLYPEPTIDE	IMMUNOGLOBULIN G FC REGION BINDING	(a)	IMMUNOGLOBULIN G FC REGION BINDING	IMMUNOGLOBULIN G FC REGION BINDING				
Unfiled	Filed	Filed	Filed	Unfiled	Filed	Filed	Unfiled	Filed	Filed	Filed	Unfiled	Issued	Issued	issued	Issued	Issued
US	وم	Ž	即	CN	SB	GB	US	ďP	Z	m	ÇN.	ŗ		CH	SE	ES
	07/01/2016	04/01/2016	07/01/2016		06/01/2016	06/11/2015		07/01/2016	04/01/2016	07/01/2016		27/08/2012	27/08/2012	27/08/2012	27/08/2012	27/08/2012
												2544785	2544785	2544785	2544785	2544785
			14823321.6		1600171.1	1519668.6			201617000159	14823829.8		11707162.1	11707162.1	11707162.1	11707162.1	11707162.1
10/07/2034	10/07/2034	10/07/2034	10/07/2034	10/07/2034	06/01/2036	06/11/2035	08/07/2034	08/07/2034	08/07/2034	08/07/2034	08/07/2034	07/03/2031	07/03/2031	07/03/2031	07/03/2031	07/03/2031

TRADEMARK	COUNTRY	REGISTRATION NO
MABTRAP	CTM	2119956
SEPHACRYL	India	516534
DROP DESIGN	Canada	TMA162525
DROP DESIGN	United States of America	1290768
DROP DESIGN	United States of America	890473
DROP DESIGN	China	356068
DROP DESIGN	China	352632
DROP DESIGN	United States of America	890315
DROP DESIGN	United States of America	1820903
DROP DESIGN	United States of America	890328
DROP DEVICE	Brazil	821505548
DROP DEVICE	Argentina	2454375
DROP DEVICE	Bangladesh	44699
DROP DEVICE	CTM	3488723
DROP DEVICE	Cuba	802002
DROP DEVICE	Malaysia	95004756
DROP DEVICE	Thailand	KOR50651
DROP DEVICE	Bangladesh	44697
DROP DEVICE	Bosnia & Herzegovina	BAZ961149
DROP DEVICE	Bangladesh	44700
DROP DEVICE	Indonesia	IDM000063828
DROP DEVICE	Bangladesh	43640
DROP DEVICE	Brazil	821505530
DROP DEVICE	Thailand	KOR53871
DROP DEVICE	Bangladesh	44698
DROP DEVICE	Bangladesh	43641
DROP DEVICE	Indonesia	IDM000063830
DROP DEVICE	India	522506
DROP DEVICE	Malaysia	97019998
DROP DEVICE	Macedonia	7713
DROP DEVICE	Taiwan	748808
DROP DEVICE	Egypt	72274
DROP DEVICE	Pakistan	175294
DROP DEVICE	Australia	880033
DROP DEVICE	Egypt	72275
DROP DEVICE	Taiwan	742479
DROP DEVICE	Egypt	72276
DROP DEVICE	India	522505
DROP DEVICE	Bangladesh	43639
DROP DEVICE	Egypt	72273
DROP DEVICE	India	522507
DROP DEVICE	Korea - Republic of (South)	341352
DROP DEVICE	Argentina	2488787

DROP DEVICE	Korea - Republic of (South)	356514
DROP DEVICE	Hong Kong	199808222
DROP DEVICE	Hong Kong	199608494
DROP DEVICE	india	1252698
DROP DEVICE	Korea - Republic of (South)	4136439
DROP DEVICE	Hong Kong	199608493
MABTRAP	India	1014075
SEPHACEL	Hungary	391334
SEPHACEL	Romania	391334
SEPHACEL	Egypt	391334
SEPHACEL	Switzerland	391334
SEPHACEL	Montenegro	391334
SEPHACEL	Austria	391334
SEPHACEL	Bosnia & Herzegovina	391334
SEPHACEL	Macedonia	391334
SEPHACEL	Benelux	391334
SEPHACEL	WIPO	391334
SEPHACEL	Italy	391334
SEPHACEL	Portugal	391334
SEPHACEL	San Marino	391334
SEPHACEL	Monaco	391334
SEPHACEL	Serbia	391334
SEPHACEL	Liechtenstein	391334
SEPHACEL	Spain	391334
SEPHACEL	France	391334
SEPHACEL	Morocco	391334
SEPHADEX	Cuba .	4792002
SEPHAROSE	Germany	414398
SEPHAROSE	WIPO	414398
SEPHAROSE	Hungary	414398
SEPHAROSE	Italy	414398
STREAMLINE	Cuba	20020473
DROP DESIGN	WIPO	365465
DROP DEVICE	Austria	365465
DROP DEVICE	Egypt	365465
DROP DEVICE	Hungary	365465
DROP DEVICE	Liechtenstein	365465
DROP DEVICE	Switzerland	365465
DROP DEVICE	Malaysia	95004751
DROP DEVICE	Bangladesh	43637
DROP DEVICE	Benelux	365465
DROP DEVICE	Portugal	365465
DROP DEVICE	italy	365465
DROP DEVICE	France	365465

DROP DEVICE	Romania	365465
DROP DEVICE	Spain	365465
DROP DEVICE	Macedonia	365465
DROP DEVICE	Montenegro	365465
DROP DEVICE	Bosnia & Herzegovina	365465
DROP DEVICE	Morocco	365465
DROP DEVICE	Malaysia	95004758

RECORDED: 12/29/2029